[{"pcpa_file_number":"78086","brand_name":"Voydeya","generic_name":"danicopan","manufacturer_negotiated_with":"Alexion Pharma GmbH","indication":"Voydeya, as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have residual hemolytic anemia due to extravascular hemolysis (EVH).","status":"Under consideration for negotiation","cda_amc_project_id":"SR0815-000","inesss_project_id":"","engagement_date":"","close_date":""},{"pcpa_file_number":"78083","brand_name":"Tezspire","generic_name":"tezepelumab","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":" As an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) inadequately controlled by systemic corticosteroids and\/or surgery","status":"Under consideration for negotiation","cda_amc_project_id":"SR0910-000","inesss_project_id":"","engagement_date":"","close_date":""},{"pcpa_file_number":"78080","brand_name":"Cablivi","generic_name":"caplacizumab","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"For the treatment of adults with acquired thrombotic thrombocytopenic purpura in combination with plasma exchange and immunosuppressive therapy","status":"Under consideration for negotiation","cda_amc_project_id":"SR0912-000","inesss_project_id":"","engagement_date":"","close_date":""},{"pcpa_file_number":"78070","brand_name":"Epysqli","generic_name":"eculizumab","manufacturer_negotiated_with":"Samsung Bioepis Co., Ltd.","indication":"Multiple Indications","status":"Under consideration for negotiation","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"","close_date":""},{"pcpa_file_number":"78056","brand_name":"Cabometyx","generic_name":"cabozantinib","manufacturer_negotiated_with":"Ipsen Biopharmaceuticals Canada, Inc.","indication":"\u200bFor the treatment of locally advanced or metastatic extra-pancreatic (ep-NET) or pancreatic neuroendocrine tumours (nPNET).","status":"Active negotiation","cda_amc_project_id":"PX0378-000","inesss_project_id":"","engagement_date":"2026-05-29","close_date":""},{"pcpa_file_number":"23625","brand_name":"Erbitux","generic_name":"cetuximab","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Braftovi, in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test","status":"Active negotiation","cda_amc_project_id":"PC0428-000","inesss_project_id":"","engagement_date":"2026-05-06","close_date":""},{"pcpa_file_number":"23620","brand_name":"Yondelis","generic_name":"trabectedin","manufacturer_negotiated_with":"Xediton Pharmaceuticals Inc.","indication":"in combination with doxorubicin as first-line treatment for advanced unresectable","status":"Active negotiation","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2026-04-29","close_date":""},{"pcpa_file_number":"23618","brand_name":"Zoryve","generic_name":"roflumilast","manufacturer_negotiated_with":"Arcutis Biotherapeutics, Inc.","indication":"Atopic dermatitis","status":"Negotiations were not pursued","cda_amc_project_id":"SR0887-000","inesss_project_id":"","engagement_date":"","close_date":"2026-06-05"},{"pcpa_file_number":"23604","brand_name":"Tolak","generic_name":"fluorouracil sodium","manufacturer_negotiated_with":"Hill Dermaceuticals, Inc.","indication":"Actinic keratosis","status":"Under consideration for negotiation","cda_amc_project_id":"SR0911-000","inesss_project_id":"","engagement_date":"","close_date":""},{"pcpa_file_number":"23600","brand_name":"Trimbow","generic_name":"beclomethasone dipropionate, glycopyrronium (as bromide) and formoterol fumarate dihydrate","manufacturer_negotiated_with":"Methapharm Specialty Pharmaceuticals","indication":"Chronic Obstructive Pulmonary Disease (COPD)","status":"Under consideration for negotiation","cda_amc_project_id":"SR0907-000","inesss_project_id":"","engagement_date":"","close_date":""},{"pcpa_file_number":"23595","brand_name":"Quillivant ER","generic_name":"Methylphenidate Hydrochloride","manufacturer_negotiated_with":"KYE Pharmaceuticals Inc.","indication":"Attention-deficit\/hyperactivity disorder (ADHD)","status":"Active negotiation","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2026-05-21","close_date":""},{"pcpa_file_number":"23593","brand_name":"Gazyva","generic_name":"obinutuzumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Active lupus nephritis","status":"Under consideration for negotiation","cda_amc_project_id":"SR0891-000","inesss_project_id":"","engagement_date":"","close_date":""},{"pcpa_file_number":"23581","brand_name":"Tevimbra","generic_name":"tislelizumab","manufacturer_negotiated_with":"BeOne Medicines (Canada) ULC","indication":"in combination with gemcitabine and platinum chemotherapy, for the first-line treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).","status":"Under consideration for negotiation","cda_amc_project_id":"PC0399-000","inesss_project_id":"","engagement_date":"","close_date":""},{"pcpa_file_number":"23574","brand_name":"Enhertu","generic_name":"trastuzumab deruxtecan","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Advanced or Metastatic Gastric Cancer or Gastro-esophageal Junction (GEJ) Adenocarcinoma","status":"Active negotiation","cda_amc_project_id":"PC0425-000","inesss_project_id":"","engagement_date":"2026-04-21","close_date":""},{"pcpa_file_number":"23570","brand_name":"Imbruvica","generic_name":"ibrutinib","manufacturer_negotiated_with":"Janssen Inc.","indication":"Venclexta, in combination with ibrutinib, for the treatment of adult patients with relapsed or","status":"Concluded with an LOI","cda_amc_project_id":"PC0402-000","inesss_project_id":"","engagement_date":"2025-12-08","close_date":"2026-03-29"},{"pcpa_file_number":"23568","brand_name":"Solufy","generic_name":"aripiprazole","manufacturer_negotiated_with":"Orimed Pharma","indication":"psychotic disorders, mood disorders, and major depressive disorder","status":"Active negotiation","cda_amc_project_id":"","inesss_project_id":"28673","engagement_date":"2026-06-03","close_date":""},{"pcpa_file_number":"23563","brand_name":"TBD","generic_name":"denosumab","manufacturer_negotiated_with":"Sun Pharma Canada Inc.","indication":"Multiple Indications","status":"Negotiations were not pursued","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"","close_date":"2026-05-06"},{"pcpa_file_number":"23558","brand_name":"Rybrevant","generic_name":"amivantamab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Non-small cell lung cancer (NSCLC), Locally advanced or metastatic, in adult patients with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2026-01-29","close_date":"2026-01-29"},{"pcpa_file_number":"23549","brand_name":"Livmarli","generic_name":"maralixibat","manufacturer_negotiated_with":"Mirum Pharmaceuticals Inc.","indication":"for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients 3 months and older.","status":"Under consideration for negotiation","cda_amc_project_id":"SR0908-000","inesss_project_id":"","engagement_date":"","close_date":""},{"pcpa_file_number":"23538","brand_name":"Ranvu","generic_name":"ranibizumab","manufacturer_negotiated_with":"Apotex Inc.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2026-02-10","close_date":"2026-03-09"},{"pcpa_file_number":"23532","brand_name":"Spevigo","generic_name":"spesolimab","manufacturer_negotiated_with":"LEO Pharma Inc.","indication":"generalized pustular psoriasis (GPP)","status":"Active negotiation","cda_amc_project_id":"SR0844-000","inesss_project_id":"","engagement_date":"2026-02-03","close_date":""},{"pcpa_file_number":"23530","brand_name":"Darzalex SC","generic_name":"Daratumumab","manufacturer_negotiated_with":"Janssen Inc.","indication":"in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are not candidates for autologous stem cell transplant.","status":"Concluded with an LOI","cda_amc_project_id":"PC0424-000","inesss_project_id":"","engagement_date":"2026-03-25","close_date":"2026-03-25"},{"pcpa_file_number":"23527","brand_name":"Venclexta","generic_name":"venetoclax","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Calquence, in combination with venetoclex, for the treatment of patients with previously","status":"Concluded with an LOI","cda_amc_project_id":"PC0412-000","inesss_project_id":"","engagement_date":"2026-02-02","close_date":"2026-03-29"},{"pcpa_file_number":"23518","brand_name":"Braftovi","generic_name":"encorafenib","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"in combination with cetuximab and chemotherapy, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test.","status":"Active negotiation","cda_amc_project_id":"PC0428-000","inesss_project_id":"","engagement_date":"2026-03-25","close_date":""},{"pcpa_file_number":"23515","brand_name":"Kisqali","generic_name":"ribociclib","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II-III early breast cancer at high risk of recurrence- In pre- or perimenopausal women, or men, the aromatase inhibitor should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.","status":"Under consideration for negotiation","cda_amc_project_id":"PC0395-000","inesss_project_id":"","engagement_date":"","close_date":""},{"pcpa_file_number":"23512","brand_name":"Kerendia","generic_name":"finerenone","manufacturer_negotiated_with":"Bayer Inc.","indication":"As an adjunct to standard of care in adults with heart failure with left ventricular ejection fraction (LVEF) ?40% to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits.","status":"Under consideration for negotiation","cda_amc_project_id":"SR0893-000","inesss_project_id":"","engagement_date":"","close_date":""},{"pcpa_file_number":"23509","brand_name":"Loqtorzi","generic_name":"toripalimab","manufacturer_negotiated_with":"Apotex Inc.","indication":"In combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC).","status":"Under consideration for negotiation","cda_amc_project_id":"PC0421-000","inesss_project_id":"","engagement_date":"","close_date":""},{"pcpa_file_number":"23503","brand_name":"Carvykti","generic_name":"ciltacabtagene autoleucel","manufacturer_negotiated_with":"Janssen Inc.","indication":"For the treatment of adult patients with multiple myeloma, who have received 1 to 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.","status":"Active negotiation","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2026-02-06","close_date":""},{"pcpa_file_number":"23502","brand_name":"Carvykti","generic_name":"ciltacabtagene autoleucel","manufacturer_negotiated_with":"Janssen Inc.","indication":"Multiple myeloma in adult patients who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and who are refractory to their last treatment","status":"Active negotiation","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2026-02-06","close_date":""},{"pcpa_file_number":"23501","brand_name":"Zepzelca (pTAP negotiation)","generic_name":"lurbinectedin","manufacturer_negotiated_with":"Jazz Pharmaceuticals Canada Inc.","indication":"For the treatment of adult patients with Stage III or metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-containing therapy.","status":"Concluded without agreement","cda_amc_project_id":"PC0431-000","inesss_project_id":"","engagement_date":"2026-02-25","close_date":"2026-06-03"},{"pcpa_file_number":"23499","brand_name":"Loqtorzi","generic_name":"toripalimab","manufacturer_negotiated_with":"Apotex Inc.","indication":"for the treatment of adults with recurrent unresectable or metastatic nasopharyngeal carcinoma (NPC) with disease progression on or after a platinum-containing chemotherapy","status":"Negotiations were not pursued","cda_amc_project_id":"PC0423-000","inesss_project_id":"","engagement_date":"","close_date":"2026-04-27"},{"pcpa_file_number":"23499","brand_name":"Loqtorzi","generic_name":"toripalimab","manufacturer_negotiated_with":"Apotex Inc.","indication":"for the treatment of adults with recurrent unresectable or metastatic nasopharyngeal carcinoma (NPC) with disease progression on or after a platinum-containing chemotherapy","status":"Negotiations were not pursued","cda_amc_project_id":"PC0423-000","inesss_project_id":"","engagement_date":"","close_date":"2026-04-27"},{"pcpa_file_number":"23493","brand_name":"Bomyntra","generic_name":"denosumab","manufacturer_negotiated_with":"Fresenius Kabi Canada Ltd.","indication":"reducing the risk of developing skeletal-related events in patients with multiple myeloma and in patients with bone metastases from breast cancer, prostate cancer, non-small cell lung cancer, and other solid tumors; treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severemorbidity; and treatment of hypercalcemia of malignancy that is refractory to intravenous bisphosphonate","status":"Active negotiation","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2026-05-06","close_date":""},{"pcpa_file_number":"23491","brand_name":"Conexxence","generic_name":"denosoumab","manufacturer_negotiated_with":"Fresenius Kabi Canada Ltd.","indication":"treatment of postmenopausal women with osteoporosis at high risk for fracture; treatment to increase bone mass in men with osteoporosis at high risk for fracture; treatment to increase bone mass in men with nonmetastatic prostate cancer receiving androgen deprivation therapy, who are at high risk for fracture; treatment to increase bone mass in women receiving adjuvant aromatase inhibitor therapy for nonmetastatic breast cancer; and treatment to increase bone mass for the treatment and prevention of glucocorticoid- induced osteoporosis in women and men at high risk for fracture","status":"Active negotiation","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2026-05-07","close_date":""},{"pcpa_file_number":"23489","brand_name":"Tzield","generic_name":"teplizumab","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"indicated to delay the onset of stage 3 type 1 diabetes (T1D) in adult and pediatric patients 8 years of age and older with stage 2 T1D","status":"Under consideration for negotiation","cda_amc_project_id":"SR0867-000","inesss_project_id":"","engagement_date":"","close_date":""},{"pcpa_file_number":"23486","brand_name":"tbc (golimumab)","generic_name":"golimumab","manufacturer_negotiated_with":"Jamp Pharma Corporation","indication":"Rheumatoid Arthritis (RA)","status":"Active negotiation","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2026-01-21","close_date":""},{"pcpa_file_number":"23484","brand_name":"Nemluvio","generic_name":"nemolizumab","manufacturer_negotiated_with":"Galderma Canada Inc.","indication":"Prurigo nodularis","status":"Active negotiation","cda_amc_project_id":"SR0861-000","inesss_project_id":"","engagement_date":"2026-03-12","close_date":""},{"pcpa_file_number":"23482","brand_name":"Nemluvio","generic_name":"nemolizumab","manufacturer_negotiated_with":"Galderma Canada Inc.","indication":"For the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 12 years and older who are candidates for systemic therapy.","status":"Active negotiation","cda_amc_project_id":"SR0869-000","inesss_project_id":"","engagement_date":"2026-03-12","close_date":""},{"pcpa_file_number":"23478","brand_name":"Tryngolza","generic_name":"Olezarsen","manufacturer_negotiated_with":"Theratechnologies Inc.","indication":"As an adjunct to diet for the treatment of adults with familial chylomicronemia syndrome (FCS) to reduce triglyceride levels.","status":"Active negotiation","cda_amc_project_id":"SR0902-000","inesss_project_id":"","engagement_date":"2026-05-04","close_date":""},{"pcpa_file_number":"23474","brand_name":"Bimzelx","generic_name":"bimekizumab","manufacturer_negotiated_with":"UCB Canada Inc.","indication":"For the treatment of adult patients with moderate to severe hidradenitis suppurativa with an inadequate response to conventional systemic therapy.","status":"Under consideration for negotiation","cda_amc_project_id":"SR0856-000","inesss_project_id":"","engagement_date":"","close_date":""},{"pcpa_file_number":"23466","brand_name":"Imfinzi","generic_name":"durvalumab","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"In combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant durvalumab monotherapy, for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC\/GEJC).","status":"Concluded with an LOI","cda_amc_project_id":"PC0427-000","inesss_project_id":"","engagement_date":"2026-04-29","close_date":"2026-04-29"},{"pcpa_file_number":"23460","brand_name":"Amvuttra","generic_name":"vutrisiran","manufacturer_negotiated_with":"Alnylam Netherlands B.V.","indication":"Cardiomyopathy due to transthyretin-mediated amyloidosis","status":"Under consideration for negotiation","cda_amc_project_id":"SR0904-000","inesss_project_id":"","engagement_date":"","close_date":""},{"pcpa_file_number":"23459","brand_name":"Komboglyze","generic_name":"saxagliptin\/metformin","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded with an LOI","cda_amc_project_id":"SR0348-000","inesss_project_id":"","engagement_date":"","close_date":"2015-01-09"},{"pcpa_file_number":"23456","brand_name":"Exjade","generic_name":"deferasirox","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Chronic Iron Overload","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2016-11-02","close_date":"2017-04-04"},{"pcpa_file_number":"23453","brand_name":"Elfabrio","generic_name":"pegunigalsidase alfa","manufacturer_negotiated_with":"Chiesi Canada Corporation","indication":"Fabry Disease","status":"Active negotiation","cda_amc_project_id":"SR0872-000","inesss_project_id":"26940","engagement_date":"2026-06-09","close_date":""},{"pcpa_file_number":"23447","brand_name":"Isturisa","generic_name":"osilodrostat","manufacturer_negotiated_with":"Recordati Rare Diseases Canada Inc.","indication":"For the treatment of adult patients with Cushing\u0026#039;s disease who have persistent or recurrent hypercortisolism after primary pituitary surgery and\/or irradiation, or for whom pituitary surgery is not an option.","status":"Active negotiation","cda_amc_project_id":"SR0804-000","inesss_project_id":"","engagement_date":"2026-04-28","close_date":""},{"pcpa_file_number":"23444","brand_name":"Opdivo-Yervoy","generic_name":"nivolumab-ipilimumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"For the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC).","status":"Concluded with an LOI","cda_amc_project_id":"PC0420-000","inesss_project_id":"","engagement_date":"2026-01-09","close_date":"2026-02-03"},{"pcpa_file_number":"23441","brand_name":"Lyvdelzi","generic_name":"seladelpar","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"For the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in adults unable to tolerate UDCA.","status":"Active negotiation","cda_amc_project_id":"SR0899-000","inesss_project_id":"","engagement_date":"2026-02-11","close_date":""},{"pcpa_file_number":"23437","brand_name":"Tecentriq","generic_name":"atezolizumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"For the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained greater than or equal to 50% of TCs or PD-L1 stained tumour-infiltrating immune cells [ICs] covering greater than or equal to 10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations.","status":"Active negotiation","cda_amc_project_id":"PC0419-000","inesss_project_id":"","engagement_date":"2026-05-25","close_date":""},{"pcpa_file_number":"23433","brand_name":"Tremfya","generic_name":"guselkumab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Ulcerative Colitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0874-000","inesss_project_id":"","engagement_date":"2025-11-14","close_date":"2025-12-19"},{"pcpa_file_number":"23431","brand_name":"Perjeta","generic_name":"pertuzumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with early-stage HER2-positive breast cancer","status":"Active negotiation","cda_amc_project_id":"PX0379-000","inesss_project_id":"","engagement_date":"2026-02-11","close_date":""},{"pcpa_file_number":"23428","brand_name":"Imfinzi","generic_name":"durvalumab","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Treatment of patients with resectable muscle invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by adjuvant IMFINZI monotherapy treatment after radical cystectomy.","status":"Concluded with an LOI","cda_amc_project_id":"PC0414-000","inesss_project_id":"","engagement_date":"2026-04-12","close_date":"2026-04-12"},{"pcpa_file_number":"23425","brand_name":"Calquence","generic_name":"Acalabrutinib","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Indicated in combination with venetoclax for the treatment of patients with previously untreated CLL.","status":"Concluded with an LOI","cda_amc_project_id":"PC0412-000","inesss_project_id":"","engagement_date":"2026-02-02","close_date":"2026-03-30"},{"pcpa_file_number":"23422","brand_name":"Okedi","generic_name":"risperidone","manufacturer_negotiated_with":"Bausch Health, Canada Inc.","indication":"Schizophrenia in Adults","status":"Concluded with an LOI","cda_amc_project_id":"SR0879-000","inesss_project_id":"","engagement_date":"2026-03-16","close_date":"2026-05-25"},{"pcpa_file_number":"23418","brand_name":"Vyvgart","generic_name":"efgartigimod alfa","manufacturer_negotiated_with":"Argenx Canada Inc.","indication":"Chronic inflammatory demyelinating polyneuropathy","status":"Under consideration for negotiation","cda_amc_project_id":"SR0894-000","inesss_project_id":"","engagement_date":"","close_date":""},{"pcpa_file_number":"23415","brand_name":"Movantik","generic_name":"naloxegol","manufacturer_negotiated_with":"Knight Therapeutics Inc.","indication":"Treatment of opioid-induced constipation (OIC) in adult patients with cancer and non-cancer pain who have had an inadequate response to laxative(s).","status":"Active negotiation","cda_amc_project_id":"SX0753-000","inesss_project_id":"","engagement_date":"2026-01-13","close_date":""},{"pcpa_file_number":"23411","brand_name":"Enhertu","generic_name":"trastuzumab deruxtecan","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"For the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+\/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting and are not considered suitable for endocrine therapy as the next line of treatment.","status":"Active negotiation","cda_amc_project_id":"PC0401-000","inesss_project_id":"","engagement_date":"2026-03-12","close_date":""},{"pcpa_file_number":"23408","brand_name":"Rinvoq","generic_name":"upadacitinib","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Giant Cell Arteritis","status":"Active negotiation","cda_amc_project_id":"SR0877-000","inesss_project_id":"","engagement_date":"2026-04-13","close_date":""},{"pcpa_file_number":"23403","brand_name":"Dupixent","generic_name":"dupilumab","manufacturer_negotiated_with":"Sanofi Genzyme Canada","indication":"Indicated as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils inadequately controlled by the combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate.","status":"Active negotiation","cda_amc_project_id":"SR0870-000","inesss_project_id":"","engagement_date":"2026-04-30","close_date":""},{"pcpa_file_number":"23401","brand_name":"Penthrox","generic_name":"methoxyflurane","manufacturer_negotiated_with":"Knight Therapeutics Inc.","indication":"Adult patients undergoing minor gynecological, ambulatory, or emergency procedures","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-10-29","close_date":"2026-01-19"},{"pcpa_file_number":"23398","brand_name":"Itovebi","generic_name":"inavolisib","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"In combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine resistant, PIK3CA-mutated, hormone receptor-positive (HR+) (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.","status":"Concluded with an LOI","cda_amc_project_id":"PC0382-000","inesss_project_id":"","engagement_date":"2026-02-18","close_date":"2026-05-26"},{"pcpa_file_number":"23394","brand_name":"Voranigo","generic_name":"vorasidenib","manufacturer_negotiated_with":"Servier Canada Inc.","indication":"For the treatment of Grade 2 WHO 2016, 2021 grading system astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.","status":"Concluded with an LOI","cda_amc_project_id":"PC0407-000","inesss_project_id":"","engagement_date":"2025-12-16","close_date":"2026-02-19"},{"pcpa_file_number":"23390","brand_name":"Nubeqa","generic_name":"Darolutamide","manufacturer_negotiated_with":"Bayer Inc.","indication":"For the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).","status":"Concluded with an LOI","cda_amc_project_id":"PC0404-000","inesss_project_id":"","engagement_date":"2025-10-22","close_date":"2025-12-01"},{"pcpa_file_number":"23387","brand_name":"Stivarga","generic_name":"regorafenib","manufacturer_negotiated_with":"Bayer Inc.","indication":"For the treatment of metastatic osteosarcoma in patients who received at least 1 prior line of therapy.","status":"Concluded with an LOI","cda_amc_project_id":"PX0374-000","inesss_project_id":"","engagement_date":"2025-10-21","close_date":"2025-11-28"},{"pcpa_file_number":"23380","brand_name":"Anzupgo","generic_name":"delgocitinib","manufacturer_negotiated_with":"LEO Pharma Inc.","indication":"Chronic hand eczema","status":"Active negotiation","cda_amc_project_id":"SR0875-000","inesss_project_id":"","engagement_date":"2026-02-25","close_date":""},{"pcpa_file_number":"23376","brand_name":"Rebyota","generic_name":"fecal microbiota","manufacturer_negotiated_with":"Ferring Canada Inc.","indication":"Clostridioides difficile infection, prevention","status":"Active negotiation","cda_amc_project_id":"SR0850-000","inesss_project_id":"","engagement_date":"2026-02-11","close_date":""},{"pcpa_file_number":"23373","brand_name":"Alyftrek","generic_name":"vanzacaftor, tezacaftor, deutivacaftor","manufacturer_negotiated_with":"Vertex Pharmaceuticals (Canada) Incorporated","indication":"Cystic fibrosis, F508del or responsive CFTR mutation, 6 years and older","status":"Active negotiation","cda_amc_project_id":"SR0896-000","inesss_project_id":"","engagement_date":"2026-02-11","close_date":""},{"pcpa_file_number":"23369","brand_name":"Tysabri","generic_name":"natalizumab","manufacturer_negotiated_with":"Biogen Canada Inc.","indication":"Multiple Sclerosis, Relapsing-Remitting","status":"Concluded without agreement","cda_amc_project_id":"SR0133-000","inesss_project_id":"","engagement_date":"2025-10-08","close_date":"2026-01-20"},{"pcpa_file_number":"23367","brand_name":"Mavenclad","generic_name":"cladribine","manufacturer_negotiated_with":"EMD Serono Canada, a division of EMD Inc.","indication":"Multiple Sclerosis, Relapsing-Remitting","status":"Concluded with an LOI","cda_amc_project_id":"SR0546-000","inesss_project_id":"","engagement_date":"2025-10-08","close_date":"2026-02-12"},{"pcpa_file_number":"23364","brand_name":"Ahzantive","generic_name":"aflibercept","manufacturer_negotiated_with":"Valorum Biologics LLC","indication":"Multiple Indications","status":"Active negotiation","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2026-01-19","close_date":""},{"pcpa_file_number":"23360","brand_name":"Talzenna","generic_name":"talazoparib","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"In combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).","status":"Active negotiation","cda_amc_project_id":"PC0417-000","inesss_project_id":"","engagement_date":"2026-01-19","close_date":""},{"pcpa_file_number":"23355","brand_name":"Dayvigo","generic_name":"lemborexant","manufacturer_negotiated_with":"Eisai Limited","indication":"Insomnia","status":"Under consideration for negotiation","cda_amc_project_id":"SR0895-000","inesss_project_id":"","engagement_date":"","close_date":""},{"pcpa_file_number":"23353","brand_name":"Hepcludex","generic_name":"bulevirtide","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"Chronic hepatitis delta virus (HDV) infection","status":"Active negotiation","cda_amc_project_id":"SR0881-000","inesss_project_id":"","engagement_date":"2026-03-16","close_date":""},{"pcpa_file_number":"23349","brand_name":"Skyrizi","generic_name":"risankizumab","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Ulcerative Colitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0890-000","inesss_project_id":"","engagement_date":"2025-11-24","close_date":"2025-11-24"},{"pcpa_file_number":"23347","brand_name":"Elahere","generic_name":"mirvetuximab soravtansine","manufacturer_negotiated_with":"AbbVie Corporation","indication":"For the treatment of adult patients with folate receptor-alpha (FR\u03b1) positive*, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.","status":"Concluded without agreement","cda_amc_project_id":"PC0394-000","inesss_project_id":"","engagement_date":"2025-12-18","close_date":"2026-05-14"},{"pcpa_file_number":"23343","brand_name":"Blenrep (belantamab mafodotin)","generic_name":"in combination with bortezomib and dexamethasone","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"For the treatment of multiple myeloma in combination with bortezomib and dexamethasone (BVd) in adult patients who have received at least one prior therapy.","status":"Active negotiation","cda_amc_project_id":"PC0379-000","inesss_project_id":"","engagement_date":"2026-04-30","close_date":""},{"pcpa_file_number":"23339","brand_name":"Blenrep (belantamab mafodotin)","generic_name":"in combination with pomalidomide and dexamethasone","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"For the treatment of multiple myeloma in combination with pomalidomide and dexamethasone (Bpd) in adult patients who have received at least one prior therapy including lenalidomide.","status":"Active negotiation","cda_amc_project_id":"PC0380-000","inesss_project_id":"","engagement_date":"2026-04-30","close_date":""},{"pcpa_file_number":"23334","brand_name":"Calquence","generic_name":"Acalabrutinib","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated MCL who are ineligible for autologous stem cell transplant.","status":"Concluded with an LOI","cda_amc_project_id":"PC0413-000","inesss_project_id":"","engagement_date":"2025-10-30","close_date":"2026-03-30"},{"pcpa_file_number":"23331","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"For the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumours express PD-L1 [Combined Positive Score (CPS) ? 1], as neoadjuvant treatment as monotherapy, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as monotherapy.","status":"Concluded with an LOI","cda_amc_project_id":"PC0410-000","inesss_project_id":"","engagement_date":"2025-10-23","close_date":"2025-10-23"},{"pcpa_file_number":"23328","brand_name":"Columvi","generic_name":"glofitamab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"In combination with gemcitabine and oxaliplatin for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are not candidates for autologous stem cell transplant (ASCT).","status":"Concluded with an LOI","cda_amc_project_id":"PC0406-000","inesss_project_id":"","engagement_date":"2025-12-17","close_date":"2026-03-16"},{"pcpa_file_number":"23324","brand_name":"Scemblix","generic_name":"asciminib","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase","status":"Concluded with an LOI","cda_amc_project_id":"PC0405-000","inesss_project_id":"","engagement_date":"2025-12-18","close_date":"2026-05-20"},{"pcpa_file_number":"23321","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"For the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy (CRT).","status":"Concluded with an LOI","cda_amc_project_id":"PC0411-000","inesss_project_id":"","engagement_date":"2025-10-23","close_date":"2025-10-23"},{"pcpa_file_number":"23318","brand_name":"Opdivo-Yervoy","generic_name":"nivolumab-ipilimumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"For the first-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.","status":"Concluded with an LOI","cda_amc_project_id":"PC0396-000","inesss_project_id":"","engagement_date":"2025-11-13","close_date":"2025-12-11"},{"pcpa_file_number":"23315","brand_name":"Scemblix","generic_name":"asciminib","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) who have previously received 1 tyrosine kinase inhibitor (second line).","status":"Under consideration for negotiation","cda_amc_project_id":"PC0418-000","inesss_project_id":"","engagement_date":"","close_date":""},{"pcpa_file_number":"23311","brand_name":"Opdivo SC","generic_name":"nivolumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-09-03","close_date":"2025-10-29"},{"pcpa_file_number":"23306","brand_name":"Andembry","generic_name":"garadacimab","manufacturer_negotiated_with":"CSL Behring Canada Inc.","indication":"Hereditary Angioedema","status":"Active negotiation","cda_amc_project_id":"SR0860-000","inesss_project_id":"","engagement_date":"2026-03-05","close_date":""},{"pcpa_file_number":"23301","brand_name":"Bylvay","generic_name":"odevixibat","manufacturer_negotiated_with":"Medison Pharma Canada Inc.","indication":"Alagille syndrome","status":"Concluded with an LOI","cda_amc_project_id":"SR0844-000","inesss_project_id":"","engagement_date":"2025-11-26","close_date":"2025-11-26"},{"pcpa_file_number":"23299","brand_name":"Venclexta","generic_name":"venetoclax","manufacturer_negotiated_with":"AbbVie Corporation","indication":"In combination with ibrutinib, is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).","status":"Concluded with an LOI","cda_amc_project_id":"PC0402-000","inesss_project_id":"","engagement_date":"2025-12-08","close_date":"2026-03-29"},{"pcpa_file_number":"23292","brand_name":"Opzelura","generic_name":"ruxolitinib","manufacturer_negotiated_with":"Incyte Biosciences Canada Corporation","indication":"Nonsegmental vitiligo","status":"Under consideration for negotiation","cda_amc_project_id":"SR0835-000","inesss_project_id":"","engagement_date":"","close_date":""},{"pcpa_file_number":"23288","brand_name":"Omvoh","generic_name":"mirikizumab","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Crohn\u0026#039;s disease","status":"Concluded with an LOI","cda_amc_project_id":"SR0880-000","inesss_project_id":"","engagement_date":"2025-10-30","close_date":"2025-12-22"},{"pcpa_file_number":"23286","brand_name":"Qalsody","generic_name":"tofersen","manufacturer_negotiated_with":"Biogen Canada Inc.","indication":"Amyotrophic Lateral Sclerosis (ALS)","status":"Active negotiation","cda_amc_project_id":"SR0883-000","inesss_project_id":"","engagement_date":"2026-03-18","close_date":""},{"pcpa_file_number":"23282","brand_name":"Nordimet","generic_name":"methotrexate","manufacturer_negotiated_with":"Nordic Pharma","indication":"Multiple Indications","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-08-25","close_date":"2025-10-30"},{"pcpa_file_number":"23280","brand_name":"Rybrevant","generic_name":"amivantamab","manufacturer_negotiated_with":"Janssen Inc.","indication":"In combination with carboplatin and pemetrexed for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal-growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.","status":"Concluded with an LOI","cda_amc_project_id":"PC0393-000","inesss_project_id":"","engagement_date":"2025-09-22","close_date":"2026-01-29"},{"pcpa_file_number":"23277","brand_name":"Verzenio","generic_name":"abemaciclib","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor (AI) in postmenopausal women as initial endocrine-based therapy.","status":"Concluded with an LOI","cda_amc_project_id":"PC0400-000","inesss_project_id":"","engagement_date":"2026-01-29","close_date":"2026-04-08"},{"pcpa_file_number":"23274","brand_name":"Tagrisso","generic_name":"osimertinib","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"For the treatment of patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during or following platinum-based chemoradiation therapy (CRT).","status":"Concluded with an LOI","cda_amc_project_id":"PC0398-000","inesss_project_id":"","engagement_date":"2025-09-29","close_date":"2025-11-13"},{"pcpa_file_number":"23271","brand_name":"Verzenio","generic_name":"abemaciclib","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"For the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer as follows: - in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy. - in combination with fulvestrant in women with disease progression following endocrine therapy. Pre- or perimenopausal women must also be treated with a gonadotropin-releasing hormone (GnRH) agonist. - as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens. At least one chemotherapy...","status":"Concluded with an LOI","cda_amc_project_id":"PC0409-000","inesss_project_id":"","engagement_date":"2026-01-29","close_date":"2026-04-08"},{"pcpa_file_number":"23268","brand_name":"Noyada","generic_name":"Captopril","manufacturer_negotiated_with":"Ethypharm Inc.","indication":"for the treatment of essential or renovascular hypertension; for the treatment of congestive heart failure; to improve survival, delay the onset of symptomatic heart failure and reduce hospitalizations for heart failure following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction of ? 40%; for the treatment of diabetic nephropathy (proteinuria ? 500 mg\/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy.","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-07-22","close_date":"2025-09-22"},{"pcpa_file_number":"23263","brand_name":"Tremfya","generic_name":"guselkumab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Crohn\u0026#039;s disease","status":"Concluded with an LOI","cda_amc_project_id":"SR0882-000","inesss_project_id":"","engagement_date":"2025-11-14","close_date":"2025-12-19"},{"pcpa_file_number":"23256","brand_name":"Longavo","generic_name":"risperidone","manufacturer_negotiated_with":"Teva Canada Innovation","indication":"Schizophrenia in Adults","status":"Concluded without agreement","cda_amc_project_id":"SR0811-000","inesss_project_id":"27210","engagement_date":"2025-11-03","close_date":"2026-05-29"},{"pcpa_file_number":"23252","brand_name":"Myfembree","generic_name":"relugolix, estradiol, and norethindrone acetate","manufacturer_negotiated_with":"Knight Therapeutics Inc.","indication":"Management of heavy menstrual bleeding associated with uterine fibroids","status":"Concluded with an LOI","cda_amc_project_id":"SR0885-000","inesss_project_id":"","engagement_date":"2025-10-21","close_date":"2025-12-12"},{"pcpa_file_number":"23247","brand_name":"Sogroya","generic_name":"somapacitan","manufacturer_negotiated_with":"Novo Nordisk Canada Inc.","indication":"Growth hormone deficiency","status":"Concluded without agreement","cda_amc_project_id":"SR0779-000","inesss_project_id":"","engagement_date":"2025-08-19","close_date":"2026-03-27"},{"pcpa_file_number":"23245","brand_name":"Methofill","generic_name":"methotrexate","manufacturer_negotiated_with":"Accord Healthcare Inc.","indication":"Multiple Indications","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-08-25","close_date":"2025-11-13"},{"pcpa_file_number":"23242","brand_name":"Vanflyta","generic_name":"quizartinib","manufacturer_negotiated_with":"Daiichi Sankyo Pharma Canada","indication":"In combination with standard cytarabineand anthracycline induction and standard cytarabine consolidationchemotherapy, and as continuation maintenance monotherapy followingconsolidation, for the treatment of adult patients with newly diagnosed acutemyeloid leukemia (AML) that is FMS-like tyrosine kinase 3 internal tandemduplication (FLT3-ITD) positive.","status":"Concluded with an LOI","cda_amc_project_id":"PC0359-000","inesss_project_id":"","engagement_date":"2025-10-22","close_date":"2026-04-29"},{"pcpa_file_number":"23235","brand_name":"Symtuza","generic_name":"darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide","manufacturer_negotiated_with":"Janssen Inc.","indication":"HIV-1 Infection","status":"Active negotiation","cda_amc_project_id":"SR0552-000","inesss_project_id":"","engagement_date":"2025-07-02","close_date":""},{"pcpa_file_number":"23234","brand_name":"Abilify Asimtufii","generic_name":"aripiprazole","manufacturer_negotiated_with":"Otsuka Canada Pharmaceutical Inc.","indication":"Schizophrenia","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-07-29","close_date":"2025-10-24"},{"pcpa_file_number":"23232","brand_name":"Pombiliti with Opfolda","generic_name":"cipaglucosidase alfa with miglustat","manufacturer_negotiated_with":"Amicus Therapeutics Canada Inc.","indication":"Pompe disease","status":"Active negotiation","cda_amc_project_id":"SR0871-000","inesss_project_id":"","engagement_date":"2025-11-13","close_date":""},{"pcpa_file_number":"23227","brand_name":"Dupixent","generic_name":"dupilumab","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Severe chronic rhinosinusitis with nasal polyps","status":"Active negotiation","cda_amc_project_id":"SR0878-000","inesss_project_id":"","engagement_date":"2025-10-01","close_date":""},{"pcpa_file_number":"23225","brand_name":"Quviviq","generic_name":"daridorexant","manufacturer_negotiated_with":"Idorsia Pharmaceuticals Canada Ltd.","indication":"Insomnia","status":"Active negotiation","cda_amc_project_id":"SR0862-000","inesss_project_id":"","engagement_date":"2026-02-11","close_date":""},{"pcpa_file_number":"23221","brand_name":"Dupixent","generic_name":"dupilumab","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Prurigo nodularis","status":"Active negotiation","cda_amc_project_id":"SR0876-000","inesss_project_id":"","engagement_date":"2025-10-01","close_date":""},{"pcpa_file_number":"23213","brand_name":"Piasky","generic_name":"crovalimab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Paroxysmal nocturnal hemoglobinuria (PNH)","status":"Concluded with an LOI","cda_amc_project_id":"SR0858-000","inesss_project_id":"","engagement_date":"2025-11-12","close_date":"2025-12-10"},{"pcpa_file_number":"23209","brand_name":"Wegovy","generic_name":"semaglutide","manufacturer_negotiated_with":"Novo Nordisk Canada Inc.","indication":"As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 30 kg\/m2 or greater (obesity), or 27 kg\/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, dyslipidemia, or obstructive sleep apnea.","status":"Concluded without agreement","cda_amc_project_id":"SR0841-000","inesss_project_id":"","engagement_date":"2025-10-02","close_date":"2025-12-01"},{"pcpa_file_number":"23204","brand_name":"Aflivu","generic_name":"aflibercept","manufacturer_negotiated_with":"Apotex Inc.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-08-01","close_date":"2025-08-19"},{"pcpa_file_number":"23202","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"In combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).","status":"Concluded with an LOI","cda_amc_project_id":"PC0387-000","inesss_project_id":"","engagement_date":"2025-07-24","close_date":"2025-07-24"},{"pcpa_file_number":"23199","brand_name":"Eydenzelt","generic_name":"aflibercept","manufacturer_negotiated_with":"Celltrion Healthcare Canada Ltd.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-08-01","close_date":"2025-08-19"},{"pcpa_file_number":"23197","brand_name":"Welireg","generic_name":"belzutifan","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"For the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).","status":"Active negotiation","cda_amc_project_id":"PC0386-000","inesss_project_id":"","engagement_date":"2026-03-20","close_date":""},{"pcpa_file_number":"23194","brand_name":"Polivy","generic_name":"Polatuzumab Vedotin","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"In combination with R-CHP for the treatment of adult patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T-cell\/histiocyte rich LBCL that is classified as activated B cell-like (ABC) subtype.","status":"Concluded with an LOI","cda_amc_project_id":"PC0397-000","inesss_project_id":"","engagement_date":"2025-09-10","close_date":"2025-11-28"},{"pcpa_file_number":"23191","brand_name":"Camcevi","generic_name":"leuprolide mesylate","manufacturer_negotiated_with":"Accord Healthcare Inc.","indication":"For the treatment of adult patients with advanced prostate cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0370-000","inesss_project_id":"","engagement_date":"2025-08-11","close_date":"2025-10-31"},{"pcpa_file_number":"23187","brand_name":"Lazcluze and Rybrevant","generic_name":"lazertinib and amivantamab","manufacturer_negotiated_with":"Janssen Inc.","indication":"For the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.","status":"Concluded with an LOI","cda_amc_project_id":"PC0392-000","inesss_project_id":"","engagement_date":"2025-09-10","close_date":"2026-01-29"},{"pcpa_file_number":"23183","brand_name":"Pavblu","generic_name":"aflibercept","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Multiple Indications","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-08-01","close_date":"2025-11-24"},{"pcpa_file_number":"23180","brand_name":"Oslya","generic_name":"denosumab","manufacturer_negotiated_with":"Mantra Pharma","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-07-02","close_date":"2025-10-14"},{"pcpa_file_number":"23177","brand_name":"Iqirvo","generic_name":"elafibranor","manufacturer_negotiated_with":"Ipsen Biopharmaceuticals Canada, Inc.","indication":"Primary biliary cholangitis","status":"Active negotiation","cda_amc_project_id":"SR0865-000","inesss_project_id":"","engagement_date":"2025-08-21","close_date":""},{"pcpa_file_number":"23174","brand_name":"TBC","generic_name":"aflibercept","manufacturer_negotiated_with":"Sandoz Canada Inc.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-08-01","close_date":"2025-08-19"},{"pcpa_file_number":"23170","brand_name":"Tepezza","generic_name":"teprotumumab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Thyroid Eye Disease","status":"Negotiations were not pursued","cda_amc_project_id":"SR0853-000","inesss_project_id":"","engagement_date":"","close_date":"2026-06-05"},{"pcpa_file_number":"23166","brand_name":"Sarclisa","generic_name":"Isatuximab","manufacturer_negotiated_with":"Sanofi Genzyme Canada","indication":"In combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).","status":"Active negotiation","cda_amc_project_id":"PC0378-000","inesss_project_id":"","engagement_date":"2026-02-20","close_date":""},{"pcpa_file_number":"23163","brand_name":"Jemperli","generic_name":"dostarlimab","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"In combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy.","status":"Concluded with an LOI","cda_amc_project_id":"PC0381-000","inesss_project_id":"","engagement_date":"2025-07-30","close_date":"2025-12-03"},{"pcpa_file_number":"23160","brand_name":"Obodence","generic_name":"denosumab","manufacturer_negotiated_with":"Samsung Bioepis Co., Ltd.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-07-02","close_date":"2025-09-16"},{"pcpa_file_number":"23158","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"For the treatment of adult patients with primary advanced or recurrent endometrial carcinoma, in combination with carboplatin and paclitaxel and then continued as monotherapy.","status":"Concluded with an LOI","cda_amc_project_id":"PC0383-000","inesss_project_id":"","engagement_date":"2025-06-24","close_date":"2025-06-24"},{"pcpa_file_number":"23155","brand_name":"Imfinzi","generic_name":"durvalumab","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"For the treatment of patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT).","status":"Concluded with an LOI","cda_amc_project_id":"PC0389-000","inesss_project_id":"","engagement_date":"2026-04-12","close_date":"2026-04-12"},{"pcpa_file_number":"23152","brand_name":"Imfinzi-Imjudo","generic_name":"durvalumab-tremelimumab","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"In combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.","status":"Concluded with an LOI","cda_amc_project_id":"PC0390-000","inesss_project_id":"","engagement_date":"2026-04-12","close_date":"2026-04-12"},{"pcpa_file_number":"23148","brand_name":"Avtozma","generic_name":"tocilizumab","manufacturer_negotiated_with":"Celltrion Healthcare Canada Ltd.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-07-04","close_date":"2025-08-26"},{"pcpa_file_number":"23146","brand_name":"Yesafili","generic_name":"aflibercept","manufacturer_negotiated_with":"Biocon Biologics Canada Inc.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-08-01","close_date":"2025-08-19"},{"pcpa_file_number":"23140","brand_name":"Daybue","generic_name":"trofinetide","manufacturer_negotiated_with":"Acadia Pharmaceuticals Canada Inc.","indication":"Rett syndrome","status":"Negotiations were not pursued","cda_amc_project_id":"SR0829-000","inesss_project_id":"","engagement_date":"","close_date":"2025-11-05"},{"pcpa_file_number":"23135","brand_name":"Rystiggo","generic_name":"rozanolixizumab","manufacturer_negotiated_with":"UCB Canada Inc.","indication":"Generalized myasthenia gravis (gMG)","status":"Concluded with an LOI","cda_amc_project_id":"SR0846-000","inesss_project_id":"","engagement_date":"2025-06-24","close_date":"2025-08-29"},{"pcpa_file_number":"23132","brand_name":"Vemlidy","generic_name":"tenofovir alafenamide","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"chronic Hepatitis B virus","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-06-10","close_date":"2025-06-30"},{"pcpa_file_number":"23122","brand_name":"Opdivo","generic_name":"nivolumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"With doxorubicin, vinblastine and dacarbazine (AVD) in previously untreated stage III or IV Hodgkin Lymphoma.","status":"Concluded with an LOI","cda_amc_project_id":"PX0376-000","inesss_project_id":"","engagement_date":"2025-08-13","close_date":"2025-09-04"},{"pcpa_file_number":"23120","brand_name":"Bilprevda","generic_name":"denosumab","manufacturer_negotiated_with":"Organon Canada Inc.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-07-02","close_date":"2025-08-28"},{"pcpa_file_number":"23118","brand_name":"Idenos","generic_name":"denosumab","manufacturer_negotiated_with":"Apotex Inc.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-07-02","close_date":"2025-08-29"},{"pcpa_file_number":"23116","brand_name":"TBC (aflibercept)","generic_name":"aflibercept","manufacturer_negotiated_with":"Organon Canada Inc.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-08-01","close_date":"2025-08-19"},{"pcpa_file_number":"23111","brand_name":"Imfinzi","generic_name":"durvalumab","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Imfinzi as monotherapy.","status":"Concluded with an LOI","cda_amc_project_id":"PC0366-000","inesss_project_id":"","engagement_date":"2025-06-12","close_date":"2026-04-12"},{"pcpa_file_number":"23108","brand_name":"Pemazyre","generic_name":"pemigatinib","manufacturer_negotiated_with":"Incyte Biosciences Canada Corporation","indication":"For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement.","status":"Concluded with an LOI","cda_amc_project_id":"PC0391-000","inesss_project_id":"","engagement_date":"2025-06-12","close_date":"2025-10-08"},{"pcpa_file_number":"23105","brand_name":"Darzalex SC","generic_name":"Daratumumab","manufacturer_negotiated_with":"Janssen Inc.","indication":"in combination with bortezomib, lenalidomide, and dexamethasone, followed by maintenance treatment in combination with lenalidomide, for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.","status":"Concluded with an LOI","cda_amc_project_id":"PC0388-000","inesss_project_id":"","engagement_date":"2025-07-08","close_date":"2026-01-29"},{"pcpa_file_number":"23102","brand_name":"Blincyto","generic_name":"blinatumomab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"For the treatment of adult and pediatric patients with Philadelphia chromosome-negative CD19 positive B-cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy in the frontline setting.","status":"Concluded with an LOI","cda_amc_project_id":"PC0365-000","inesss_project_id":"","engagement_date":"2025-05-30","close_date":"2025-09-29"},{"pcpa_file_number":"23099","brand_name":"Signifor LAR","generic_name":"pasireotide","manufacturer_negotiated_with":"Recordati Rare Diseases Canada Inc.","indication":"Acromegaly in Adults","status":"Concluded without agreement","cda_amc_project_id":"SR0859-000","inesss_project_id":"","engagement_date":"2025-09-26","close_date":"2026-01-19"},{"pcpa_file_number":"23094","brand_name":"Skyclarys","generic_name":"omaveloxolone","manufacturer_negotiated_with":"Biogen Canada Inc.","indication":"Friedreich\u0026#039;s ataxia","status":"Concluded without agreement","cda_amc_project_id":"SR0864-000","inesss_project_id":"","engagement_date":"2025-08-21","close_date":"2026-06-10"},{"pcpa_file_number":"23090","brand_name":"Epuris","generic_name":"isotretinoin","manufacturer_negotiated_with":"Cipher","indication":"Acne Vulgaris","status":"Active negotiation","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2026-02-18","close_date":""},{"pcpa_file_number":"23088","brand_name":"Bildyos","generic_name":"denosumab","manufacturer_negotiated_with":"Organon Canada Inc.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-07-02","close_date":"2025-08-28"},{"pcpa_file_number":"23086","brand_name":"Osdenza","generic_name":"denosumab","manufacturer_negotiated_with":"Apotex Inc.","indication":"Osteoporosis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-07-02","close_date":"2025-08-29"},{"pcpa_file_number":"23083","brand_name":"Ofev","generic_name":"nintedanib","manufacturer_negotiated_with":"Boehringer Ingelheim (Canada) Ltd.","indication":"Idiopathic pulmonary fibrosis and PF-ILD","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-03-27","close_date":"2026-02-05"},{"pcpa_file_number":"23081","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"For the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery.","status":"Concluded with an LOI","cda_amc_project_id":"PC0385-000","inesss_project_id":"","engagement_date":"2025-04-25","close_date":"2025-04-25"},{"pcpa_file_number":"23077","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"In combination with enfortumab vedotin, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC.","status":"Concluded with an LOI","cda_amc_project_id":"PC0353-000","inesss_project_id":"","engagement_date":"2025-02-21","close_date":"2025-05-26"},{"pcpa_file_number":"23073","brand_name":"Gazyva","generic_name":"obinutuzumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"In combination with Venclexta, for the treatment of patients with previously untreated chronic lymphocytic leukemia","status":"Concluded with an LOI","cda_amc_project_id":"PC0362-000","inesss_project_id":"","engagement_date":"2025-02-10","close_date":"2025-06-17"},{"pcpa_file_number":"23071","brand_name":"Remdantry","generic_name":"infliximab","manufacturer_negotiated_with":"Celltrion Healthcare Canada Ltd.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-02-10","close_date":"2025-03-17"},{"pcpa_file_number":"23066","brand_name":"Fabhalta","generic_name":"iptacopan","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Paroxysmal nocturnal hemoglobinuria (PNH)","status":"Concluded without agreement","cda_amc_project_id":"SR0851-000","inesss_project_id":"","engagement_date":"2025-06-03","close_date":"2026-03-06"},{"pcpa_file_number":"23063","brand_name":"Opdivo-Yervoy","generic_name":"nivolumab-ipilimumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"In neoadjuvant setting for resectable stage III melanoma.","status":"Concluded with an LOI","cda_amc_project_id":"PX0371-000","inesss_project_id":"","engagement_date":"2025-02-06","close_date":"2025-02-21"},{"pcpa_file_number":"23060","brand_name":"Opdivo-Yervoy","generic_name":"nivolumab-ipilimumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"In combination, for the first-line treatment of adult patients with advanced (unresectable or metastatic) melanoma when patients progress during or within 6 months of adjuvant PD-1 therapy.","status":"Concluded with an LOI","cda_amc_project_id":"PX0347-000","inesss_project_id":"","engagement_date":"2025-02-06","close_date":"2025-02-21"},{"pcpa_file_number":"23056","brand_name":"Blincyto","generic_name":"blinatumomab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Indicated for the pediatric patients with Philadelphia chromosome negative relapsed\/refractory B precursor acute lymphoblastic leukemia (ALL) who are in first relapse.","status":"Concluded with an LOI","cda_amc_project_id":"PX0367-000","inesss_project_id":"","engagement_date":"2025-05-09","close_date":"2025-09-29"},{"pcpa_file_number":"23047","brand_name":"Xcopri","generic_name":"cenobamate","manufacturer_negotiated_with":"Paladin Labs Inc.","indication":"Epilepsy, partial-onset seizures","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-03-31","close_date":"2025-03-31"},{"pcpa_file_number":"23046","brand_name":"Imdelltra","generic_name":"tarlatamab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"For the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy including platinum-based chemotherapy","status":"Negotiation on hold","cda_amc_project_id":"PC0351-000","inesss_project_id":"","engagement_date":"2025-06-05","close_date":""},{"pcpa_file_number":"23040","brand_name":"TheraSphere Y-90 Glass Micropheres","generic_name":"Yttrium-90 microspheres","manufacturer_negotiated_with":"Boston Scientific Corporation","indication":"As selective internal radiation therapy (SIRT) for local tumor control of solitary tumors in patients with intermediate- or advanced-stage hepatocellular carcinoma (HCC), including those with recurrent or unresectable HCC. In addition to HCC","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-06-26","close_date":"2025-06-26"},{"pcpa_file_number":"23037","brand_name":"Enhertu (concluded with pTAP LOI)","generic_name":"trastuzumab deruxtecan","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"As monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti-HER2-based regimen","status":"Concluded with an LOI","cda_amc_project_id":"PC0367-000","inesss_project_id":"Enhertu (JGO HER2+)","engagement_date":"2025-01-17","close_date":"2025-04-24"},{"pcpa_file_number":"23033","brand_name":"Niopeg","generic_name":"pegfilgrastim","manufacturer_negotiated_with":"Nora Pharma Inc.","indication":"To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drug.","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-03-12","close_date":"2025-05-23"},{"pcpa_file_number":"23030","brand_name":"Yesintek","generic_name":"ustekinumab","manufacturer_negotiated_with":"Biocon Biologics Canada Inc.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-07-10","close_date":"2025-09-16"},{"pcpa_file_number":"23027","brand_name":"Otulfi","generic_name":"ustekinumab","manufacturer_negotiated_with":"Fresenius Kabi Canada Ltd.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-07-10","close_date":"2025-09-16"},{"pcpa_file_number":"23025","brand_name":"Vabysmo","generic_name":"faricimab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Retinal vein occlusion","status":"Concluded with an LOI","cda_amc_project_id":"SR0832-000","inesss_project_id":"","engagement_date":"2025-03-21","close_date":"2025-06-20"},{"pcpa_file_number":"23022","brand_name":"Breyanzi","generic_name":"lisocabtagene maraleucel","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBCL), and DLBCL arising from follicular lymphoma, who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy, and who are candidates for autologous hematopoietic stem cell transplant (HSCT)","status":"Concluded with an LOI","cda_amc_project_id":"PG0358-000","inesss_project_id":"","engagement_date":"2025-03-07","close_date":"2025-06-06"},{"pcpa_file_number":"23017","brand_name":"Vyloy","generic_name":"zolbetuximab","manufacturer_negotiated_with":"Astellas Pharma Inc.","indication":"In combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive","status":"Concluded with an LOI","cda_amc_project_id":"PC0338-000","inesss_project_id":"","engagement_date":"2025-04-02","close_date":"2025-07-31"},{"pcpa_file_number":"23013","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"As monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors","status":"Concluded with an LOI","cda_amc_project_id":"PC0377-000","inesss_project_id":"","engagement_date":"2025-02-20","close_date":"2025-02-20"},{"pcpa_file_number":"23010","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"as monotherapy for the adjuvant treatment of adult patients with Stage IB (T2a 4 cm), II, or IIIA NSCLC, and with PD-L1 tumor proportion score (TPS) less than 50% who have undergone complete resection and platinum-based chemotherapy.","status":"Concluded with an LOI","cda_amc_project_id":"PC0369-000","inesss_project_id":"","engagement_date":"2025-02-20","close_date":"2025-02-20"},{"pcpa_file_number":"23007","brand_name":"Opzelura","generic_name":"ruxolitinib","manufacturer_negotiated_with":"Incyte Biosciences Canada Corporation","indication":"Atopic dermatitis","status":"Concluded without agreement","cda_amc_project_id":"SR0807-000","inesss_project_id":"","engagement_date":"2026-02-25","close_date":"2026-05-20"},{"pcpa_file_number":"23004","brand_name":"Nextstellis","generic_name":"est\u00e9trol (monohydrate d\u0026#039;)\/drospir\u00e9none","manufacturer_negotiated_with":"Searchlight Pharma Inc.","indication":"Conception Control","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-01-22","close_date":"2025-04-18"},{"pcpa_file_number":"23001","brand_name":"Zilbrysq","generic_name":"zilucoplan","manufacturer_negotiated_with":"UCB Canada Inc.","indication":"Generalized myasthenia gravis (gMG)","status":"Concluded with an LOI","cda_amc_project_id":"SR0838-000","inesss_project_id":"","engagement_date":"2025-04-17","close_date":"2025-08-29"},{"pcpa_file_number":"22998","brand_name":"Xtandi","generic_name":"enzalutamide","manufacturer_negotiated_with":"Astellas Pharma Inc.","indication":"For the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR)","status":"Concluded with an LOI","cda_amc_project_id":"PX0366-000","inesss_project_id":"","engagement_date":"2025-03-25","close_date":"2025-03-25"},{"pcpa_file_number":"22995","brand_name":"Ryaltris","generic_name":"olopatadine hydrochloride and mometasone","manufacturer_negotiated_with":"Bausch Health, Canada Inc.","indication":"Seasonal allergic rhinitis","status":"Negotiations were not pursued","cda_amc_project_id":"SR0848-000","inesss_project_id":"","engagement_date":"","close_date":"2025-06-06"},{"pcpa_file_number":"22992","brand_name":"Venclexta","generic_name":"venetoclax","manufacturer_negotiated_with":"AbbVie Corporation","indication":"for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL), including those with 17p deletion (in combination with Imbruvica)","status":"Concluded with an LOI","cda_amc_project_id":"PC0317-000","inesss_project_id":"","engagement_date":"2024-12-05","close_date":"2025-01-17"},{"pcpa_file_number":"22990","brand_name":"Remsima SC","generic_name":"infliximab","manufacturer_negotiated_with":"Celltrion Healthcare Canada Ltd.","indication":"Rheumatoid Arthritis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-11-26","close_date":"2024-11-26"},{"pcpa_file_number":"22989","brand_name":"Rybrevant","generic_name":"amivantamab","manufacturer_negotiated_with":"Janssen Inc.","indication":"In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) exon 20 insertion mutations.","status":"Concluded with an LOI","cda_amc_project_id":"PC0376-000","inesss_project_id":"","engagement_date":"2025-05-07","close_date":"2026-01-29"},{"pcpa_file_number":"22986","brand_name":"Balversa","generic_name":"erdafitinib","manufacturer_negotiated_with":"Janssen Inc.","indication":"Adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.","status":"Concluded with an LOI","cda_amc_project_id":"PC0375-000","inesss_project_id":"","engagement_date":"2025-03-25","close_date":"2025-08-13"},{"pcpa_file_number":"22982","brand_name":"Ojjaara","generic_name":"momelotinib","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"For the treatment of splenomegaly and\/or disease-related symptoms, in adult patients with intermediate or high-risk primary myelofibrosis (MF), post polycythemia vera myelofibrosis or post essential thrombocythemia MF who have moderate to severe anemia.","status":"Concluded with an LOI","cda_amc_project_id":"PC0355-000","inesss_project_id":"","engagement_date":"2025-03-27","close_date":"2025-09-22"},{"pcpa_file_number":"22972","brand_name":"Casgevy","generic_name":"exagamglogene autotemcel","manufacturer_negotiated_with":"Vertex Pharmaceuticals (Canada) Incorporated","indication":"Sickle cell disease","status":"Active negotiation","cda_amc_project_id":"SG0830-000","inesss_project_id":"","engagement_date":"2025-07-29","close_date":""},{"pcpa_file_number":"22969","brand_name":"Casgevy","generic_name":"exagamglogene autotemcel","manufacturer_negotiated_with":"Vertex Pharmaceuticals (Canada) Incorporated","indication":"Transfusion-dependent ?-thalassemia","status":"Active negotiation","cda_amc_project_id":"SG0831-000","inesss_project_id":"","engagement_date":"2025-07-29","close_date":""},{"pcpa_file_number":"22965","brand_name":"Ultomiris","generic_name":"ravulizumab","manufacturer_negotiated_with":"Alexion Pharma GmbH","indication":"Generalized myasthenia gravis (gMG)","status":"Concluded with an LOI","cda_amc_project_id":"SR0855-000","inesss_project_id":"","engagement_date":"2025-01-27","close_date":"2025-07-03"},{"pcpa_file_number":"22963","brand_name":"Spevigo","generic_name":"spesolimab","manufacturer_negotiated_with":"Boehringer Ingelheim (Canada) Ltd.","indication":"generalized pustular psoriasis (GPP)","status":"Concluded without agreement","cda_amc_project_id":"SR0844-000","inesss_project_id":"","engagement_date":"2025-06-09","close_date":"2026-02-03"},{"pcpa_file_number":"22959","brand_name":"Ferinject","generic_name":"ferric carboxymaltose","manufacturer_negotiated_with":"CSL Vifor","indication":"Iron Deficiency Anemia","status":"Concluded with an LOI","cda_amc_project_id":"SR0842-000","inesss_project_id":"","engagement_date":"2025-08-21","close_date":"2025-10-17"},{"pcpa_file_number":"22957","brand_name":"Ferinject","generic_name":"ferric carboxymaltose","manufacturer_negotiated_with":"CSL Vifor","indication":"Iron deficiency in adult patients with heart failure","status":"Concluded with an LOI","cda_amc_project_id":"SR0852-000","inesss_project_id":"","engagement_date":"2025-08-21","close_date":"2025-10-17"},{"pcpa_file_number":"22952","brand_name":"Venclexta","generic_name":"venetoclax","manufacturer_negotiated_with":"AbbVie Corporation","indication":"In combination with Gazyva, for the treatment of patients with previously untreated chronic lymphocytic leukemia","status":"Concluded with an LOI","cda_amc_project_id":"PC0362-000","inesss_project_id":"","engagement_date":"2025-02-10","close_date":"2025-06-17"},{"pcpa_file_number":"22944","brand_name":"Padcev","generic_name":"enfortumab vedotin","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"In combination with pembrolizumab, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC.","status":"Concluded with an LOI","cda_amc_project_id":"PC0353-000","inesss_project_id":"","engagement_date":"2025-02-21","close_date":"2025-06-06"},{"pcpa_file_number":"22941","brand_name":"Fruzaqla","generic_name":"fruquintinib","manufacturer_negotiated_with":"Takeda Canada Inc.","indication":"For the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with or are not considered candidates for available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF agent, an anti-EGFR agent (if RAS wild-type), and either trifluridine-tipiracil or regorafenib.","status":"Concluded with an LOI","cda_amc_project_id":"PC0352-000","inesss_project_id":"","engagement_date":"2025-01-23","close_date":"2025-07-02"},{"pcpa_file_number":"22937","brand_name":"Talvey","generic_name":"talquetamab","manufacturer_negotiated_with":"Janssen Inc.","indication":"For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on or after the last therapy.","status":"Concluded without agreement","cda_amc_project_id":"PC0363-000","inesss_project_id":"","engagement_date":"2026-01-23","close_date":"2026-06-16"},{"pcpa_file_number":"22933","brand_name":"Winlevi","generic_name":"clascoterone","manufacturer_negotiated_with":"Sun Pharma Canada Inc.","indication":"Acne Vulgaris","status":"Negotiations were not pursued","cda_amc_project_id":"SR0863-000","inesss_project_id":"","engagement_date":"","close_date":"2025-07-04"},{"pcpa_file_number":"22926","brand_name":"Ayvakyt","generic_name":"avapritinib","manufacturer_negotiated_with":"Medison Pharma Canada Inc.","indication":"Advanced Systemic Mastocytosis","status":"Concluded with an LOI","cda_amc_project_id":"PC0335-000","inesss_project_id":"","engagement_date":"2024-12-23","close_date":"2025-10-17"},{"pcpa_file_number":"22922","brand_name":"Alecensaro","generic_name":"alectinib","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).","status":"Concluded with an LOI","cda_amc_project_id":"PC0350-000","inesss_project_id":"","engagement_date":"2025-01-14","close_date":"2025-04-28"},{"pcpa_file_number":"22916","brand_name":"Carvykti","generic_name":"ciltacabtagene autoleucel","manufacturer_negotiated_with":"Janssen Inc.","indication":"For the treatment of adult patients with multiple myeloma, who have received 1 to 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.","status":"Concluded without agreement","cda_amc_project_id":"PG0361-000","inesss_project_id":"","engagement_date":"2025-01-23","close_date":"2025-09-18"},{"pcpa_file_number":"22913","brand_name":"Filra","generic_name":"filgrastim","manufacturer_negotiated_with":"Jamp Pharma Corporation","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-03-13","close_date":"2025-06-17"},{"pcpa_file_number":"22911","brand_name":"Winrevair","generic_name":"sotatercept","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Pulmonary Arterial Hypertension (WHO group 1)","status":"Concluded with an LOI","cda_amc_project_id":"SR0828-000","inesss_project_id":"","engagement_date":"2025-04-02","close_date":"2025-11-18"},{"pcpa_file_number":"22906","brand_name":"Wainua","generic_name":"eplontersen","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Polyneuropathy in hereditary transthyretin-mediated amyloidosis","status":"Concluded with an LOI","cda_amc_project_id":"SR0826-000","inesss_project_id":"","engagement_date":"2025-02-18","close_date":"2025-05-07"},{"pcpa_file_number":"22902","brand_name":"Cabtreo","generic_name":"clindamycin plus benzoyl peroxide and adapalene","manufacturer_negotiated_with":"Bausch Health, Canada Inc.","indication":"Acne Vulgaris","status":"Concluded with an LOI","cda_amc_project_id":"SR0794-000","inesss_project_id":"","engagement_date":"2025-02-06","close_date":"2025-04-04"},{"pcpa_file_number":"22899","brand_name":"Voydeya","generic_name":"danicopan","manufacturer_negotiated_with":"Alexion Pharma GmbH","indication":"Paroxysmal nocturnal hemoglobinuria (PNH)","status":"Concluded without agreement","cda_amc_project_id":"SR0815-000","inesss_project_id":"","engagement_date":"2025-05-05","close_date":"2025-08-26"},{"pcpa_file_number":"22896","brand_name":"Trikafta","generic_name":"elexacaftor\/tezacaftor\/ivacaftor and ivacaftor","manufacturer_negotiated_with":"Vertex Pharmaceuticals (Canada) Incorporated","indication":"Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older","status":"Concluded with an LOI","cda_amc_project_id":"SR0837-000","inesss_project_id":"","engagement_date":"2024-11-04","close_date":"2024-11-04"},{"pcpa_file_number":"22892","brand_name":"Omnipod 5","generic_name":"Automated Insulin Delivery System","manufacturer_negotiated_with":"Insulet Canada Corporation","indication":"Patients with Type 1 Diabetes aged 2 years and old","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-08-12","close_date":"2025-12-11"},{"pcpa_file_number":"22889","brand_name":"Libtayo","generic_name":"cemiplimab","manufacturer_negotiated_with":"Regeneron","indication":"Non-small cell lung cancer (NSCLC) expressing PD-L1 in ? 50% of tumour cells (Tumour Proportion Score [TPS] ? 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, first-line treatment of adult patients who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-08-30","close_date":"2025-03-03"},{"pcpa_file_number":"22887","brand_name":"Libtayo","generic_name":"cemiplimab","manufacturer_negotiated_with":"Regeneron","indication":"For the treatment of patients with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-08-30","close_date":"2025-03-03"},{"pcpa_file_number":"22886","brand_name":"Tibsovo","generic_name":"ivosidenib","manufacturer_negotiated_with":"Servier Canada Inc.","indication":"In combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy","status":"Concluded with an LOI","cda_amc_project_id":"PC0349-000","inesss_project_id":"","engagement_date":"2025-01-07","close_date":"2025-05-30"},{"pcpa_file_number":"22882","brand_name":"Tagrisso","generic_name":"osimertinib","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"In combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies), or metastatic NSCLC whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations","status":"Concluded with an LOI","cda_amc_project_id":"PC0336-000","inesss_project_id":"","engagement_date":"2024-12-03","close_date":"2025-01-29"},{"pcpa_file_number":"22879","brand_name":"Verzenio","generic_name":"abemaciclib","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"In combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features","status":"Concluded with an LOI","cda_amc_project_id":"PC0345-000","inesss_project_id":"","engagement_date":"2024-10-25","close_date":"2024-10-25"},{"pcpa_file_number":"22876","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"In combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.","status":"Concluded with an LOI","cda_amc_project_id":"PC0356-000","inesss_project_id":"","engagement_date":"2024-11-15","close_date":"2024-11-15"},{"pcpa_file_number":"22871","brand_name":"Osenvelt","generic_name":"denosumab","manufacturer_negotiated_with":"Celltrion Healthcare Canada Ltd.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-12-02","close_date":"2025-03-10"},{"pcpa_file_number":"22869","brand_name":"Omlyclo","generic_name":"omalizumab","manufacturer_negotiated_with":"Celltrion Healthcare Canada Ltd.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2025-02-11","close_date":"2025-07-14"},{"pcpa_file_number":"22867","brand_name":"Stoboclo","generic_name":"denosumab","manufacturer_negotiated_with":"Celltrion Healthcare Canada Ltd.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-12-02","close_date":"2025-03-10"},{"pcpa_file_number":"22864","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Neoadjuvant-adjuvant treatment of adult patients with stage III or stage IV melanoma","status":"Concluded with an LOI","cda_amc_project_id":"PX0346-000","inesss_project_id":"","engagement_date":"2024-08-19","close_date":"2024-08-19"},{"pcpa_file_number":"22861","brand_name":"Cosentyx","generic_name":"secukinumab","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Hidradenitis Suppurativa","status":"Concluded with an LOI","cda_amc_project_id":"SR0781-000","inesss_project_id":"","engagement_date":"2025-03-07","close_date":"2025-05-01"},{"pcpa_file_number":"22859","brand_name":"Olumiant","generic_name":"baricitinib","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Alopecia areata, severe","status":"Concluded with an LOI","cda_amc_project_id":"SR0843-000","inesss_project_id":"","engagement_date":"2025-05-30","close_date":"2025-11-10"},{"pcpa_file_number":"22856","brand_name":"Adcetris","generic_name":"brentuximab vedotin","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Hodgkin\u0026#039;s Lymphoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0371-000","inesss_project_id":"","engagement_date":"2025-02-12","close_date":"2025-02-12"},{"pcpa_file_number":"22853","brand_name":"Truqap","generic_name":"capivasertib","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Breast cancer, locally advanced or metastatic (HR-positive, HER2-negative)","status":"Concluded with an LOI","cda_amc_project_id":"PC0341-000","inesss_project_id":"","engagement_date":"2024-11-15","close_date":"2025-02-12"},{"pcpa_file_number":"22849","brand_name":"Ixifi","generic_name":"infliximab","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-11-18","close_date":"2025-02-28"},{"pcpa_file_number":"22844","brand_name":"Vectibix","generic_name":"panitumumab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Metastatic Colorectal Cancer (mCRC) patients with left-sided primary tumours that express wild-type RAS (In combination with chemotherapy)","status":"Concluded with an LOI","cda_amc_project_id":"PX0333-000","inesss_project_id":"","engagement_date":"2024-07-22","close_date":"2024-10-16"},{"pcpa_file_number":"22841","brand_name":"Axberi\/Axberi HP","generic_name":"enoxaparin sodium solution for injection","manufacturer_negotiated_with":"Baxter Corporation","indication":"Thrombosis and cardiovascular conditions (prevention or treatment)","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-11-19","close_date":"2025-02-28"},{"pcpa_file_number":"22830","brand_name":"Leqvio","generic_name":"inclisiran","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Primary hypercholesterolemia","status":"Concluded with an LOI","cda_amc_project_id":"SR0791-000","inesss_project_id":"","engagement_date":"2025-04-02","close_date":"2025-08-13"},{"pcpa_file_number":"22827","brand_name":"Vraylar","generic_name":"cariprazine","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Schizophrenia","status":"Concluded with an LOI","cda_amc_project_id":"SR0827-000","inesss_project_id":"","engagement_date":"2024-10-18","close_date":"2024-10-18"},{"pcpa_file_number":"22823","brand_name":"Velsipity","generic_name":"Etrasimod","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Ulcerative Colitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0795-000","inesss_project_id":"","engagement_date":"2024-11-18","close_date":"2025-04-29"},{"pcpa_file_number":"22813","brand_name":"Veklury","generic_name":"remdesivir","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"COVID-19 in hospitalized patients","status":"Concluded with an LOI","cda_amc_project_id":"SR0833-000","inesss_project_id":"","engagement_date":"2025-02-18","close_date":"2025-02-18"},{"pcpa_file_number":"22810","brand_name":"Veklury","generic_name":"remdesivir","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"COVID-19 in non-hospitalized patients","status":"Concluded with an LOI","cda_amc_project_id":"SR0834-000","inesss_project_id":"","engagement_date":"2025-02-18","close_date":"2025-02-18"},{"pcpa_file_number":"22807","brand_name":"Apretude","generic_name":"cabotegravir","manufacturer_negotiated_with":"ViiV Healthcare","indication":"HIV-1 infection, pre-exposure prophylaxis","status":"Concluded with an LOI","cda_amc_project_id":"SR0825-000","inesss_project_id":"","engagement_date":"2024-10-29","close_date":"2025-02-07"},{"pcpa_file_number":"22803","brand_name":"Ebglyss","generic_name":"lebrikizumab","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Atopic dermatitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0819-000","inesss_project_id":"","engagement_date":"2025-04-22","close_date":"2025-08-28"},{"pcpa_file_number":"22796","brand_name":"Opdivo","generic_name":"nivolumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Renal Cell Carcinoma (RCC), advanced (not amenable to curative surgery or radiation therapy) or metastatic, first-line treatment of adult patients (in combination with nivolumab)","status":"Concluded with an LOI","cda_amc_project_id":"PC0312-000","inesss_project_id":"","engagement_date":"2024-07-03","close_date":"2024-07-17"},{"pcpa_file_number":"22788","brand_name":"Teva Naloxone Nasal Spray","generic_name":"naloxone hydrochloride","manufacturer_negotiated_with":"Teva Canada Ltd.","indication":"Opioid overdose, known or suspected, for emergency use","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-06-28","close_date":"2024-10-08"},{"pcpa_file_number":"22781","brand_name":"Crysvita","generic_name":"burosumab","manufacturer_negotiated_with":"Kyowa Kirin Canada, Inc.","indication":"X-Linked Hypophosphatemia","status":"Concluded with an LOI","cda_amc_project_id":"SR0818-000","inesss_project_id":"","engagement_date":"2025-02-21","close_date":"2025-07-21"},{"pcpa_file_number":"22777","brand_name":"Qulipta","generic_name":"atogepant","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Migraine, prevention","status":"Concluded with an LOI","cda_amc_project_id":"SR0817-000","inesss_project_id":"","engagement_date":"2024-08-09","close_date":"2024-09-25"},{"pcpa_file_number":"22766","brand_name":"Tyenne","generic_name":"tocilizumab","manufacturer_negotiated_with":"Fresenius Kabi Canada Ltd.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-10-03","close_date":"2025-03-18"},{"pcpa_file_number":"22762","brand_name":"Maviret","generic_name":"glecaprevir\/pibrentasvir granules","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Chronic Hepatitis C (Pediatric)","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-05-17","close_date":"2024-05-17"},{"pcpa_file_number":"22760","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Gastric or gastroesophageal junction (GEJ) adenocarcinoma in adult patients, locally advanced unresectable or metastatic, HER2-positive, first-line treatment in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, whose tumors express PD-L1 [Combined Positive Score (CPS) ?1] as determined by a validated test","status":"Concluded with an LOI","cda_amc_project_id":"PC0343-000","inesss_project_id":"","engagement_date":"2024-08-19","close_date":"2024-08-19"},{"pcpa_file_number":"22757","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Biliary tract carcinoma (BTC) in adult patients, locally advanced unresectable or metastatic, in combination with chemotherapy","status":"Concluded with an LOI","cda_amc_project_id":"PC0344-000","inesss_project_id":"","engagement_date":"2024-08-19","close_date":"2024-08-19"},{"pcpa_file_number":"22746","brand_name":"Remsima SC","generic_name":"infliximab","manufacturer_negotiated_with":"Celltrion Healthcare Canada Ltd.","indication":"Crohn\u0026#039;s disease","status":"Concluded with an LOI","cda_amc_project_id":"SR0816-000","inesss_project_id":"","engagement_date":"2024-09-06","close_date":"2024-11-26"},{"pcpa_file_number":"22741","brand_name":"Repatha","generic_name":"evolocumab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Atherosclerotic cardiovascular disease","status":"Concluded with an LOI","cda_amc_project_id":"SR0821-000","inesss_project_id":"","engagement_date":"2025-02-07","close_date":"2025-11-18"},{"pcpa_file_number":"22737","brand_name":"Fulphila","generic_name":"pegfilgrastim","manufacturer_negotiated_with":"Biocon Biologics Canada Inc.","indication":"Febrile neutropenia in non-myeloid malignancies","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-11-29","close_date":"2025-02-05"},{"pcpa_file_number":"22735","brand_name":"Pexegra","generic_name":"pegfilgrastim","manufacturer_negotiated_with":"Jamp Pharma Corporation","indication":"Febrile neutropenia in non-myeloid malignancies","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-11-29","close_date":"2025-06-17"},{"pcpa_file_number":"22732","brand_name":"Jamteki","generic_name":"ustekinumab","manufacturer_negotiated_with":"Jamp Pharma Corporation","indication":"Ulcerative Colitis and Crohn\u0026#039;s Disease","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"","close_date":"2025-04-25"},{"pcpa_file_number":"22728","brand_name":"Orgovyx","generic_name":"relugolix","manufacturer_negotiated_with":"Sumitomo Pharma Canada, Inc.","indication":"Advanced prostate cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0342-000","inesss_project_id":"","engagement_date":"2024-08-26","close_date":"2025-02-06"},{"pcpa_file_number":"22724","brand_name":"Elrexfio","generic_name":"elranatamab","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Multiple myeloma, relapsed or refractory, in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy","status":"Concluded without agreement","cda_amc_project_id":"PC0315-000","inesss_project_id":"","engagement_date":"2024-10-08","close_date":"2025-03-27"},{"pcpa_file_number":"22721","brand_name":"Opdivo","generic_name":"nivolumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Stage IIB or IIC melanoma following complete resection, monotherapy for the adjuvant treatment of adult patients","status":"Concluded with an LOI","cda_amc_project_id":"PC0339-000","inesss_project_id":"","engagement_date":"2024-07-03","close_date":"2024-07-17"},{"pcpa_file_number":"22719","brand_name":"Bimzelx","generic_name":"bimekizumab","manufacturer_negotiated_with":"UCB Canada Inc.","indication":"Psoriatic Arthritis","status":"Concluded with an LOI","cda_amc_project_id":"SR0803-000","inesss_project_id":"","engagement_date":"2024-09-20","close_date":"2025-02-15"},{"pcpa_file_number":"22717","brand_name":"Bimzelx","generic_name":"bimekizumab","manufacturer_negotiated_with":"UCB Canada Inc.","indication":"Ankylosing spondylitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0809-000","inesss_project_id":"","engagement_date":"2024-09-20","close_date":"2025-02-15"},{"pcpa_file_number":"22715","brand_name":"Awiqli","generic_name":"insulin icodec","manufacturer_negotiated_with":"Novo Nordisk Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded without agreement","cda_amc_project_id":"SR0790-000","inesss_project_id":"","engagement_date":"2024-09-12","close_date":"2025-06-23"},{"pcpa_file_number":"22708","brand_name":"Epkinly (concluded with pTAP LOI)","generic_name":"epcoritamab","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) Relapsed or refractory , DLBCL transformed from indolent lymphoma, high grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL) or follicular lymphoma Grade 3B (FLG3b), in adult patients, after two or more lines of systemic therapy and who have previously received or are unable to receive CAR-T cell therapy.","status":"Concluded with an LOI","cda_amc_project_id":"PC0334-000","inesss_project_id":"","engagement_date":"2024-04-12","close_date":"2024-07-19"},{"pcpa_file_number":"22700","brand_name":"Tecentriq SC","generic_name":"atezolizumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-08-15","close_date":"2024-11-19"},{"pcpa_file_number":"22696","brand_name":"Jemperli","generic_name":"dostarlimab","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Primary advanced or recurrent mismatch repair deficient (dMMR)\/microsatellite instability-high (MSI-H) endometrial cancer in adult patients who are candidates for systemic therapy (in combination with carboplatin and paclitaxel)","status":"Concluded with an LOI","cda_amc_project_id":"PC0325-000","inesss_project_id":"","engagement_date":"2024-07-11","close_date":"2024-10-11"},{"pcpa_file_number":"22694","brand_name":"Libtayo","generic_name":"cemiplimab","manufacturer_negotiated_with":"Regeneron","indication":"in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) whose tumors have no epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or c-ROS oncogene 1 (ROS1) aberrations and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC","status":"Concluded with an LOI","cda_amc_project_id":"PC0331-000","inesss_project_id":"","engagement_date":"2024-08-30","close_date":"2025-03-03"},{"pcpa_file_number":"22686","brand_name":"Abevmy","generic_name":"bevacizumab","manufacturer_negotiated_with":"Biocon Biologics Canada Inc.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"","close_date":"2024-06-20"},{"pcpa_file_number":"22684","brand_name":"Pyzchiva","generic_name":"ustekinumab","manufacturer_negotiated_with":"Sandoz Canada Inc.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-04-12","close_date":"2024-06-19"},{"pcpa_file_number":"22681","brand_name":"Wyost","generic_name":"denosumab 120 mg\/1.7 mL","manufacturer_negotiated_with":"Sandoz Canada Inc.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-04-12","close_date":"2024-05-24"},{"pcpa_file_number":"22678","brand_name":"Epidiolex","generic_name":"cannabidiol","manufacturer_negotiated_with":"Jazz Pharmaceuticals Canada Inc.","indication":"Seizures associated with Tuberous Sclerosis Complex (TSC)","status":"Concluded with an LOI","cda_amc_project_id":"SR0798-000","inesss_project_id":"","engagement_date":"2024-08-16","close_date":"2025-03-12"},{"pcpa_file_number":"22676","brand_name":"Epidiolex","generic_name":"cannabidiol","manufacturer_negotiated_with":"Jazz Pharmaceuticals Canada Inc.","indication":"Dravet Syndrome (DS)","status":"Concluded with an LOI","cda_amc_project_id":"SR0799-000","inesss_project_id":"","engagement_date":"2024-08-16","close_date":"2025-03-12"},{"pcpa_file_number":"22674","brand_name":"Leqvio","generic_name":"inclisiran","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Primary hypercholesterolemia (non-familial and heterozygous familial) with atherosclerotic cardiovascular disease","status":"Negotiations were not pursued","cda_amc_project_id":"SR0791-001","inesss_project_id":"","engagement_date":"","close_date":"2024-08-14"},{"pcpa_file_number":"22670","brand_name":"Epidiolex","generic_name":"cannabidiol","manufacturer_negotiated_with":"Jazz Pharmaceuticals Canada Inc.","indication":"Lennox-Gastaut Syndrome (LGS)","status":"Concluded with an LOI","cda_amc_project_id":"SR0800-000","inesss_project_id":"","engagement_date":"2024-08-16","close_date":"2025-03-12"},{"pcpa_file_number":"22667","brand_name":"Remsima SC","generic_name":"infliximab","manufacturer_negotiated_with":"Celltrion Healthcare Canada Ltd.","indication":"Ulcerative Colitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0816-001","inesss_project_id":"","engagement_date":"2024-09-06","close_date":"2024-11-26"},{"pcpa_file_number":"22663","brand_name":"Hemgenix","generic_name":"etranacogene dezaparvovec","manufacturer_negotiated_with":"CSL Behring Canada Inc.","indication":"Hemophilia B","status":"Concluded with an LOI","cda_amc_project_id":"SG0805-000","inesss_project_id":"","engagement_date":"2024-08-09","close_date":"2025-09-22"},{"pcpa_file_number":"22654","brand_name":"Tecvayli","generic_name":"teclistamab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Multiple myeloma, relapsed or refractory, in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy","status":"Concluded with an LOI","cda_amc_project_id":"PC0332-000","inesss_project_id":"","engagement_date":"2024-10-08","close_date":"2025-04-10"},{"pcpa_file_number":"22645","brand_name":"SIR-Spheres Y-90 resin microspheres","generic_name":"Yttrium-90 microspheres","manufacturer_negotiated_with":"Sirtex Medical","indication":"Hepatocellular carcinoma (HCC)","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-02-20","close_date":"2024-08-14"},{"pcpa_file_number":"22641","brand_name":"TheraSphere Y-90 Glass Micropheres","generic_name":"Yttrium-90 microspheres","manufacturer_negotiated_with":"Boston Scientific Corporation","indication":"Hepatocellular carcinoma (HCC)","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-02-20","close_date":"2024-07-11"},{"pcpa_file_number":"22637","brand_name":"Eylea HD","generic_name":"aflibercept 8mg\/0.07mL","manufacturer_negotiated_with":"Bayer Inc.","indication":"Age-Related Macular Degeneration","status":"Concluded with an LOI","cda_amc_project_id":"SR0812-000","inesss_project_id":"","engagement_date":"2024-08-08","close_date":"2024-10-31"},{"pcpa_file_number":"22635","brand_name":"Eylea HD","generic_name":"aflibercept 8mg\/0.07mL","manufacturer_negotiated_with":"Bayer Inc.","indication":"Diabetic Macular Edema","status":"Concluded with an LOI","cda_amc_project_id":"SR0813-000","inesss_project_id":"","engagement_date":"2024-08-08","close_date":"2024-10-31"},{"pcpa_file_number":"22632","brand_name":"Uplizna","generic_name":"inebilizumab","manufacturer_negotiated_with":"Horizon Therapeutics Canada","indication":"Neuromyelitis optica spectrum disorder (NMOSD)","status":"Concluded with an LOI","cda_amc_project_id":"SR0793-000","inesss_project_id":"","engagement_date":"2024-08-09","close_date":"2025-05-12"},{"pcpa_file_number":"22628","brand_name":"Slynd","generic_name":"drospirenone","manufacturer_negotiated_with":"Duchesnay Inc.","indication":"Contraceptive, oral","status":"Concluded with an LOI","cda_amc_project_id":"SR0806-000","inesss_project_id":"","engagement_date":"2024-08-20","close_date":"2024-09-11"},{"pcpa_file_number":"22625","brand_name":"Ultomiris","generic_name":"ravulizumab","manufacturer_negotiated_with":"Alexion Pharma GmbH","indication":"Neuromyelitis optica spectrum disorder (NMOSD)","status":"Concluded with an LOI","cda_amc_project_id":"SR0785-000","inesss_project_id":"","engagement_date":"2024-08-09","close_date":"2025-07-03"},{"pcpa_file_number":"22621","brand_name":"Steqeyma","generic_name":"ustekinumab","manufacturer_negotiated_with":"Celltrion Healthcare Canada Ltd.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-03-27","close_date":"2024-06-20"},{"pcpa_file_number":"22618","brand_name":"Veklury","generic_name":"remdesivir","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"COVID-19","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"","close_date":"2024-05-10"},{"pcpa_file_number":"22614","brand_name":"Lonsurf","generic_name":"trifluridine\/tipiracil","manufacturer_negotiated_with":"Taiho Pharma Canada Inc.","indication":"Metastatic colorectal cancer in adult patients who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents. ( in combination with bevacizumab)","status":"Concluded with an LOI","cda_amc_project_id":"PC0330-000","inesss_project_id":"","engagement_date":"2024-06-04","close_date":"2024-07-29"},{"pcpa_file_number":"22611","brand_name":"Myalepta","generic_name":"metreleptin","manufacturer_negotiated_with":"Medison Pharma Canada Inc.","indication":"Leptin deficiency in lipodystrophy","status":"Concluded with an LOI","cda_amc_project_id":"SR0784-000","inesss_project_id":"","engagement_date":"2024-10-25","close_date":"2025-06-10"},{"pcpa_file_number":"22608","brand_name":"Trecondyv","generic_name":"treosulfan","manufacturer_negotiated_with":"Medexus Pharmaceuticals, Inc.","indication":"As part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult patients with AML or MDS at increased risk for standard conditioning therapies (In combination with fludarabine)","status":"Concluded with an LOI","cda_amc_project_id":"PC0324-000","inesss_project_id":"","engagement_date":"2024-07-30","close_date":"2024-11-04"},{"pcpa_file_number":"22603","brand_name":"Suboxone (film)","generic_name":"buprenorphine and naloxone","manufacturer_negotiated_with":"Indivior UK Limited","indication":"Opioid Dependence","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"","close_date":"2024-04-23"},{"pcpa_file_number":"22602","brand_name":"Beqvez","generic_name":"fidanacogene elaparvovec","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Hemophilia B (congenital Factor IX deficiency) in adults (aged 18 years or older), moderately severe to severe, who are negative for neutralizing antibodies to variant AAV serotype Rh74","status":"Concluded without agreement","cda_amc_project_id":"SG0802-000","inesss_project_id":"","engagement_date":"2024-08-09","close_date":"2025-04-04"},{"pcpa_file_number":"22595","brand_name":"Rezurock","generic_name":"belumosudil","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Chronic graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older, after failure of at least two prior lines of systemic therapy.","status":"Concluded with an LOI","cda_amc_project_id":"SR0789-000","inesss_project_id":"","engagement_date":"2024-07-03","close_date":"2025-10-07"},{"pcpa_file_number":"22592","brand_name":"Paxlovid","generic_name":"nirmatrelvir\/ritonavir","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Mild-to-moderate COVID-19, treatment","status":"Concluded with an LOI","cda_amc_project_id":"SR0808-000","inesss_project_id":"","engagement_date":"2024-01-25","close_date":"2024-05-06"},{"pcpa_file_number":"22587","brand_name":"Columvi","generic_name":"glofitamab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), relapsed or refractory, DLBCL arising from follicular lymphoma (trFL), or primary mediastinal B-cell lymphoma (PMBCL), who have received two or more lines of systemic therapy and are ineligible to receive or cannot receive CAR-T cell therapy or have previously received CAR-T cell therapy, in adult patients","status":"Concluded with an LOI","cda_amc_project_id":"PC0320-000","inesss_project_id":"","engagement_date":"2024-04-03","close_date":"2024-07-22"},{"pcpa_file_number":"22584","brand_name":"Polivy","generic_name":"Polatuzumab Vedotin","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T-cell\/histiocyte rich LBCL, previously untreated in adult patients. (in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP))","status":"Concluded with an LOI","cda_amc_project_id":"PC0313-000","inesss_project_id":"","engagement_date":"2024-07-26","close_date":"2025-01-10"},{"pcpa_file_number":"22581","brand_name":"Opdualag","generic_name":"nivolumab and relatlimab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Unresectable or metastatic melanoma in adult and pediatric patients 12 years of age or older who have not received prior systemic therapy for unresectable or metastatic melanoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0329-000","inesss_project_id":"","engagement_date":"2024-06-21","close_date":"2024-08-08"},{"pcpa_file_number":"22577","brand_name":"Trodelvy","generic_name":"sacituzumab govitecan","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"Breast cancer, unresectable locally advanced or metastatic, HR-positive, HER2-negative (IHC 0, IHC 1+, or IHC 2+\/ISH-) in adult patients who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting","status":"Concluded with an LOI","cda_amc_project_id":"PC0323-000","inesss_project_id":"","engagement_date":"2024-06-19","close_date":"2025-04-14"},{"pcpa_file_number":"22575","brand_name":"Lynparza","generic_name":"olaparib","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Metastatic castration-resistant prostate cancer (mCRPC) in adult patients (in combination with abiraterone and prednisone or prednisolone)","status":"Concluded with an LOI","cda_amc_project_id":"PC0319-000","inesss_project_id":"","engagement_date":"2024-03-12","close_date":"2024-05-08"},{"pcpa_file_number":"22571","brand_name":"Akeega","generic_name":"niraparib abiraterone acetate","manufacturer_negotiated_with":"Janssen Inc.","indication":"Deleterious or suspected deleterious BRCA mutated (germline and\/or somatic) metastatic castration resistant prostate cancer (mCRPC) in adult patients who are asymptomatic\/mildly symptomatic, and in whom chemotherapy is not clinically indicated. (in combination with prednisone or prednisolone)","status":"Concluded with an LOI","cda_amc_project_id":"PC0326-000","inesss_project_id":"","engagement_date":"2024-07-09","close_date":"2024-10-31"},{"pcpa_file_number":"22562","brand_name":"Amvuttra","generic_name":"vutrisiran","manufacturer_negotiated_with":"Alnylam Netherlands B.V.","indication":"Hereditary transthyretin-mediated amyloidosis","status":"Concluded with an LOI","cda_amc_project_id":"SR0801-000","inesss_project_id":"","engagement_date":"2024-07-05","close_date":"2024-10-15"},{"pcpa_file_number":"22550","brand_name":"Bylvay","generic_name":"odevixibat","manufacturer_negotiated_with":"Medison Pharma Canada Inc.","indication":"Pruritus in patients aged 6 months or older with progressive familial intrahepatic cholestasis (PFIC).","status":"Concluded with an LOI","cda_amc_project_id":"SR0788-000","inesss_project_id":"","engagement_date":"2024-08-20","close_date":"2025-08-06"},{"pcpa_file_number":"22544","brand_name":"Rinvoq","generic_name":"upadacitinib","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Crohn\u0026#039;s disease","status":"Concluded with an LOI","cda_amc_project_id":"SR0775-000","inesss_project_id":"","engagement_date":"2024-01-31","close_date":"2024-04-26"},{"pcpa_file_number":"22543","brand_name":"Doptelet","generic_name":"avatrombopag","manufacturer_negotiated_with":"Sobi Canada Inc.","indication":"Chronic Immune Thrombocytopenia","status":"Negotiations were not pursued","cda_amc_project_id":"SR0721-000","inesss_project_id":"","engagement_date":"","close_date":"2024-10-03"},{"pcpa_file_number":"22541","brand_name":"Imbruvica","generic_name":"ibrutinib","manufacturer_negotiated_with":"Janssen Inc.","indication":"Waldenstr\ufffdm\u0026#039;s Macroglobulinemia","status":"Concluded with an LOI","cda_amc_project_id":"PC0328-000","inesss_project_id":"","engagement_date":"2024-10-03","close_date":"2025-01-17"},{"pcpa_file_number":"22540","brand_name":"Asparlas","generic_name":"calaspargase pegol","manufacturer_negotiated_with":"Servier Canada Inc.","indication":"Acute Lymphoblastic Leukemia (ALL)","status":"Concluded with an LOI","cda_amc_project_id":"PC0321-000","inesss_project_id":"","engagement_date":"2024-03-22","close_date":"2024-06-21"},{"pcpa_file_number":"22535","brand_name":"Nucala","generic_name":"mepolizumab","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Severe eosinophilic asthma, add-on maintenance treatment of  in children (aged 6 years and older)","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-04-18","close_date":"2024-04-18"},{"pcpa_file_number":"22533","brand_name":"Pemazyre","generic_name":"pemigatinib","manufacturer_negotiated_with":"Incyte Biosciences Canada Corporation","indication":"Unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement and a ECOG performance status of 0 to 2, Previously treated, in adults","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-03-07","close_date":"2024-12-20"},{"pcpa_file_number":"22531","brand_name":"Adtralza","generic_name":"tralokinumab","manufacturer_negotiated_with":"LEO Pharma Inc.","indication":"Atopic dermatitis","status":"Negotiations were not pursued","cda_amc_project_id":"SR0787-000","inesss_project_id":"","engagement_date":"","close_date":"2024-07-02"},{"pcpa_file_number":"22530","brand_name":"Vyvgart","generic_name":"efgartigimod alfa","manufacturer_negotiated_with":"Argenx Canada Inc.","indication":"Generalized myasthenia gravis (gMG)","status":"Concluded with an LOI","cda_amc_project_id":"SR0782-000","inesss_project_id":"","engagement_date":"2024-05-27","close_date":"2024-12-13"},{"pcpa_file_number":"22526","brand_name":"Rybelsus","generic_name":"semaglutide","manufacturer_negotiated_with":"Novo Nordisk Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2023-11-07","close_date":"2023-12-17"},{"pcpa_file_number":"22524","brand_name":"Repatha","generic_name":"evolocumab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Primary hyperlipidemia and mixed dyslipidemia","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2023-11-01","close_date":"2024-06-03"},{"pcpa_file_number":"22517","brand_name":"Ozempic","generic_name":"semaglutide","manufacturer_negotiated_with":"Novo Nordisk Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2023-10-30","close_date":"2023-12-17"},{"pcpa_file_number":"22515","brand_name":"Atriance","generic_name":"nelarabine","manufacturer_negotiated_with":"Sandoz Canada Inc.","indication":"Intermediate- or high-risk T-cell acute lymphoblastic leukemia (T-ALL), addition to front-line multi-agent therapy of pediatric, adolescent, and young adult (AYA) patients (aged 1 year to 30 years at diagnosis)","status":"Negotiations were not pursued","cda_amc_project_id":"PC0307-000","inesss_project_id":"","engagement_date":"","close_date":"2023-12-04"},{"pcpa_file_number":"22511","brand_name":"Octasa","generic_name":"mesalamine DR","manufacturer_negotiated_with":"Pendopharm, a division of Pharmascience Inc.","indication":"Ulcerative Colitis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2023-10-25","close_date":"2024-03-20"},{"pcpa_file_number":"22506","brand_name":"Livmarli","generic_name":"maralixibat","manufacturer_negotiated_with":"Mirum Pharmaceuticals Inc.","indication":"Alagille syndrome","status":"Concluded with an LOI","cda_amc_project_id":"SR0780-000","inesss_project_id":"","engagement_date":"2024-08-20","close_date":"2025-06-10"},{"pcpa_file_number":"22502","brand_name":"Sogroya","generic_name":"somapacitan","manufacturer_negotiated_with":"Novo Nordisk Canada Inc.","indication":"Growth hormone deficiency","status":"Negotiations were not pursued","cda_amc_project_id":"SR0779-000","inesss_project_id":"","engagement_date":"","close_date":"2024-09-26"},{"pcpa_file_number":"22500","brand_name":"Evkeeza","generic_name":"evinacumab","manufacturer_negotiated_with":"Ultragenyx Pharmaceutical Inc.","indication":"Homozygous Familial Hypercholesterolemia","status":"Concluded with an LOI","cda_amc_project_id":"SR0778-000","inesss_project_id":"","engagement_date":"2024-09-04","close_date":"2025-07-08"},{"pcpa_file_number":"22496","brand_name":"Dupixent","generic_name":"dupilumab","manufacturer_negotiated_with":"Sanofi Genzyme Canada","indication":"Atopic dermatitis, pediatrics","status":"Active negotiation","cda_amc_project_id":"SR0774-000","inesss_project_id":"","engagement_date":"2024-10-09","close_date":""},{"pcpa_file_number":"22494","brand_name":"Yescarta","generic_name":"axicabtagene ciloleucel","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"Follicular lymphoma (FL), Relapsed or refractory, grade 1, 2 or 3a, in adult patients after two or more lines of systemic therapy","status":"Concluded with an LOI","cda_amc_project_id":"PG0314-000","inesss_project_id":"","engagement_date":"2024-02-14","close_date":"2024-09-06"},{"pcpa_file_number":"22493","brand_name":"Imfinzi and Imjudo","generic_name":"durvalumab and tremelimumab","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Unresectable hepatocellular carcinoma (uHCC) in adult patients who require systemic therapy, first-line treatment","status":"Concluded with an LOI","cda_amc_project_id":"PC0308-000","inesss_project_id":"","engagement_date":"2023-12-08","close_date":"2024-02-28"},{"pcpa_file_number":"22491","brand_name":"Cabometyx","generic_name":"cabozantinib","manufacturer_negotiated_with":"Ipsen Biopharmaceuticals Canada, Inc.","indication":"Renal Cell Carcinoma (RCC), advanced (not amenable to curative surgery or radiation therapy) or metastatic, first-line treatment of adult patients (in combination with nivolumab)","status":"Concluded with an LOI","cda_amc_project_id":"PC0312-000","inesss_project_id":"","engagement_date":"2024-04-03","close_date":"2024-07-31"},{"pcpa_file_number":"22489","brand_name":"Imbruvica","generic_name":"ibrutinib","manufacturer_negotiated_with":"Janssen Inc.","indication":"In combination with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL), including those with 17p deletion.","status":"Concluded with an LOI","cda_amc_project_id":"PC0317-000","inesss_project_id":"","engagement_date":"2024-10-03","close_date":"2025-01-17"},{"pcpa_file_number":"22488","brand_name":"Lumakras","generic_name":"sotorasib","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Advanced non-small cell lung cancer, KRAS G12C-mutated","status":"Negotiations were not pursued","cda_amc_project_id":"PC0300-000","inesss_project_id":"","engagement_date":"2025-07-11","close_date":"2025-12-03"},{"pcpa_file_number":"22485","brand_name":"Imcivree","generic_name":"setmelanotide","manufacturer_negotiated_with":"Rhythm Pharmaceuticals, Inc.","indication":"Bardet-Biedl syndrome","status":"Concluded with an LOI","cda_amc_project_id":"SR0769-000","inesss_project_id":"","engagement_date":"2024-08-06","close_date":"2025-05-29"},{"pcpa_file_number":"22481","brand_name":"Omvoh","generic_name":"mirikizumab","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Ulcerative Colitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0773-000","inesss_project_id":"","engagement_date":"2024-03-15","close_date":"2024-08-29"},{"pcpa_file_number":"22479","brand_name":"Trikafta","generic_name":"elexacaftor\/tezacaftor\/ivacaftor and ivacaftor","manufacturer_negotiated_with":"Vertex Pharmaceuticals (Canada) Incorporated","indication":"Cystic fibrosis, F508del CFTR mutation, 2 years and older","status":"Concluded with an LOI","cda_amc_project_id":"SR0776-000","inesss_project_id":"","engagement_date":"2023-12-12","close_date":"2023-12-12"},{"pcpa_file_number":"22477","brand_name":"Cablivi","generic_name":"caplacizumab","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Acquired Thrombotic Thrombocytopenic Purpura (aTTP)","status":"Negotiations were not pursued","cda_amc_project_id":"SR0736-000","inesss_project_id":"","engagement_date":"","close_date":"2023-10-06"},{"pcpa_file_number":"22472","brand_name":"Onivyde","generic_name":"irinotecan liposome","manufacturer_negotiated_with":"Ipsen Biopharmaceuticals Canada, Inc.","indication":"Metastatic Pancreatic Cancer","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-03-07","close_date":"2024-05-16"},{"pcpa_file_number":"22470","brand_name":"Kymriah","generic_name":"tisagenlecleucel","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Follicular lymphoma (FL), Relapsed or refractory, grade 1, 2 or 3a, in adult patients after two or more lines of systemic therapy","status":"Concluded with an LOI","cda_amc_project_id":"PG0306-000","inesss_project_id":"","engagement_date":"2024-12-04","close_date":"2025-06-12"},{"pcpa_file_number":"22466","brand_name":"Xcopri","generic_name":"cenobamate","manufacturer_negotiated_with":"Paladin Labs Inc.","indication":"Epilepsy, partial-onset seizures","status":"Concluded without agreement","cda_amc_project_id":"SR0770-000","inesss_project_id":"","engagement_date":"2023-12-22","close_date":"2024-10-04"},{"pcpa_file_number":"22462","brand_name":"Rinvoq","generic_name":"upadacitinib","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Ulcerative Colitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0730-000","inesss_project_id":"","engagement_date":"2024-01-31","close_date":"2024-04-26"},{"pcpa_file_number":"22458","brand_name":"Brukinsa","generic_name":"zanubrutinib","manufacturer_negotiated_with":"BeiGene, Ltd.","indication":"Chronic lymphocytic leukemia (CLL) in adult patients","status":"Concluded with an LOI","cda_amc_project_id":"PC0310-000","inesss_project_id":"","engagement_date":"2023-11-02","close_date":"2023-11-02"},{"pcpa_file_number":"22455","brand_name":"Welireg","generic_name":"belzutifan","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Von Hippel-Lindau (VHL) disease in adult patients who require therapy for associated non-metastatic renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or non-metastatic pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.","status":"Concluded with an LOI","cda_amc_project_id":"PC0309-000","inesss_project_id":"","engagement_date":"2023-12-07","close_date":"2024-08-30"},{"pcpa_file_number":"22447","brand_name":"Jubbonti","generic_name":"denosumab 60 mg\/mL","manufacturer_negotiated_with":"Sandoz Canada Inc.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2024-04-12","close_date":"2024-05-24"},{"pcpa_file_number":"22444","brand_name":"Mezera","generic_name":"mesalazine","manufacturer_negotiated_with":"AVIR Pharma Inc.","indication":"Ulcerative Colitis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2023-09-08","close_date":"2023-12-17"},{"pcpa_file_number":"22442","brand_name":"Zoryve","generic_name":"roflumilast","manufacturer_negotiated_with":"Arcutis Biotherapeutics, Inc.","indication":"Plaque psoriasis","status":"Concluded without agreement","cda_amc_project_id":"SR0771-000","inesss_project_id":"","engagement_date":"2024-02-13","close_date":"2024-06-14"},{"pcpa_file_number":"22437","brand_name":"Tavneos","generic_name":"avacopan","manufacturer_negotiated_with":"Otsuka Canada Pharmaceutical Inc.","indication":"Antineutrophil cytoplasmic antibody-associated vasculitis","status":"Concluded without agreement","cda_amc_project_id":"SR0732-000","inesss_project_id":"","engagement_date":"2024-10-29","close_date":"2025-02-03"},{"pcpa_file_number":"22432","brand_name":"Sotyktu","generic_name":"deucravacitinib","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Psoriasis, moderate to severe plaque","status":"Concluded with an LOI","cda_amc_project_id":"SR0756-000","inesss_project_id":"","engagement_date":"2024-05-17","close_date":"2024-07-17"},{"pcpa_file_number":"22427","brand_name":"Ultomiris","generic_name":"ravulizumab","manufacturer_negotiated_with":"Alexion Pharma GmbH","indication":"Generalized Myasthenia Gravis, AChR antibody-positive","status":"Negotiations were not pursued","cda_amc_project_id":"SR0765-000","inesss_project_id":"","engagement_date":"","close_date":"2024-02-27"},{"pcpa_file_number":"22424","brand_name":"Tremfya","generic_name":"guselkumab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Psoriasis, moderate to severe plaque","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2023-08-21","close_date":"2023-08-21"},{"pcpa_file_number":"22422","brand_name":"Korsuva","generic_name":"difelikefalin","manufacturer_negotiated_with":"Otsuka Canada Pharmaceutical Inc.","indication":"Moderate to severe pruritus associated with chronic kidney disease in adult patients on hemodialysis","status":"Negotiations were not pursued","cda_amc_project_id":"SR0752-000","inesss_project_id":"","engagement_date":"","close_date":"2024-04-23"},{"pcpa_file_number":"22413","brand_name":"Wezlana","generic_name":"ustekinumab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2023-10-27","close_date":"2024-01-25"},{"pcpa_file_number":"22410","brand_name":"Enhertu","generic_name":"trastuzumab deruxtecan","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Breast cancer, monotherapy for the treatment of adult patients, unresectable or metastatic HER2-low (IHC 1+ or IHC 2+\/ISH-)","status":"Concluded with an LOI","cda_amc_project_id":"PC0305-000","inesss_project_id":"","engagement_date":"2023-09-20","close_date":"2024-02-02"},{"pcpa_file_number":"22403","brand_name":"Vyalev","generic_name":"foslevodopa foscarbidopa","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Motor fluctuations in patients with advanced levodopa-responsive Parkinson\u0026#039;s disease.","status":"Concluded with an LOI","cda_amc_project_id":"SR0768-000","inesss_project_id":"","engagement_date":"2024-02-22","close_date":"2024-04-26"},{"pcpa_file_number":"22399","brand_name":"Verquvo","generic_name":"vericiguat","manufacturer_negotiated_with":"Bayer Inc.","indication":"Symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent heart failure decompensation event requiring hospitalization and\/or intravenous diuretic therapy","status":"Concluded with an LOI","cda_amc_project_id":"SR0758-000","inesss_project_id":"","engagement_date":"2023-12-18","close_date":"2024-06-28"},{"pcpa_file_number":"22394","brand_name":"Qulipta","generic_name":"atogepant","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Episodic migraine in adults (prevention)","status":"Concluded with an LOI","cda_amc_project_id":"SR0724-000","inesss_project_id":"","engagement_date":"2023-08-16","close_date":"2023-10-12"},{"pcpa_file_number":"22384","brand_name":"Sohonos","generic_name":"palovarotene","manufacturer_negotiated_with":"Ipsen Biopharmaceuticals Canada, Inc.","indication":"Fibrodysplasia Ossificans Progressiva","status":"Concluded with an LOI","cda_amc_project_id":"SR0761-000","inesss_project_id":"","engagement_date":"2023-12-20","close_date":"2025-01-27"},{"pcpa_file_number":"22379","brand_name":"Rinvoq","generic_name":"upadacitinib","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Ankylosing spondylitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0759-000","inesss_project_id":"","engagement_date":"2024-01-31","close_date":"2024-04-26"},{"pcpa_file_number":"22375","brand_name":"Koselugo","generic_name":"selumetinib","manufacturer_negotiated_with":"Alexion Pharma GmbH","indication":"Neurofibromatosis type 1 in pediatric patients aged 2 years and above, who have symptomatic, inoperable plexiform neurofibromas","status":"Concluded with an LOI","cda_amc_project_id":"SR0764-000","inesss_project_id":"","engagement_date":"2024-03-12","close_date":"2024-11-19"},{"pcpa_file_number":"22371","brand_name":"Rukobia","generic_name":"fostemsavir","manufacturer_negotiated_with":"ViiV Healthcare","indication":"HIV-1 infection, in combination with other antiretroviral agents, in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen due to resistance, intolerance or safety considerations","status":"Concluded without agreement","cda_amc_project_id":"SR0760-000","inesss_project_id":"","engagement_date":"2024-02-13","close_date":"2024-05-22"},{"pcpa_file_number":"22367","brand_name":"Skyrizi","generic_name":"risankizumab","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Moderately to severely active Crohn\u0026#039;s disease in adults","status":"Concluded with an LOI","cda_amc_project_id":"SR0767-000","inesss_project_id":"","engagement_date":"2023-09-26","close_date":"2024-01-24"},{"pcpa_file_number":"22363","brand_name":"Carvykti","generic_name":"ciltacabtagene autoleucel","manufacturer_negotiated_with":"Janssen Inc.","indication":"Multiple myeloma (MM) in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, and who are refractory to their last treatment.","status":"Concluded without agreement","cda_amc_project_id":"PG0302-000","inesss_project_id":"","engagement_date":"2023-11-10","close_date":"2025-09-18"},{"pcpa_file_number":"22359","brand_name":"Jamteki","generic_name":"ustekinumab","manufacturer_negotiated_with":"Jamp Pharma Corporation","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2023-10-27","close_date":"2024-02-09"},{"pcpa_file_number":"22356","brand_name":"Rylaze","generic_name":"crisantaspase recombinant","manufacturer_negotiated_with":"Jazz Pharmaceuticals Canada Inc.","indication":"Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 year or older who have developed hypersensitivity to E. coli-derived asparaginase.","status":"Concluded with an LOI","cda_amc_project_id":"PC0301-000","inesss_project_id":"","engagement_date":"2023-06-02","close_date":"2023-07-04"},{"pcpa_file_number":"22352","brand_name":"Lapelga","generic_name":"pegfilgrastim","manufacturer_negotiated_with":"Apobiologix, a Division of Apotex Inc.","indication":"To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drug.","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2023-05-19","close_date":"2023-08-03"},{"pcpa_file_number":"22347","brand_name":"Trurapi","generic_name":"insulin aspart","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Diabetes mellitus in patients who require insulin for the control of hyperglycemia (normally to be used in regimens together with an intermediate or long-acting insulin), or continuous subcutaneous insulin infusion (CSII) in pump systems which are licensed in Canada for Trurapi insulin infusion","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2023-05-19","close_date":"2023-10-10"},{"pcpa_file_number":"22344","brand_name":"Camzyos","generic_name":"mavacamten","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) Class II-III in adult patients.","status":"Concluded with an LOI","cda_amc_project_id":"SR0755-000","inesss_project_id":"","engagement_date":"2024-01-15","close_date":"2024-06-20"},{"pcpa_file_number":"22340","brand_name":"Tecartus","generic_name":"brexucabtagene autoleucel","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"Acute lymphoblastic leukemia (ALL), B-cell precursor, in adult patients, relapsed or refractory","status":"Concluded with an LOI","cda_amc_project_id":"PG0304-000","inesss_project_id":"","engagement_date":"2023-05-19","close_date":"2023-10-27"},{"pcpa_file_number":"22337","brand_name":"Opdivo","generic_name":"nivolumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Resectable Non-small cell lung cancer (tumours ?4cm or node positive), neoadjuvant treatment of adult patients, when used in combination with platinum-doublet chemotherapy","status":"Concluded with an LOI","cda_amc_project_id":"PC0303-000","inesss_project_id":"","engagement_date":"2023-05-10","close_date":"2023-05-25"},{"pcpa_file_number":"22333","brand_name":"Empaveli","generic_name":"pegcetacoplan","manufacturer_negotiated_with":"Sobi Canada Inc.","indication":"Paroxysmal nocturnal hemoglobinuria (PNH) in adult patients who have an inadequate response to, or are intolerant of, a C5 inhibitor","status":"Concluded with an LOI","cda_amc_project_id":"SR0748-000","inesss_project_id":"","engagement_date":"2023-09-08","close_date":"2024-01-17"},{"pcpa_file_number":"22329","brand_name":"Ranopto","generic_name":"ranibizumab","manufacturer_negotiated_with":"Teva Canada Ltd.","indication":"Neovascular (wet) age-related macular degeneration (AMD), or visual impairment due to diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO), choroidal neovascularisation (CNV) secondary to pathologic myopia (PM), choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, post-inflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2023-05-03","close_date":"2023-07-07"},{"pcpa_file_number":"22323","brand_name":"Kerendia","generic_name":"finerenone","manufacturer_negotiated_with":"Bayer Inc.","indication":"Adjunct to standard of care therapy for chronic kidney disease and type 2 diabetes","status":"Concluded with an LOI","cda_amc_project_id":"SR0737-000","inesss_project_id":"","engagement_date":"2023-08-15","close_date":"2023-11-16"},{"pcpa_file_number":"22319","brand_name":"Lynparza","generic_name":"olaparib","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer,  for adjuvant treatment of adult patients who have been treated with neoadjuvant or adjuvant chemotherapy","status":"Concluded with an LOI","cda_amc_project_id":"PC0299-000","inesss_project_id":"","engagement_date":"2023-04-19","close_date":"2023-06-06"},{"pcpa_file_number":"22315","brand_name":"Pluvicto","generic_name":"lutetium vipivotide tetraxetan","manufacturer_negotiated_with":"Advanced Accelerator Applications","indication":"Prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) in adult patients who have received at least one androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy.","status":"Concluded with an LOI","cda_amc_project_id":"PC0297-000","inesss_project_id":"","engagement_date":"2023-08-29","close_date":"2024-12-12"},{"pcpa_file_number":"22311","brand_name":"Rybrevant","generic_name":"amivantamab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Non-small cell lung cancer (NSCLC), Locally advanced or metastatic, in adult patients with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy","status":"Concluded without agreement","cda_amc_project_id":"PC0289-000","inesss_project_id":"","engagement_date":"2023-06-01","close_date":"2023-11-03"},{"pcpa_file_number":"22307","brand_name":"Ultomiris","generic_name":"ravulizumab","manufacturer_negotiated_with":"Alexion Pharma GmbH","indication":"Atypical hemolytic uremic syndrome","status":"Concluded with an LOI","cda_amc_project_id":"SR0740-000","inesss_project_id":"","engagement_date":"2023-05-18","close_date":"2023-10-12"},{"pcpa_file_number":"22304","brand_name":"Lorbrena","generic_name":"lorlatinib","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic, monotherapy for first-line treatment of adult patients","status":"Concluded with an LOI","cda_amc_project_id":"PC0249-000","inesss_project_id":"","engagement_date":"2023-03-20","close_date":"2023-05-19"},{"pcpa_file_number":"22300","brand_name":"Orladeyo","generic_name":"berotralstat","manufacturer_negotiated_with":"BioCryst Pharmaceuticals Inc.","indication":"Hereditary Angioedema","status":"Concluded with an LOI","cda_amc_project_id":"SR0723-000","inesss_project_id":"","engagement_date":"2024-01-31","close_date":"2024-09-12"},{"pcpa_file_number":"22294","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer in adult patients, whose tumours have progressed following prior therapy and who have no satisfactory alternative treatment options, as monotherapy.","status":"Concluded with an LOI","cda_amc_project_id":"PC0280-000","inesss_project_id":"","engagement_date":"2023-03-08","close_date":"2023-03-08"},{"pcpa_file_number":"22289","brand_name":"Imfinzi","generic_name":"durvalumab","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Locally advanced or metastatic biliary tract cancer (BTC) in combination with gemcitabine-based chemotherapy","status":"Concluded with an LOI","cda_amc_project_id":"PC0296-000","inesss_project_id":"","engagement_date":"2023-06-07","close_date":"2024-02-28"},{"pcpa_file_number":"22285","brand_name":"Yescarta","generic_name":"axicabtagene ciloleucel","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"Diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL), in adult patients, that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy","status":"Concluded with an LOI","cda_amc_project_id":"PG0293-000","inesss_project_id":"","engagement_date":"2023-09-26","close_date":"2024-09-06"},{"pcpa_file_number":"22276","brand_name":"Oxlumo","generic_name":"lumasiran","manufacturer_negotiated_with":"Alnylam Netherlands B.V.","indication":"Primary Hyperoxaluria Type 1","status":"Concluded with an LOI","cda_amc_project_id":"SR0734-000","inesss_project_id":"","engagement_date":"2023-09-08","close_date":"2024-04-26"},{"pcpa_file_number":"22270","brand_name":"Dupixent","generic_name":"dupilumab","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Asthma","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2023-03-10","close_date":"2023-03-10"},{"pcpa_file_number":"22214","brand_name":"Dupixent","generic_name":"dupilumab","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Atopic dermatitis","status":"Concluded with an LOI","cda_amc_project_id":"SF0754-000","inesss_project_id":"","engagement_date":"2023-04-04","close_date":"2023-04-04"},{"pcpa_file_number":"22211","brand_name":"Saphnelo","generic_name":"anifrolumab","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Systemic lupus erythematosus","status":"Concluded with an LOI","cda_amc_project_id":"SR0717-000","inesss_project_id":"","engagement_date":"2023-04-24","close_date":"2023-10-25"},{"pcpa_file_number":"22206","brand_name":"Benlysta","generic_name":"belimumab","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Active lupus nephritis","status":"Concluded with an LOI","cda_amc_project_id":"SR0746-000","inesss_project_id":"","engagement_date":"2023-04-24","close_date":"2024-01-18"},{"pcpa_file_number":"22202","brand_name":"Ferriprox","generic_name":"deferiprone","manufacturer_negotiated_with":"Chiesi Canada Corporation","indication":"Transfusional iron overload due to sickle cell disease or other anemias","status":"Concluded without agreement","cda_amc_project_id":"SR0741-000","inesss_project_id":"","engagement_date":"2023-07-31","close_date":"2023-10-27"},{"pcpa_file_number":"22195","brand_name":"Ozurdex","generic_name":"dexamethasone","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Diabetic Macular Edema","status":"Negotiations were not pursued","cda_amc_project_id":"SR0739-000","inesss_project_id":"","engagement_date":"","close_date":"2023-03-09"},{"pcpa_file_number":"22193","brand_name":"Beovu","generic_name":"brolucizumab","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Diabetic Macular Edema","status":"Concluded with an LOI","cda_amc_project_id":"SR0747-000","inesss_project_id":"","engagement_date":"2023-03-06","close_date":"2023-04-11"},{"pcpa_file_number":"22191","brand_name":"Nubeqa","generic_name":"Darolutamide","manufacturer_negotiated_with":"Bayer Inc.","indication":"Metastatic castration sensitive prostate cancer (mCSPC) in combination with docetaxel","status":"Concluded with an LOI","cda_amc_project_id":"PC0294-000","inesss_project_id":"","engagement_date":"2023-09-20","close_date":"2023-11-01"},{"pcpa_file_number":"22188","brand_name":"Dayvigo","generic_name":"lemborexant","manufacturer_negotiated_with":"Eisai Limited","indication":"Insomnia","status":"Concluded without agreement","cda_amc_project_id":"SR0716-000","inesss_project_id":"","engagement_date":"2023-05-09","close_date":"2023-09-29"},{"pcpa_file_number":"22184","brand_name":"Blood glucose test strips","generic_name":"blood glucose test strips","manufacturer_negotiated_with":"Tykess Pharmaceuticals Inc.","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-06-24","close_date":"2021-08-12"},{"pcpa_file_number":"22180","brand_name":"Blood glucose test strips","generic_name":"blood glucose test strips","manufacturer_negotiated_with":"Dex Medical Distribution Inc.","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-06-24","close_date":"2020-12-09"},{"pcpa_file_number":"22176","brand_name":"Blood glucose test strips","generic_name":"blood glucose test strips","manufacturer_negotiated_with":"Roche Diabetes Care, division of Hoffmann-La Roche Ltd.","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-06-24","close_date":"2020-12-09"},{"pcpa_file_number":"22172","brand_name":"Blood glucose test strips","generic_name":"blood glucose test strips","manufacturer_negotiated_with":"Bionime USA Corporation","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-06-24","close_date":"2021-01-22"},{"pcpa_file_number":"22165","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Triple-negative breast cancer (TNBC), locally recurrent unresectable or metastatic, in adult patients who have not received prior chemotherapy for metastatic disease and whose tumors express PD-L1 (CPS ? 10) as determined by a validated test (in combination with chemotherapy)","status":"Concluded with an LOI","cda_amc_project_id":"PC0295-000","inesss_project_id":"","engagement_date":"2023-03-08","close_date":"2023-03-08"},{"pcpa_file_number":"22149","brand_name":"Kimmtrak","generic_name":"tebentafusp","manufacturer_negotiated_with":"Medison Pharma Canada Inc.","indication":"Unresectable or metastatic uveal melanoma in adult patients who are Human leukocyte antigen (HLA)-A*02:01-positive","status":"Concluded with an LOI","cda_amc_project_id":"PC0290-000","inesss_project_id":"","engagement_date":"2023-05-09","close_date":"2023-10-23"},{"pcpa_file_number":"22141","brand_name":"Dificid","generic_name":"fidaxomicin","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Clostridium difficile infection","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2023-01-26","close_date":"2023-09-14"},{"pcpa_file_number":"22140","brand_name":"Ruzurgi","generic_name":"Amifampridine","manufacturer_negotiated_with":"M\ufffddunik Canada Inc.","indication":"Lambert-Eaton Myasthenic Syndrome (LEMS)","status":"Concluded with an LOI","cda_amc_project_id":"SR0660-000","inesss_project_id":"","engagement_date":"2023-01-23","close_date":"2023-01-26"},{"pcpa_file_number":"22138","brand_name":"Radicava","generic_name":"edaravone","manufacturer_negotiated_with":"Mitsubishi Tanabe Pharma Canada, Inc.","indication":"Amyotrophic Lateral Sclerosis (ALS)","status":"Concluded with an LOI","cda_amc_project_id":"SR0727-000","inesss_project_id":"","engagement_date":"2023-03-14","close_date":"2023-07-10"},{"pcpa_file_number":"22136","brand_name":"Vyepti","generic_name":"eptinezumab","manufacturer_negotiated_with":"Lundbeck Canada Inc.","indication":"Migraine, prevention","status":"Concluded with an LOI","cda_amc_project_id":"SR0743-000","inesss_project_id":"","engagement_date":"2023-02-16","close_date":"2023-06-16"},{"pcpa_file_number":"22131","brand_name":"Uceris","generic_name":"budesonide","manufacturer_negotiated_with":"Bausch Health, Canada Inc.","indication":"Active mild to moderate distal ulcerative colitis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2023-10-23","close_date":"2024-02-02"},{"pcpa_file_number":"22128","brand_name":"Zepzelca","generic_name":"lurbinectedin","manufacturer_negotiated_with":"Jazz Pharmaceuticals Canada Inc.","indication":"Stage III or metastatic small cell lung cancer (SCLC) in adult patients who have progressed on or after platinum-containing therapy","status":"Negotiations were not pursued","cda_amc_project_id":"PC0281-000","inesss_project_id":"","engagement_date":"","close_date":"2023-08-04"},{"pcpa_file_number":"22118","brand_name":"Wakix","generic_name":"pitolisant hydrochloride","manufacturer_negotiated_with":"Paladin Labs Inc.","indication":"Excessive daytime sleepiness or cataplexy in adult patients with narcolepsy","status":"Concluded without agreement","cda_amc_project_id":"SR0715-000","inesss_project_id":"","engagement_date":"2023-01-25","close_date":"2023-05-03"},{"pcpa_file_number":"22113","brand_name":"Blood glucose test strips","generic_name":"blood glucose test strips","manufacturer_negotiated_with":"Tremblay Harrison Inc.","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-06-25","close_date":"2020-12-09"},{"pcpa_file_number":"22109","brand_name":"Blood glucose test strips","generic_name":"blood glucose test strips","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-06-25","close_date":"2020-12-09"},{"pcpa_file_number":"22107","brand_name":"Blood glucose test strips","generic_name":"blood glucose test strips","manufacturer_negotiated_with":"Nova Biomedical Canada Ltd.","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-06-25","close_date":"2020-12-09"},{"pcpa_file_number":"22103","brand_name":"Blood glucose test strips","generic_name":"blood glucose test strips","manufacturer_negotiated_with":"Auto Control Medical Inc","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-06-24","close_date":"2020-12-09"},{"pcpa_file_number":"22099","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS ? 1) as determined by a validated test, in combination with chemotherapy with or without bevacizumab, in adult patients","status":"Concluded with an LOI","cda_amc_project_id":"PC0292-000","inesss_project_id":"","engagement_date":"2023-03-08","close_date":"2023-03-08"},{"pcpa_file_number":"22096","brand_name":"Zeposia","generic_name":"ozanimod","manufacturer_negotiated_with":"Celgene Inc.","indication":"Ulcerative Colitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0714-000","inesss_project_id":"","engagement_date":"2023-08-15","close_date":"2023-11-10"},{"pcpa_file_number":"22094","brand_name":"Tremfya","generic_name":"guselkumab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Psoriatic Arthritis","status":"Concluded with an LOI","cda_amc_project_id":"SR0733-000","inesss_project_id":"","engagement_date":"2023-04-20","close_date":"2023-08-08"},{"pcpa_file_number":"22092","brand_name":"Nucala","generic_name":"mepolizumab","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Severe chronic rhinosinusitis with nasal polyps","status":"Concluded with an LOI","cda_amc_project_id":"SR0735-000","inesss_project_id":"","engagement_date":"2023-08-31","close_date":"2024-04-18"},{"pcpa_file_number":"22089","brand_name":"Tezspire","generic_name":"tezepelumab","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Severe asthma, add-on maintenance treatment in adults and adolescents 12 years and older","status":"Concluded with an LOI","cda_amc_project_id":"SR0731-000","inesss_project_id":"","engagement_date":"2023-06-20","close_date":"2023-09-15"},{"pcpa_file_number":"22085","brand_name":"Xydalba","generic_name":"dalbavancin","manufacturer_negotiated_with":"Paladin Labs Inc.","indication":"Acute bacterial skin and skin structure infections","status":"Concluded with an LOI","cda_amc_project_id":"SR0728-000","inesss_project_id":"","engagement_date":"2023-04-03","close_date":"2024-01-23"},{"pcpa_file_number":"22082","brand_name":"Rymti","generic_name":"etanercept","manufacturer_negotiated_with":"Lupin Pharma Canada Ltd.","indication":"Ankylosing Spondylitis, Plaque Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis and Polyarticular Juvenile Idiopathic Arthritis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2023-02-22","close_date":"2023-10-04"},{"pcpa_file_number":"22079","brand_name":"Vraylar","generic_name":"cariprazine","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Bipolar Disorder","status":"Negotiations were not pursued","cda_amc_project_id":"SR0718-000","inesss_project_id":"","engagement_date":"","close_date":"2022-12-16"},{"pcpa_file_number":"22076","brand_name":"Palynziq","generic_name":"pegvaliase","manufacturer_negotiated_with":"BioMarin Pharmaceutical Inc.","indication":"Phenylketonuria","status":"Concluded without agreement","cda_amc_project_id":"SR0712-000","inesss_project_id":"","engagement_date":"2024-05-13","close_date":"2025-02-03"},{"pcpa_file_number":"22073","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Stage IIB or IIC melanoma following complete resection, for adjuvant treatment of adult and pediatric (12 years and older) patients","status":"Concluded with an LOI","cda_amc_project_id":"PC0286-000","inesss_project_id":"","engagement_date":"2023-03-08","close_date":"2023-03-08"},{"pcpa_file_number":"22070","brand_name":"Livtencity","generic_name":"maribavir","manufacturer_negotiated_with":"Takeda Canada Inc.","indication":"Post-transplant Cytomegalovirus (CMV) Infection\/disease","status":"Concluded with an LOI","cda_amc_project_id":"SR0720-000","inesss_project_id":"","engagement_date":"2023-05-19","close_date":"2024-05-10"},{"pcpa_file_number":"22065","brand_name":"Rozlytrek","generic_name":"Entrectinib","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, in adult patients, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options","status":"Concluded with an LOI","cda_amc_project_id":"PC0278-000","inesss_project_id":"","engagement_date":"2022-12-08","close_date":"2023-03-16"},{"pcpa_file_number":"22062","brand_name":"Cabometyx","generic_name":"cabozantinib","manufacturer_negotiated_with":"Ipsen Biopharmaceuticals Canada, Inc.","indication":"Differentiated thyroid carcinoma (DTC), locally advanced or metastatic, in adult patients who are radioactive iodine-refractory (RAI-R) or ineligible, that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy","status":"Concluded with an LOI","cda_amc_project_id":"PC0287-000","inesss_project_id":"","engagement_date":"2023-04-25","close_date":"2023-09-14"},{"pcpa_file_number":"22059","brand_name":"Jardiance","generic_name":"empagliflozin","manufacturer_negotiated_with":"Boehringer Ingelheim (Canada) Ltd.","indication":"Adjunct to standard of care therapy for the treatment of chronic heart failure in adults","status":"Concluded without agreement","cda_amc_project_id":"SR0726-000","inesss_project_id":"","engagement_date":"2024-07-23","close_date":"2025-06-09"},{"pcpa_file_number":"22056","brand_name":"Vabysmo","generic_name":"faricimab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Diabetic Macular Edema","status":"Concluded with an LOI","cda_amc_project_id":"SR0729-000","inesss_project_id":"","engagement_date":"2023-02-17","close_date":"2023-04-27"},{"pcpa_file_number":"22052","brand_name":"Minjuvi","generic_name":"tafasitamab","manufacturer_negotiated_with":"Incyte Biosciences Canada Corporation","indication":"Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), relapsed or refractory, including DLBCL arising from low grade lymphoma, in adult patients who are not eligible for autologous stem cell transplant (in combination with lenalidomide)","status":"Concluded with an LOI","cda_amc_project_id":"PC0266-000","inesss_project_id":"","engagement_date":"2023-05-26","close_date":"2023-08-08"},{"pcpa_file_number":"22048","brand_name":"Retevmo","generic_name":"selpercatinib","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Medullary thyroid cancer (MTC), rearranged during transfection (RET)-mutant, in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease","status":"Concluded with an LOI","cda_amc_project_id":"PC0264-000","inesss_project_id":"","engagement_date":"2022-11-17","close_date":"2023-03-31"},{"pcpa_file_number":"22045","brand_name":"Enhertu","generic_name":"trastuzumab deruxtecan","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in adult patients who have received a prior treatment with an anti-HER2-based regimen in the metastatic setting or developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy","status":"Concluded with an LOI","cda_amc_project_id":"PC0285-000","inesss_project_id":"","engagement_date":"2022-12-21","close_date":"2023-05-29"},{"pcpa_file_number":"22041","brand_name":"Opdivo","generic_name":"nivolumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Urothelial carcinoma (UC), monotherapy for the adjuvant treatment of adult patients who are at high risk of recurrence after undergoing radical resection of UC","status":"Concluded with an LOI","cda_amc_project_id":"PC0272-000","inesss_project_id":"","engagement_date":"2022-12-09","close_date":"2022-12-23"},{"pcpa_file_number":"22038","brand_name":"Verzenio","generic_name":"abemaciclib","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Early breast cancer, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, at high risk of disease recurrence based on clinicopathological features and a Ki-67 score ?20%,for the adjuvant treatment of adult patients (in combination with endocrine therapy)","status":"Concluded with an LOI","cda_amc_project_id":"PC0282-000","inesss_project_id":"","engagement_date":"2023-03-13","close_date":"2023-07-18"},{"pcpa_file_number":"22035","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Renal cell carcinoma (RCC), for adjuvant treatment of adult patients, at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions","status":"Concluded with an LOI","cda_amc_project_id":"PC0273-000","inesss_project_id":"","engagement_date":"2022-12-15","close_date":"2022-12-15"},{"pcpa_file_number":"22032","brand_name":"Gavreto","generic_name":"pralsetinib","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), rearranged during transfection (RET) fusion-positive, in adult patients","status":"Concluded without agreement","cda_amc_project_id":"PC0283-000","inesss_project_id":"","engagement_date":"2023-06-12","close_date":"2023-07-24"},{"pcpa_file_number":"22028","brand_name":"Lutathera","generic_name":"lutetium 177 dotatate","manufacturer_negotiated_with":"Advanced Accelerator Applications","indication":"Unresectable or metastatic, well-differentiated, somatostatin receptor (SSR)-positive pancreatic neuroendocrine tumours (pNETs) in adults whose disease has progressed after treatment with a somatostatin analogue (SSA), unless there is a contraindication or intolerance","status":"Concluded with an LOI","cda_amc_project_id":"PC0284-000","inesss_project_id":"","engagement_date":"2023-04-24","close_date":"2023-10-17"},{"pcpa_file_number":"22025","brand_name":"Wegovy","generic_name":"semaglutide","manufacturer_negotiated_with":"Novo Nordisk Canada Inc.","indication":"Chronic weight management","status":"Negotiations were not pursued","cda_amc_project_id":"SR0725-000","inesss_project_id":"","engagement_date":"","close_date":"2022-10-25"},{"pcpa_file_number":"22021","brand_name":"Jakavi","generic_name":"ruxolintib","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Acute Graft-Versus-Host disease","status":"Concluded with an LOI","cda_amc_project_id":"SR0688-000","inesss_project_id":"","engagement_date":"2023-02-06","close_date":"2023-05-05"},{"pcpa_file_number":"22016","brand_name":"Lenvima","generic_name":"lenvatinib","manufacturer_negotiated_with":"Eisai Limited","indication":"Advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), in adult patients who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation (in combination with pembrolizumab)","status":"Concluded with an LOI","cda_amc_project_id":"PC0288-000","inesss_project_id":"","engagement_date":"2022-10-21","close_date":"2023-05-10"},{"pcpa_file_number":"22014","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), in adult patients who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation. (in combination with Lenvatinib (Lenvima))","status":"Concluded with an LOI","cda_amc_project_id":"PC0288-000","inesss_project_id":"","engagement_date":"2022-10-21","close_date":"2023-05-12"},{"pcpa_file_number":"22011","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"High-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, in adult patients","status":"Concluded with an LOI","cda_amc_project_id":"PC0279-000","inesss_project_id":"","engagement_date":"2022-10-07","close_date":"2022-10-07"},{"pcpa_file_number":"22008","brand_name":"Byooviz","generic_name":"ranibizumab","manufacturer_negotiated_with":"Biogen Canada Inc.","indication":"Neovascular (wet) age-related macular degeneration (AMD), or visual impairment due to diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO), choroidal neovascularisation (CNV) secondary to pathologic myopia (PM), choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, post-inflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2023-01-24","close_date":"2023-05-11"},{"pcpa_file_number":"22003","brand_name":"Spinraza","generic_name":"nusinersen","manufacturer_negotiated_with":"Biogen Canada Inc.","indication":"Spinal Muscular Atrophy in adult patients over 18 years of age","status":"Negotiations were not pursued","cda_amc_project_id":"SR0713-000","inesss_project_id":"","engagement_date":"","close_date":"2022-11-14"},{"pcpa_file_number":"22000","brand_name":"Tecentriq","generic_name":"atezolizumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Non-small cell lung cancer (NSCLC) in adult patients whose tumours have PD-L1 expression on ? 50% of tumour cells (TCs) and do not have EGFR or ALK genomic tumour aberrations, monotherapy for adjuvant treatment following resection and platinum-based chemotherapy, Stage II to IIIA (per the American Joint Committee on Cancer [AJCC], 7th edition)","status":"Concluded with an LOI","cda_amc_project_id":"PC0269-000","inesss_project_id":"","engagement_date":"2022-11-28","close_date":"2023-03-14"},{"pcpa_file_number":"21997","brand_name":"Tepmetko","generic_name":"tepotinib","manufacturer_negotiated_with":"EMD Serono Canada, a division of EMD Inc.","indication":"Non-small cell lung cancer (NSCLC), locally advanced unresectable metastatic, harbouring mesenchymal-epithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations, in adult patients","status":"Concluded with an LOI","cda_amc_project_id":"PC0255-000","inesss_project_id":"","engagement_date":"2023-03-09","close_date":"2023-06-22"},{"pcpa_file_number":"21991","brand_name":"Jemperli","generic_name":"dostarlimab","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum containing regimen, in adult patients","status":"Negotiations were not pursued","cda_amc_project_id":"PC0263-000","inesss_project_id":"","engagement_date":"","close_date":"2022-10-19"},{"pcpa_file_number":"21987","brand_name":"Cibinqo","generic_name":"abrocitinib","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Atopic Dermatitis, Moderate to Severe","status":"Concluded with an LOI","cda_amc_project_id":"SR0686-000","inesss_project_id":"","engagement_date":"2023-02-14","close_date":"2023-07-21"},{"pcpa_file_number":"21983","brand_name":"Poteligeo","generic_name":"mogamulizumab","manufacturer_negotiated_with":"Kyowa Kirin Canada, Inc.","indication":"Mycosis Fungoides (MF), S\ufffdzary Syndrome (SS)","status":"Concluded with an LOI","cda_amc_project_id":"PC0244-000","inesss_project_id":"","engagement_date":"2022-12-19","close_date":"2024-03-13"},{"pcpa_file_number":"21977","brand_name":"Vabysmo","generic_name":"faricimab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Neovascular (Wet) Age-related Macular Degeneration (nAMD)","status":"Concluded with an LOI","cda_amc_project_id":"SR0719-000","inesss_project_id":"","engagement_date":"2023-02-17","close_date":"2023-04-27"},{"pcpa_file_number":"21973","brand_name":"Vraylar","generic_name":"cariprazine","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Schizophrenia in Adults","status":"Concluded with an LOI","cda_amc_project_id":"SR0708-000","inesss_project_id":"","engagement_date":"2023-01-25","close_date":"2023-03-28"},{"pcpa_file_number":"21967","brand_name":"Kirsty","generic_name":"insulin aspart","manufacturer_negotiated_with":"BGP Pharma ULC, d.b.a. Viatris Canada","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2022-11-14","close_date":"2022-11-14"},{"pcpa_file_number":"21965","brand_name":"Brukinsa","generic_name":"zanubrutinib","manufacturer_negotiated_with":"BeiGene, Ltd.","indication":"Mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.","status":"Negotiations were not pursued","cda_amc_project_id":"PC0267-000","inesss_project_id":"","engagement_date":"","close_date":"2022-09-07"},{"pcpa_file_number":"21962","brand_name":"Xpovio","generic_name":"selinexor","manufacturer_negotiated_with":"Forus Therapeutics Inc.","indication":"Multiple myeloma (MM) in adults with who have received at least one prior therapy (In combination with bortezomib (V) and dexamethasone (d))","status":"Concluded with an LOI","cda_amc_project_id":"PC0276-000","inesss_project_id":"","engagement_date":"2022-12-20","close_date":"2023-05-15"},{"pcpa_file_number":"21956","brand_name":"Scemblix","generic_name":"asciminib","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with two or more tyrosine kinase inhibitors, in adult patients","status":"Concluded with an LOI","cda_amc_project_id":"PC0275-000","inesss_project_id":"","engagement_date":"2022-10-21","close_date":"2023-03-09"},{"pcpa_file_number":"21952","brand_name":"Vegzelma","generic_name":"bevacizumab","manufacturer_negotiated_with":"Celltrion Healthcare Canada Ltd.","indication":"Metastatic Colorectal Cancer (mCRC); Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC); Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; and Malignant Glioma (WHO Grade IV) - Glioblastoma","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2023-01-10","close_date":"2023-03-23"},{"pcpa_file_number":"21950","brand_name":"Inqovi","generic_name":"decitabine-cedazuridine","manufacturer_negotiated_with":"Taiho Pharma Canada Inc.","indication":"Myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups, in adult patients","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2022-08-25","close_date":"2022-08-25"},{"pcpa_file_number":"21948","brand_name":"Jakavi","generic_name":"ruxolintib","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Chronic Graft-versus-host Disease","status":"Concluded with an LOI","cda_amc_project_id":"SR0706-000","inesss_project_id":"","engagement_date":"2023-02-06","close_date":"2023-05-05"},{"pcpa_file_number":"21945","brand_name":"Albrioza","generic_name":"sodium phenylbutyrate and ursodoxicoltaurine","manufacturer_negotiated_with":"Amylyx Canada","indication":"Amyotrophic Lateral Sclerosis (ALS)","status":"Concluded with an LOI","cda_amc_project_id":"SR0711-000","inesss_project_id":"","engagement_date":"2022-08-09","close_date":"2023-06-12"},{"pcpa_file_number":"21939","brand_name":"Breyanzi","generic_name":"lisocabtagene maraleucel","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Adult patients with relapsed or refractory (R\/R) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma","status":"Concluded with an LOI","cda_amc_project_id":"PG0258-000","inesss_project_id":"","engagement_date":"2023-01-20","close_date":"2023-12-12"},{"pcpa_file_number":"21935","brand_name":"Nexviazyme","generic_name":"avalglucosidase alfa","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Late-Onset Pompe Disease","status":"Concluded without agreement","cda_amc_project_id":"SR0703-000","inesss_project_id":"","engagement_date":"2023-07-11","close_date":"2023-09-29"},{"pcpa_file_number":"21931","brand_name":"Retevmo","generic_name":"selpercatinib","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Differentiated thyroid carcinoma (DTC), Rearranged during transfection (RET) fusion-positive, in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) monotherapy treatment following prior treatment with sorafenib and\/or lenvatinib","status":"Concluded with an LOI","cda_amc_project_id":"PC0274-000","inesss_project_id":"","engagement_date":"2022-11-17","close_date":"2023-03-31"},{"pcpa_file_number":"21928","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Advanced or metastatic renal cell carcinoma (RCC) in adult patients with no prior systemic therapy for metastatic RCC (in combination with Lenvima)","status":"Concluded with an LOI","cda_amc_project_id":"PC0268-000","inesss_project_id":"","engagement_date":"2022-10-21","close_date":"2023-05-12"},{"pcpa_file_number":"21925","brand_name":"Lenvima","generic_name":"lenvatinib","manufacturer_negotiated_with":"Eisai Limited","indication":"Advanced or metastatic renal cell carcinoma (RCC) with no prior systemic therapy for metastatic renal cell carcinoma (RCC), in adult patients (In combination with pembrolizumab)","status":"Concluded with an LOI","cda_amc_project_id":"PC0268-000","inesss_project_id":"","engagement_date":"2022-10-21","close_date":"2023-05-10"},{"pcpa_file_number":"21922","brand_name":"Vyndaqel","generic_name":"tafamidis","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Cardiomyopathy due to transthyretin-mediated amyloidosis","status":"Concluded with an LOI","cda_amc_project_id":"SF0722-000","inesss_project_id":"","engagement_date":"2022-09-07","close_date":"2022-09-07"},{"pcpa_file_number":"21919","brand_name":"Firdapse","generic_name":"amifampridine phosphate","manufacturer_negotiated_with":"KYE Pharmaceuticals Inc.","indication":"Lambert-Eaton Myasthenic Syndrome (LEMS)","status":"Concluded with an LOI","cda_amc_project_id":"SR0664-000","inesss_project_id":"","engagement_date":"2022-12-21","close_date":"2023-04-25"},{"pcpa_file_number":"21916","brand_name":"pdp-Amlodipine","generic_name":"amlodipine","manufacturer_negotiated_with":"Pendopharm, a division of Pharmascience Inc.","indication":"Mild to moderate essential hypertension and management of chronic stable angina","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2022-07-18","close_date":"2022-11-14"},{"pcpa_file_number":"21913","brand_name":"Arazlo","generic_name":"tazarotene","manufacturer_negotiated_with":"Bausch Health, Canada Inc.","indication":"Acne Vulgaris","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2022-07-13","close_date":"2022-08-29"},{"pcpa_file_number":"21910","brand_name":"Bryhali","generic_name":"halobetasol propionate","manufacturer_negotiated_with":"Bausch Health, Canada Inc.","indication":"Corticosteroid-Responsive Dermatoses and The Topical Treatment of Plaque Psoriasis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2022-07-13","close_date":"2022-09-27"},{"pcpa_file_number":"21907","brand_name":"Rinvoq","generic_name":"upadacitinib","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Atopic dermatitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0685-000","inesss_project_id":"","engagement_date":"2023-02-14","close_date":"2023-09-19"},{"pcpa_file_number":"21904","brand_name":"Elonox and Elonox HP","generic_name":"enoxaparin sodium","manufacturer_negotiated_with":"Fresenius Kabi Canada Ltd.","indication":"Thrombosis and cardiovascular conditions (prevention or treatment)","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2022-09-13","close_date":"2023-01-09"},{"pcpa_file_number":"21901","brand_name":"Trikafta","generic_name":"elexacaftor\/tezacaftor\/ivacaftor and ivacaftor","manufacturer_negotiated_with":"Vertex Pharmaceuticals (Canada) Incorporated","indication":"Cystic Fibrosis, F508del CFTR mutation in patients aged 6 years and older","status":"Concluded with an LOI","cda_amc_project_id":"SR0710-000","inesss_project_id":"","engagement_date":"2022-07-07","close_date":"2022-07-07"},{"pcpa_file_number":"21898","brand_name":"Libtayo","generic_name":"cemiplimab","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Non-small cell lung cancer (NSCLC) expressing PD-L1 in ? 50% of tumour cells (Tumour Proportion Score [TPS] ? 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, first-line treatment of adult patients who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC","status":"Concluded without agreement","cda_amc_project_id":"PC0262-000","inesss_project_id":"","engagement_date":"2022-10-03","close_date":"2023-07-28"},{"pcpa_file_number":"21895","brand_name":"Osphena","generic_name":"ospemifene","manufacturer_negotiated_with":"Duchesnay Inc.","indication":"Dyspareunia and\/or Vaginal Dryness","status":"Concluded without agreement","cda_amc_project_id":"SR0709-000","inesss_project_id":"","engagement_date":"2022-12-15","close_date":"2023-04-14"},{"pcpa_file_number":"21891","brand_name":"Nypozi","generic_name":"filgrastim","manufacturer_negotiated_with":"Tanvex BioPharma USA, Inc.","indication":"Neutropenia in various indications (Prevention or treatment)","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2022-12-15","close_date":"2023-03-10"},{"pcpa_file_number":"21887","brand_name":"Semglee","generic_name":"Insulin Glargine","manufacturer_negotiated_with":"BGP Pharma ULC, d.b.a. Viatris Canada","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2022-08-17","close_date":"2022-11-07"},{"pcpa_file_number":"21883","brand_name":"Blood glucose test strips","generic_name":"blood glucose test strips","manufacturer_negotiated_with":"ForaCare Technology Canada, Inc.","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-06-25","close_date":"2021-01-22"},{"pcpa_file_number":"21880","brand_name":"Blood glucose test strips","generic_name":"blood glucose test strips","manufacturer_negotiated_with":"Skymed Monitors Inc.","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-06-25","close_date":"2021-02-26"},{"pcpa_file_number":"21877","brand_name":"Blood glucose test strips","generic_name":"blood glucose test strips","manufacturer_negotiated_with":"MediSure Canada Inc.","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-06-25","close_date":"2020-12-09"},{"pcpa_file_number":"21874","brand_name":"Blood glucose test strips","generic_name":"blood glucose test strips","manufacturer_negotiated_with":"LifeScan Canada ULC","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-06-25","close_date":"2020-12-09"},{"pcpa_file_number":"21871","brand_name":"Blood glucose test strips","generic_name":"blood glucose test strips","manufacturer_negotiated_with":"I-Sens, Inc.","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-06-25","close_date":"2020-12-09"},{"pcpa_file_number":"21868","brand_name":"Blood glucose test strips","generic_name":"blood glucose test strips","manufacturer_negotiated_with":"BTNX Inc.","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-06-24","close_date":"2020-12-09"},{"pcpa_file_number":"21865","brand_name":"Blood glucose test strips","generic_name":"blood glucose test strips","manufacturer_negotiated_with":"Ascensia Diabetes Care","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-06-24","close_date":"2020-12-09"},{"pcpa_file_number":"21862","brand_name":"Blood glucose test strips","generic_name":"blood glucose test strips","manufacturer_negotiated_with":"Spirit Healthcare Group","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-06-24","close_date":"2020-12-09"},{"pcpa_file_number":"21859","brand_name":"Blood glucose test strips","generic_name":"blood glucose test strips","manufacturer_negotiated_with":"Abbott Diabetes Care","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-06-24","close_date":"2020-12-09"},{"pcpa_file_number":"21856","brand_name":"Retevmo","generic_name":"selpercatinib","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Metastatic RET fusion-positive non-small cell lung cancer (NSCLC), Monotherapy for the treatment of adult patients","status":"Concluded with an LOI","cda_amc_project_id":"PC0261-000","inesss_project_id":"","engagement_date":"2022-11-17","close_date":"2023-03-31"},{"pcpa_file_number":"21850","brand_name":"Qinlock","generic_name":"ripretinib","manufacturer_negotiated_with":"Medison Pharma Canada Inc.","indication":"Advanced gastrointestinal stromal tumor (GIST) in adult patients who have received prior treatment with imatinib, sunitinib, and regorafenib","status":"Concluded with an LOI","cda_amc_project_id":"PC0265-000","inesss_project_id":"","engagement_date":"2022-07-12","close_date":"2023-05-12"},{"pcpa_file_number":"21844","brand_name":"Insulin pumps and pump supplies","generic_name":"Insulin pumps and pump supplies","manufacturer_negotiated_with":"Insulet Canada Corporation","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-06-29","close_date":"2022-09-20"},{"pcpa_file_number":"21841","brand_name":"Insulin pumps and pump supplies","generic_name":"Insulin pumps and pump supplies","manufacturer_negotiated_with":"Ypsomed Canada Inc.","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-06-29","close_date":"2022-03-08"},{"pcpa_file_number":"21834","brand_name":"Insulin pumps and pump supplies","generic_name":"Insulin pumps and pump supplies","manufacturer_negotiated_with":"Medtronic Canada","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-06-29","close_date":"2022-03-08"},{"pcpa_file_number":"21831","brand_name":"Intrarosa","generic_name":"prasterone","manufacturer_negotiated_with":"Lupin Pharma Canada Ltd.","indication":"Postmenopausal vulvovaginal atrophy","status":"Concluded without agreement","cda_amc_project_id":"SR0707-000","inesss_project_id":"","engagement_date":"2022-12-15","close_date":"2023-04-14"},{"pcpa_file_number":"21827","brand_name":"Tavalisse","generic_name":"fostamatinib","manufacturer_negotiated_with":"Medison Pharma Canada Inc.","indication":"Chronic Immune Thrombocytopenia","status":"Negotiations were not pursued","cda_amc_project_id":"SR0701-000","inesss_project_id":"","engagement_date":"","close_date":"2022-05-09"},{"pcpa_file_number":"21821","brand_name":"Bimzelx","generic_name":"bimekizumab","manufacturer_negotiated_with":"UCB Canada Inc.","indication":"Psoriasis, moderate to severe plaque","status":"Concluded with an LOI","cda_amc_project_id":"SR0698-000","inesss_project_id":"","engagement_date":"2022-09-13","close_date":"2022-12-09"},{"pcpa_file_number":"21817","brand_name":"Pemazyre","generic_name":"pemigatinib","manufacturer_negotiated_with":"Incyte Biosciences Canada Corporation","indication":"Unresectable Locally Advanced or Metastatic Cholangiocarcinoma (CCA) in adults with previously treated CCA with a FGFR2 fusion or other rearrangement","status":"Negotiations were not pursued","cda_amc_project_id":"PC0252-000","inesss_project_id":"","engagement_date":"","close_date":"2022-07-29"},{"pcpa_file_number":"21811","brand_name":"Lorbrena","generic_name":"lorlatinib","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic, monotherapy for first-line treatment of adult patients","status":"Concluded without agreement","cda_amc_project_id":"PC0249-000","inesss_project_id":"","engagement_date":"2022-06-08","close_date":"2022-08-26"},{"pcpa_file_number":"21808","brand_name":"Adtralza","generic_name":"tralokinumab","manufacturer_negotiated_with":"LEO Pharma Inc.","indication":"Atopic dermatitis","status":"Negotiations were not pursued","cda_amc_project_id":"SR0689-000","inesss_project_id":"","engagement_date":"","close_date":"2022-05-03"},{"pcpa_file_number":"21804","brand_name":"Myinfla","generic_name":"colchicine","manufacturer_negotiated_with":"Pendopharm, a division of Pharmascience Inc.","indication":"Atherothrombotic Events in Coronary Artery Disease","status":"Negotiations were not pursued","cda_amc_project_id":"SR0691-000","inesss_project_id":"","engagement_date":"","close_date":"2022-05-03"},{"pcpa_file_number":"21798","brand_name":"Ngenla","generic_name":"somatrogon","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Growth hormone deficiency","status":"Concluded with an LOI","cda_amc_project_id":"SR0683-000","inesss_project_id":"","engagement_date":"2022-08-17","close_date":"2022-11-28"},{"pcpa_file_number":"21794","brand_name":"Libtayo","generic_name":"cemiplimab","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"For the treatment of patients with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor","status":"Concluded without agreement","cda_amc_project_id":"PC0260-000","inesss_project_id":"","engagement_date":"2022-10-03","close_date":"2023-07-28"},{"pcpa_file_number":"21791","brand_name":"Opdivo","generic_name":"nivolumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma in adult patients (in combination with fluoropyrimidine- and platinum-containing chemotherapy)","status":"Concluded with an LOI","cda_amc_project_id":"PC0259-000","inesss_project_id":"","engagement_date":"2022-06-28","close_date":"2022-08-25"},{"pcpa_file_number":"21788","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Carcinoma of the esophagus or HER-2 negative gastroesophageal junction adenocarcinoma, locally advanced unresectable or metastatic, in combination with platinum and fluoropyrimidine based chemotherapy, in adult patients (First-line treatment)","status":"Concluded with an LOI","cda_amc_project_id":"PC0250-000","inesss_project_id":"","engagement_date":"2022-02-11","close_date":"2022-02-11"},{"pcpa_file_number":"21784","brand_name":"Leqvio","generic_name":"inclisiran","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Primary hypercholesterolemia (non-familial and heterozygous familial)","status":"Concluded with an LOI","cda_amc_project_id":"SR0681-000","inesss_project_id":"","engagement_date":"2025-04-02","close_date":"2025-08-13"},{"pcpa_file_number":"21780","brand_name":"Ultomiris","generic_name":"ravulizumab","manufacturer_negotiated_with":"Alexion Pharma GmbH","indication":"Paroxysmal nocturnal hemoglobinuria (PNH)","status":"Concluded with an LOI","cda_amc_project_id":"SR0700-000","inesss_project_id":"","engagement_date":"2023-05-18","close_date":"2023-10-12"},{"pcpa_file_number":"21774","brand_name":"Bijuva","generic_name":"estradiol and progesterone","manufacturer_negotiated_with":"Knight Therapeutics Inc.","indication":"Vasomotor symptoms associated with menopause","status":"Concluded with an LOI","cda_amc_project_id":"SR0697-000","inesss_project_id":"","engagement_date":"2022-07-13","close_date":"2023-05-30"},{"pcpa_file_number":"21770","brand_name":"Waymade-Trientine","generic_name":"trientine hydrochloride","manufacturer_negotiated_with":"Waymade Canada Inc","indication":"Wilson\u0026#039;s Disease","status":"Concluded with an LOI","cda_amc_project_id":"SR0696-000","inesss_project_id":"","engagement_date":"2022-04-13","close_date":"2022-08-11"},{"pcpa_file_number":"21764","brand_name":"Vectibix","generic_name":"panitumumab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Metastatic Colorectal Cancer","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2022-03-07","close_date":"2022-10-18"},{"pcpa_file_number":"21762","brand_name":"Phesgo SC","generic_name":"perjeta and herceptin","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Metastatic breast cancer (HER2-positive) first-line treatment","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2022-02-28","close_date":"2022-05-19"},{"pcpa_file_number":"21759","brand_name":"Darzalex SC","generic_name":"Daratumumab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Light chain amyloidosis (AL), newly diagnosed in adult patients (in combination with bortezomib, cyclophosphamide, and dexamethasone)","status":"Concluded with an LOI","cda_amc_project_id":"PC0257-000","inesss_project_id":"","engagement_date":"2022-03-04","close_date":"2022-03-11"},{"pcpa_file_number":"21756","brand_name":"Trodelvy","generic_name":"sacituzumab govitecan","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"Triple-negative breast cancer (mTNBC), unresectable locally advanced or metastatic, in adult patients who have received two or more prior therapies, at least one of them for metastatic disease","status":"Concluded with an LOI","cda_amc_project_id":"PC0254-000","inesss_project_id":"","engagement_date":"2022-07-29","close_date":"2023-03-09"},{"pcpa_file_number":"21752","brand_name":"Sarclisa","generic_name":"Isatuximab","manufacturer_negotiated_with":"Sanofi Genzyme Canada","indication":"Multiple myeloma, relapsed or refractory, in patients who have received 1 to 3 prior lines of therapy (in combination with carfilzomib and dexamethasone)","status":"Concluded with an LOI","cda_amc_project_id":"PC0256-000","inesss_project_id":"","engagement_date":"2022-05-13","close_date":"2023-03-07"},{"pcpa_file_number":"21749","brand_name":"Piqray","generic_name":"alpelisib","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Advanced or metastatic breast cancer, Hormone receptor-positive, HER2-negative, PIK3CA mutated, after disease progression following an endocrine-based regimen, in postmenopausal women and men (In combination with fulvestrant)","status":"Concluded without agreement","cda_amc_project_id":"PC0247-000","inesss_project_id":"","engagement_date":"2022-12-16","close_date":"2023-03-14"},{"pcpa_file_number":"21745","brand_name":"Opdivo","generic_name":"nivolumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Esophageal or gastroesophageal junction cancer, completely resected, adjuvant treatment in patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT)","status":"Concluded with an LOI","cda_amc_project_id":"PC0253-000","inesss_project_id":"","engagement_date":"2022-06-28","close_date":"2022-08-25"},{"pcpa_file_number":"21742","brand_name":"Perjeta","generic_name":"pertuzumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Breast cancer, Locally advanced, inflammatory, or early stage HER2-positive (either 2 cm in diameter or node positive), for neoadjuvant treatment of patients (in combination with trastuzumab and chemotherapy)","status":"Concluded without agreement","cda_amc_project_id":"PC0241-000","inesss_project_id":"","engagement_date":"2023-06-28","close_date":"2023-12-21"},{"pcpa_file_number":"21738","brand_name":"Increlex","generic_name":"mecasermin","manufacturer_negotiated_with":"Ipsen Biopharmaceuticals Canada, Inc.","indication":"Severe Primary Insulin-like Growth Factor-1 Deficiency","status":"Concluded with an LOI","cda_amc_project_id":"SR0692-000","inesss_project_id":"","engagement_date":"2022-06-13","close_date":"2023-02-06"},{"pcpa_file_number":"21732","brand_name":"Dojolvi","generic_name":"triheptanoin","manufacturer_negotiated_with":"Ultragenyx Canada Inc.","indication":"Long-Chain Fatty Acid Oxidation Disorders","status":"Concluded with an LOI","cda_amc_project_id":"SR0684-000","inesss_project_id":"","engagement_date":"2022-04-22","close_date":"2023-03-14"},{"pcpa_file_number":"21728","brand_name":"Trazimera","generic_name":"trastuzumab","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Metastatic breast cancer (HER2-positive) in patients who have not received prior antiHER2 therapy or chemotherapy for metastatic disease","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2022-02-16","close_date":"2022-05-10"},{"pcpa_file_number":"21726","brand_name":"Herzuma","generic_name":"trastuzumab","manufacturer_negotiated_with":"Teva Canada Ltd.","indication":"Metastatic breast cancer (HER2-positive) in patients who have not received prior antiHER2 therapy or chemotherapy for metastatic disease","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2022-02-16","close_date":"2022-05-10"},{"pcpa_file_number":"21724","brand_name":"Ogivri","generic_name":"trastuzumab","manufacturer_negotiated_with":"BGP Pharma ULC","indication":"Metastatic breast cancer (HER2-positive) in patients who have not received prior antiHER2 therapy or chemotherapy for metastatic disease","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2022-02-16","close_date":"2022-05-17"},{"pcpa_file_number":"21722","brand_name":"Kanjinti","generic_name":"trastuzumab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Metastatic breast cancer (HER2-positive) in patients who have not received prior antiHER2 therapy or chemotherapy for metastatic disease","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2022-02-16","close_date":"2022-05-16"},{"pcpa_file_number":"21720","brand_name":"Imvexxy","generic_name":"estradiol","manufacturer_negotiated_with":"Knight Therapeutics Inc.","indication":"Postmenopausal dyspareunia, moderate to severe","status":"Concluded with an LOI","cda_amc_project_id":"SR0694-000","inesss_project_id":"","engagement_date":"2022-07-13","close_date":"2023-01-20"},{"pcpa_file_number":"21713","brand_name":"Tagrisso","generic_name":"osimertinib","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Non-small cell lung cancer (NSCLC) adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations","status":"Concluded with an LOI","cda_amc_project_id":"PC0246-000","inesss_project_id":"","engagement_date":"2022-05-16","close_date":"2022-10-07"},{"pcpa_file_number":"21710","brand_name":"Opdivo-Yervoy","generic_name":"nivolumab-ipilimumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations, first-line treatment (in combination with ipilimumab and 2 cycles of platinum-based chemotherapy)","status":"Concluded with an LOI","cda_amc_project_id":"PC0218-000","inesss_project_id":"","engagement_date":"2021-11-01","close_date":"2022-01-18"},{"pcpa_file_number":"21707","brand_name":"Kyprolis","generic_name":"carfilzomib","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Multiple Myeloma (including relapsed)","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2022-02-03","close_date":"2022-05-09"},{"pcpa_file_number":"21705","brand_name":"Padcev","generic_name":"enfortumab vedotin","manufacturer_negotiated_with":"Seagen Canada Inc.","indication":"Unresectable, locally advanced or metastatic urothelial cancer in adult patients who have previously received a platinum-containing chemotherapy and programmed death receptor-1 or programmed death-ligand 1 inhibitor therapy","status":"Concluded with an LOI","cda_amc_project_id":"PC0251-000","inesss_project_id":"","engagement_date":"2022-06-28","close_date":"2022-11-28"},{"pcpa_file_number":"21701","brand_name":"Ontruzant","generic_name":"trastuzumab","manufacturer_negotiated_with":"Organon Canada Inc.","indication":"Metastatic breast cancer (HER2-positive) in patients with who have not received prior antiHER2 therapy or chemotherapy for metastatic disease; Early Breast Cancer (EBC); Metastatic Breast Cancer (MBC); and Metastatic Gastric Cancer (MGC)","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2022-02-16","close_date":"2022-05-16"},{"pcpa_file_number":"21696","brand_name":"Mvasi","generic_name":"bevacizumab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Carcinoma of the colon or rectum, metastatic, first-line treatment in combination with fluoropyrimidine based chemotherapy or patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer, in combination with carboplatin\/paclitaxel chemotherapy regimen","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2022-01-14","close_date":"2022-01-14"},{"pcpa_file_number":"21694","brand_name":"Opsynvi","generic_name":"macitentan and tadalafil","manufacturer_negotiated_with":"Janssen Inc.","indication":"Pulmonary Arterial Hypertension","status":"Concluded without agreement","cda_amc_project_id":"SR0690-000","inesss_project_id":"","engagement_date":"2022-02-16","close_date":"2022-05-09"},{"pcpa_file_number":"21690","brand_name":"Emgality","generic_name":"galcanezumab","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Migraine, prevention","status":"Concluded with an LOI","cda_amc_project_id":"SR0693-000","inesss_project_id":"","engagement_date":"2022-03-29","close_date":"2022-11-22"},{"pcpa_file_number":"21686","brand_name":"Reblozyl","generic_name":"luspatercept","manufacturer_negotiated_with":"Celgene Inc.","indication":"Myelodysplastic Syndromes Associated Anemia","status":"Concluded with an LOI","cda_amc_project_id":"SR0670-000","inesss_project_id":"","engagement_date":"2022-03-07","close_date":"2022-10-18"},{"pcpa_file_number":"21683","brand_name":"Brukinsa","generic_name":"zanubrutinib","manufacturer_negotiated_with":"BeiGene, Ltd.","indication":"Waldenstr\ufffdm\u0026#039;s Macroglobulinemia","status":"Concluded with an LOI","cda_amc_project_id":"PC0248-000","inesss_project_id":"","engagement_date":"2022-10-05","close_date":"2022-12-22"},{"pcpa_file_number":"21677","brand_name":"Ledaga","generic_name":"chlormethine hydrochloride","manufacturer_negotiated_with":"Recordati Rare Diseases Canada Inc.","indication":"Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL)","status":"Concluded without agreement","cda_amc_project_id":"PC0242-000","inesss_project_id":"","engagement_date":"2022-10-21","close_date":"2023-01-27"},{"pcpa_file_number":"21668","brand_name":"Evenity","generic_name":"romosozumab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Osteoporosis","status":"Concluded with an LOI","cda_amc_project_id":"SR0676-000","inesss_project_id":"","engagement_date":"2022-03-31","close_date":"2023-06-28"},{"pcpa_file_number":"21665","brand_name":"MAR-Trientine","generic_name":"trientine","manufacturer_negotiated_with":"Marcan Pharmaceuticals Inc.","indication":"Wilson\u0026#039;s Disease","status":"Concluded with an LOI","cda_amc_project_id":"SR0680-000","inesss_project_id":"","engagement_date":"2021-12-07","close_date":"2022-03-25"},{"pcpa_file_number":"21661","brand_name":"Tukysa","generic_name":"tucatinib","manufacturer_negotiated_with":"Seagen Canada Inc.","indication":"Breast cancer, locally advanced unresectable or metastatic, HER2-positive, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination (in combination with trastuzumab and capecitabine)","status":"Concluded with an LOI","cda_amc_project_id":"PC0243-000","inesss_project_id":"","engagement_date":"2022-05-18","close_date":"2022-09-14"},{"pcpa_file_number":"21655","brand_name":"Abecma","generic_name":"idecabtagene vicleucel","manufacturer_negotiated_with":"Celgene Inc.","indication":"Multiple myeloma (MM) in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, and who are refractory to their last treatment.","status":"Negotiations were not pursued","cda_amc_project_id":"PG0240-000","inesss_project_id":"","engagement_date":"","close_date":"2024-04-18"},{"pcpa_file_number":"21650","brand_name":"Zaxine","generic_name":"rifaximin","manufacturer_negotiated_with":"Lupin Pharma Canada Ltd.","indication":"Hepatic Encephalopathy","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-11-10","close_date":"2022-10-18"},{"pcpa_file_number":"21649","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT","status":"Concluded with an LOI","cda_amc_project_id":"PC0236-000","inesss_project_id":"","engagement_date":"2021-11-18","close_date":"2021-11-18"},{"pcpa_file_number":"21646","brand_name":"Aybintio","generic_name":"bevacizumab","manufacturer_negotiated_with":"Organon Canada Inc.","indication":"Metastatic Colorectal Cancer (mCRC); Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC); Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; and Malignant Glioma (WHO Grade IV) - Glioblastoma","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2022-01-14","close_date":"2022-03-16"},{"pcpa_file_number":"21641","brand_name":"Onureg","generic_name":"azacitidine","manufacturer_negotiated_with":"Celgene Inc.","indication":"Acute myeloid leukemia (AML), Maintenance therapy in adult patients who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation (HSCT)","status":"Concluded with an LOI","cda_amc_project_id":"PC0245-000","inesss_project_id":"","engagement_date":"2022-01-27","close_date":"2022-06-07"},{"pcpa_file_number":"21637","brand_name":"Abrilada","generic_name":"adalimumab","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn\u0026#039;s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-11-03","close_date":"2022-02-28"},{"pcpa_file_number":"21634","brand_name":"Yuflyma","generic_name":"adalimumab","manufacturer_negotiated_with":"Celltrion Healthcare Canada Ltd.","indication":"Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn\u0026#039;s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-11-03","close_date":"2022-03-01"},{"pcpa_file_number":"21631","brand_name":"Kirsty","generic_name":"insulin aspart","manufacturer_negotiated_with":"BGP Pharma ULC, d.b.a. Viatris Canada","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2022-02-28","close_date":"2022-06-01"},{"pcpa_file_number":"21627","brand_name":"Givlaari","generic_name":"givosiran","manufacturer_negotiated_with":"Alnylam Netherlands B.V.","indication":"Acute Hepatic Porphyria","status":"Concluded with an LOI","cda_amc_project_id":"SR0679-000","inesss_project_id":"","engagement_date":"2022-03-25","close_date":"2023-04-27"},{"pcpa_file_number":"21621","brand_name":"Xeomin","generic_name":"incobotulinumtoxinA","manufacturer_negotiated_with":"Merz Therapeutics Canada","indication":"Chronic Sialorrhea associated with neurological disorders","status":"Concluded without agreement","cda_amc_project_id":"SR0678-000","inesss_project_id":"","engagement_date":"2022-01-28","close_date":"2022-12-23"},{"pcpa_file_number":"21615","brand_name":"Perseris","generic_name":"risperidone","manufacturer_negotiated_with":"HLS Therapeutics Inc.","indication":"Schizophrenia","status":"Concluded without agreement","cda_amc_project_id":"SR0671-000","inesss_project_id":"","engagement_date":"2022-02-28","close_date":"2022-06-01"},{"pcpa_file_number":"21608","brand_name":"Inqovi","generic_name":"decitabine-cedazuridine","manufacturer_negotiated_with":"Taiho Pharma Canada Inc.","indication":"Myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups, in adult patients","status":"Concluded without agreement","cda_amc_project_id":"PC0228-000","inesss_project_id":"","engagement_date":"2022-02-16","close_date":"2022-04-22"},{"pcpa_file_number":"21602","brand_name":"Saxenda","generic_name":"liraglutide","manufacturer_negotiated_with":"Novo Nordisk Canada Inc.","indication":"Chronic weight management","status":"Negotiations were not pursued","cda_amc_project_id":"SR0668-000","inesss_project_id":"","engagement_date":"","close_date":"2021-11-22"},{"pcpa_file_number":"21598","brand_name":"Vitrakvi","generic_name":"larotrectinib","manufacturer_negotiated_with":"Bayer Inc.","indication":"Solid tumours in adult and pediatric patients that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options.","status":"Concluded with an LOI","cda_amc_project_id":"PC0221-000","inesss_project_id":"","engagement_date":"2022-03-31","close_date":"2022-11-07"},{"pcpa_file_number":"21595","brand_name":"Breztri Aerosphere","generic_name":"budesonide\/glycopyrronium\/ formeterol fumarate dihydrate","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Chronic Obstructive Pulmonary Disease (COPD)","status":"Concluded with an LOI","cda_amc_project_id":"SR0675-000","inesss_project_id":"","engagement_date":"2022-02-28","close_date":"2022-06-15"},{"pcpa_file_number":"21591","brand_name":"Trikafta","generic_name":"elexacaftor\/tezacaftor\/ivacaftor and ivacaftor","manufacturer_negotiated_with":"Vertex Pharmaceuticals (Canada) Incorporated","indication":"Cystic Fibrosis, F508del CFTR mutation","status":"Concluded with an LOI","cda_amc_project_id":"SR0673-000","inesss_project_id":"","engagement_date":"2021-09-17","close_date":"2021-09-17"},{"pcpa_file_number":"21588","brand_name":"Vyxeos","generic_name":"daunorubicin and cytarabine","manufacturer_negotiated_with":"Jazz Pharmaceuticals Canada Inc.","indication":"Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) or newly diagnosed therapy-related acute myeloid leukaemia (t-AML) , in adults","status":"Concluded with an LOI","cda_amc_project_id":"PC0237-000","inesss_project_id":"","engagement_date":"2022-01-13","close_date":"2022-04-27"},{"pcpa_file_number":"21582","brand_name":"Tecartus","generic_name":"brexucabtagene autoleucel","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"Mantle cell lymphoma (MCL), relapsed or refractory, in adult patients who have received treatment with a Bruton\u0026#039;s tyrosine kinase inhibitor (BTKi)","status":"Concluded with an LOI","cda_amc_project_id":"PG0219-000","inesss_project_id":"","engagement_date":"2021-11-22","close_date":"2022-11-10"},{"pcpa_file_number":"21578","brand_name":"Evrysdi","generic_name":"risdiplam","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Spinal Muscular Atrophy","status":"Concluded with an LOI","cda_amc_project_id":"SR0661-000","inesss_project_id":"","engagement_date":"2021-08-27","close_date":"2022-01-19"},{"pcpa_file_number":"21574","brand_name":"Rinvoq","generic_name":"upadacitinib","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Psoriatic Arthritis","status":"Concluded with an LOI","cda_amc_project_id":"SR0658-000","inesss_project_id":"","engagement_date":"2022-02-28","close_date":"2022-08-08"},{"pcpa_file_number":"21571","brand_name":"Entuzity KwikPen","generic_name":"human insulin","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"SR0672-000","inesss_project_id":"","engagement_date":"2021-11-18","close_date":"2022-02-07"},{"pcpa_file_number":"21567","brand_name":"Jorveza","generic_name":"budesonide","manufacturer_negotiated_with":"AVIR Pharma Inc.","indication":"Eosinophilic Esophagitis (Maintenance)","status":"Concluded without agreement","cda_amc_project_id":"SR0666-000","inesss_project_id":"","engagement_date":"2021-10-22","close_date":"2022-07-20"},{"pcpa_file_number":"21564","brand_name":"Venclexta","generic_name":"venetoclax","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Acute myeloid leukemia (AML) Newly diagnosed in patients who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy (In combination with low-dose cytarabine)","status":"Negotiations were not pursued","cda_amc_project_id":"PC0239-000","inesss_project_id":"","engagement_date":"","close_date":"2021-09-28"},{"pcpa_file_number":"21561","brand_name":"Venclexta","generic_name":"venetoclax","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Acute myeloid leukemia (AML) newly diagnosed in patients who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy (in combination with azacitidine)","status":"Concluded with an LOI","cda_amc_project_id":"PC0238-000","inesss_project_id":"","engagement_date":"2021-09-29","close_date":"2021-12-06"},{"pcpa_file_number":"21558","brand_name":"Entresto","generic_name":"sacubitril\/valsartan","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Heart failure, NYHA class II or III","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-08-20","close_date":"2022-08-17"},{"pcpa_file_number":"21557","brand_name":"Opdivo-Yervoy","generic_name":"nivolumab-ipilimumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Unresectable malignant pleural mesothelioma (MPM) in adult patients who have not received prior systemic therapy for MPM (in combination with ipilimumab)","status":"Concluded with an LOI","cda_amc_project_id":"PC0229-000","inesss_project_id":"","engagement_date":"2021-10-29","close_date":"2022-01-18"},{"pcpa_file_number":"21553","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), for first-line treatment of adult patients","status":"Concluded with an LOI","cda_amc_project_id":"PC0235-000","inesss_project_id":"","engagement_date":"2021-08-11","close_date":"2021-08-11"},{"pcpa_file_number":"21550","brand_name":"Imfinzi","generic_name":"durvalumab","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Extensive-stage small cell lung cancer (ES-SCLC) in adult patients, first-line treatment (in combination with etoposide and either carboplatin or cisplatin)","status":"Concluded with an LOI","cda_amc_project_id":"PC0234-000","inesss_project_id":"","engagement_date":"2021-10-21","close_date":"2022-05-18"},{"pcpa_file_number":"21548","brand_name":"Braftovi","generic_name":"encorafenib","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Metastatic colorectal cancer (mCRC)  in patients with a BRAF V600E mutation, as detected by a validated test, after prior therapy (in combination with cetuximab)","status":"Concluded with an LOI","cda_amc_project_id":"PC0233-000","inesss_project_id":"","engagement_date":"2021-11-03","close_date":"2022-07-06"},{"pcpa_file_number":"21544","brand_name":"Braftovi\/Mektovi","generic_name":"encorfenib\/binimetinib","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test, (encorafenib and binimetinib in combination)","status":"Concluded with an LOI","cda_amc_project_id":"PC0232-000","inesss_project_id":"","engagement_date":"2021-11-03","close_date":"2022-07-06"},{"pcpa_file_number":"21540","brand_name":"Unituxin","generic_name":"dinutuximab","manufacturer_negotiated_with":"United Therapeutics","indication":"High-risk Neuroblastoma in patients in their first relapse or determination of refractory disease, in combination with irinotecan, temozolomide, and granulocyte macrophage colony-stimulating factor","status":"Concluded with an LOI","cda_amc_project_id":"PC0222-000","inesss_project_id":"","engagement_date":"2021-11-16","close_date":"2022-02-24"},{"pcpa_file_number":"21527","brand_name":"Inrebic","generic_name":"fedrantinib","manufacturer_negotiated_with":"Celgene Inc.","indication":"Splenomegaly and\/or disease-related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib","status":"Concluded with an LOI","cda_amc_project_id":"PC0205-000","inesss_project_id":"","engagement_date":"2021-12-21","close_date":"2022-05-13"},{"pcpa_file_number":"21521","brand_name":"Zeposia","generic_name":"ozanimod","manufacturer_negotiated_with":"Celgene Inc.","indication":"Multiple Sclerosis, Relapsing-Remitting","status":"Negotiations were not pursued","cda_amc_project_id":"SR0652-000","inesss_project_id":"","engagement_date":"","close_date":"2021-07-29"},{"pcpa_file_number":"21518","brand_name":"Rybelsus","generic_name":"semaglutide","manufacturer_negotiated_with":"Novo Nordisk Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded without agreement","cda_amc_project_id":"SR0637-000","inesss_project_id":"","engagement_date":"2021-11-04","close_date":"2022-12-20"},{"pcpa_file_number":"21515","brand_name":"Insulin pumps and pump supplies","generic_name":"Insulin pumps and pump supplies","manufacturer_negotiated_with":"Tandem Diabetes Care Canada, Inc.","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-06-29","close_date":"2022-03-29"},{"pcpa_file_number":"21512","brand_name":"Veltassa","generic_name":"patiromer","manufacturer_negotiated_with":"Otsuka Canada Pharmaceutical Inc.","indication":"Hyperkalemia","status":"Concluded without agreement","cda_amc_project_id":"SR0665-000","inesss_project_id":"","engagement_date":"2021-11-18","close_date":"2022-02-18"},{"pcpa_file_number":"21506","brand_name":"Reblozyl","generic_name":"luspatercept","manufacturer_negotiated_with":"Celgene Inc.","indication":"Beta-Thalassemia Associated Anemia","status":"Concluded with an LOI","cda_amc_project_id":"SR0669-000","inesss_project_id":"","engagement_date":"2022-03-07","close_date":"2022-10-18"},{"pcpa_file_number":"21501","brand_name":"Dupixent","generic_name":"dupilumab","manufacturer_negotiated_with":"Sanofi Genzyme Canada","indication":"Asthma","status":"Concluded without agreement","cda_amc_project_id":"SR0667-000","inesss_project_id":"","engagement_date":"2021-11-01","close_date":"2022-06-28"},{"pcpa_file_number":"21500","brand_name":"Tafinlar\/Mekinist","generic_name":"dabrafenib\/trametinib","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation in patients who have not received any prior anti-cancer therapy for metastatic disease","status":"Concluded without agreement","cda_amc_project_id":"PC0226-000","inesss_project_id":"","engagement_date":"2021-09-10","close_date":"2022-09-30"},{"pcpa_file_number":"21496","brand_name":"Ilumya","generic_name":"tildrakizumab","manufacturer_negotiated_with":"Sun Pharma Canada Inc.","indication":"Psoriasis, moderate to severe plaque","status":"Concluded with an LOI","cda_amc_project_id":"SR0624-000","inesss_project_id":"","engagement_date":"2021-09-17","close_date":"2021-12-20"},{"pcpa_file_number":"21494","brand_name":"Simlandi","generic_name":"adalimumab","manufacturer_negotiated_with":"Jamp Pharma Corporation","indication":"Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn\u0026#039;s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-11-03","close_date":"2022-03-03"},{"pcpa_file_number":"21489","brand_name":"Corzyna","generic_name":"ranolazine","manufacturer_negotiated_with":"KYE Pharmaceuticals Inc.","indication":"Angina Pectoris","status":"Concluded without agreement","cda_amc_project_id":"SR0655-000","inesss_project_id":"","engagement_date":"2022-10-24","close_date":"2023-01-23"},{"pcpa_file_number":"21484","brand_name":"Zejula","generic_name":"Niraparib","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Ovarian Cancer: Maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy","status":"Concluded with an LOI","cda_amc_project_id":"PC0224-000","inesss_project_id":"","engagement_date":"2021-06-01","close_date":"2021-08-11"},{"pcpa_file_number":"21480","brand_name":"Odomzo","generic_name":"sonidegib","manufacturer_negotiated_with":"Sun Pharma Canada Inc.","indication":"Basal Cell Carcinoma (BCC), locally advanced in adult patients with histologically confirmed laBCC that is not amenable to radiation therapy or curative surgery","status":"Negotiations were not pursued","cda_amc_project_id":"PC0215-000","inesss_project_id":"","engagement_date":"","close_date":"2021-06-04"},{"pcpa_file_number":"21474","brand_name":"Bambevi","generic_name":"bevacizumab","manufacturer_negotiated_with":"Apotex Inc.","indication":"Metastatic Colorectal Cancer (mCRC) Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer Malignant Glioma (WHO Grade IV) - Glioblastoma","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-06-11","close_date":"2021-08-18"},{"pcpa_file_number":"21471","brand_name":"Polivy","generic_name":"Polatuzumab Vedotin","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), relapsed or refractory, in adult patients who are not eligible for autologous stem cell transplant \u0026amp; have received at least one prior therapy (In combination with bendamustine \u0026amp; rituximab)","status":"Concluded with an LOI","cda_amc_project_id":"PC0227-000","inesss_project_id":"","engagement_date":"2021-07-21","close_date":"2021-12-01"},{"pcpa_file_number":"21467","brand_name":"Alunbrig","generic_name":"brigatinib","manufacturer_negotiated_with":"Takeda Canada Inc.","indication":"Non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic, previously untreated with an ALK inhibitor, in adult patients","status":"Concluded with an LOI","cda_amc_project_id":"PC0230-000","inesss_project_id":"","engagement_date":"2021-10-29","close_date":"2021-12-16"},{"pcpa_file_number":"21464","brand_name":"Lynparza","generic_name":"olaparib","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Metastatic Castration-Resistant Prostate Cancer and Deleterious or suspected deleterious germline\/somatic mutations in the HRR genes BRCA or ATM, monotherapy for the treatment of adult patients with mCRPC who have progressed following prior treatment with a NHA","status":"Concluded with an LOI","cda_amc_project_id":"PC0223-000","inesss_project_id":"","engagement_date":"2021-07-07","close_date":"2022-01-17"},{"pcpa_file_number":"21461","brand_name":"Rozlytrek","generic_name":"Entrectinib","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"ROS1-positive Non-Small Cell Lung Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0206-000","inesss_project_id":"","engagement_date":"2021-05-04","close_date":"2021-07-06"},{"pcpa_file_number":"21457","brand_name":"Ruzurgi","generic_name":"Amifampridine","manufacturer_negotiated_with":"M\ufffddunik Canada Inc.","indication":"Lambert-Eaton Myasthenic Syndrome (LEMS)","status":"Concluded without agreement","cda_amc_project_id":"SR0660-000","inesss_project_id":"","engagement_date":"2021-10-18","close_date":"2022-06-01"},{"pcpa_file_number":"21451","brand_name":"Enspryng","generic_name":"satralizumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Neuromyelitis optica spectrum disorder (NMOSD)","status":"Concluded with an LOI","cda_amc_project_id":"SR0663-000","inesss_project_id":"","engagement_date":"2021-06-30","close_date":"2022-06-28"},{"pcpa_file_number":"21447","brand_name":"Osnuvo","generic_name":"teriparatide","manufacturer_negotiated_with":"AVIR Pharma Inc.","indication":"Osteoporosis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-06-04","close_date":"2021-09-15"},{"pcpa_file_number":"21444","brand_name":"Sarclisa","generic_name":"Isatuximab","manufacturer_negotiated_with":"Sanofi Genzyme Canada","indication":"Multiple myeloma, relapsed and refractory, in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. (in combination with pomalidomide and dexamethasone)","status":"Concluded with an LOI","cda_amc_project_id":"PC0220-000","inesss_project_id":"","engagement_date":"2022-05-13","close_date":"2023-03-07"},{"pcpa_file_number":"21440","brand_name":"Remsima SC","generic_name":"infliximab","manufacturer_negotiated_with":"Celltrion Healthcare Canada Ltd.","indication":"Rheumatoid Arthritis","status":"Concluded without agreement","cda_amc_project_id":"SR0659-000","inesss_project_id":"","engagement_date":"2021-06-04","close_date":"2022-03-10"},{"pcpa_file_number":"21437","brand_name":"Abevmy","generic_name":"bevacizumab","manufacturer_negotiated_with":"BGP Pharma ULC","indication":"Metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung Cancer (NSCLC), platinum-resistant recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, and glioblastoma","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-06-11","close_date":"2021-10-25"},{"pcpa_file_number":"21433","brand_name":"Bavencio","generic_name":"avelumab","manufacturer_negotiated_with":"EMD Serono Canada, a division of EMD Inc.","indication":"Urothelial carcinoma (UC), first-line maintenance treatment of patients with locally advanced or metastatic whose disease has not progressed with first-line platinum-based induction chemotherapy","status":"Concluded with an LOI","cda_amc_project_id":"PC0225-000","inesss_project_id":"","engagement_date":"2021-07-22","close_date":"2021-12-15"},{"pcpa_file_number":"21431","brand_name":"Ajovy","generic_name":"fremanezumab","manufacturer_negotiated_with":"Teva Canada Ltd.","indication":"Prevention of Migraine in Adults","status":"Concluded with an LOI","cda_amc_project_id":"SR0641-000","inesss_project_id":"","engagement_date":"2021-07-16","close_date":"2021-12-03"},{"pcpa_file_number":"21423","brand_name":"Entresto","generic_name":"sacubitril\/valsartan","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Heart failure, NYHA class II or III","status":"Concluded with an LOI","cda_amc_project_id":"SR0644-000","inesss_project_id":"","engagement_date":"2022-08-17","close_date":"2022-08-17"},{"pcpa_file_number":"21416","brand_name":"Calquence","generic_name":"Acalabrutinib","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Chronic Lymphocytic Leukemia (CLL) (previously untreated): With or without obinutuzumab, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) for whom a fludarabine-based regimen is inappropriate","status":"Concluded with an LOI","cda_amc_project_id":"PC0210-000","inesss_project_id":"","engagement_date":"2021-05-27","close_date":"2021-10-05"},{"pcpa_file_number":"21413","brand_name":"Calquence","generic_name":"Acalabrutinib","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.","status":"Concluded with an LOI","cda_amc_project_id":"PC0211-000","inesss_project_id":"","engagement_date":"2021-05-27","close_date":"2021-10-05"},{"pcpa_file_number":"21410","brand_name":"Kynmobi","generic_name":"apomorphine hydrochloride","manufacturer_negotiated_with":"Sunovion Pharmaceuticals Canada Inc.","indication":"Parkinson\u0026#039;s disease","status":"Concluded with an LOI","cda_amc_project_id":"SR0650-000","inesss_project_id":"","engagement_date":"2021-09-03","close_date":"2022-04-04"},{"pcpa_file_number":"21407","brand_name":"Kesimpta","generic_name":"ofatumumab","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Multiple Sclerosis, Relapsing-Remitting","status":"Concluded with an LOI","cda_amc_project_id":"SR0657-000","inesss_project_id":"","engagement_date":"2021-08-27","close_date":"2022-03-02"},{"pcpa_file_number":"21403","brand_name":"Ofev","generic_name":"nintedanib","manufacturer_negotiated_with":"Boehringer Ingelheim (Canada) Ltd.","indication":"Chronic fibrosing interstitial lung diseases","status":"Concluded with an LOI","cda_amc_project_id":"SR0654-000","inesss_project_id":"","engagement_date":"2021-07-16","close_date":"2022-02-05"},{"pcpa_file_number":"21400","brand_name":"Darzalex SC","generic_name":"Daratumumab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Multiple Myeloma","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-02-26","close_date":"2022-02-25"},{"pcpa_file_number":"21399","brand_name":"Daurismo","generic_name":"Glasdegib","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Acute Myeloid Leukemia (AML)","status":"Negotiations were not pursued","cda_amc_project_id":"PC0207-000","inesss_project_id":"","engagement_date":"","close_date":"2021-02-23"},{"pcpa_file_number":"21396","brand_name":"pdp-levETIRAcetam","generic_name":"levetiracetam","manufacturer_negotiated_with":"Pendopharm, a division of Pharmascience Inc.","indication":"Epilepsy","status":"Concluded with an LOI","cda_amc_project_id":"SR0653-000","inesss_project_id":"","engagement_date":"2021-11-23","close_date":"2022-08-05"},{"pcpa_file_number":"21392","brand_name":"Zolgensma","generic_name":"onasemnogene abeparvovec","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Spinal Muscular Atrophy","status":"Concluded with an LOI","cda_amc_project_id":"SG0649-000","inesss_project_id":"","engagement_date":"2021-02-19","close_date":"2021-10-08"},{"pcpa_file_number":"21390","brand_name":"Tecentriq \u0026amp; Avastin","generic_name":"Atezolizumab \u0026amp; Bevacizumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Unresectable or metastatic hepatocellular carcinoma (HCC) in adult patients who require systemic therapy","status":"Concluded with an LOI","cda_amc_project_id":"PC0217-000","inesss_project_id":"","engagement_date":"2021-03-26","close_date":"2021-10-14"},{"pcpa_file_number":"21386","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Head and Neck Squamous Cell Carcinoma (HNSCC)","status":"Concluded with an LOI","cda_amc_project_id":"PC0216-000","inesss_project_id":"","engagement_date":"2021-02-10","close_date":"2021-02-10"},{"pcpa_file_number":"21379","brand_name":"Forxiga","generic_name":"dapagliflozin","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Heart failure, NYHA class II or III","status":"Concluded with an LOI","cda_amc_project_id":"SR0642-000","inesss_project_id":"","engagement_date":"2021-06-17","close_date":"2021-11-18"},{"pcpa_file_number":"21377","brand_name":"Entyvio (SC)","generic_name":"vedolizumab","manufacturer_negotiated_with":"Takeda Canada Inc.","indication":"Crohn\u0026#039;s disease","status":"Concluded with an LOI","cda_amc_project_id":"SR0647-000","inesss_project_id":"","engagement_date":"2021-04-15","close_date":"2021-08-13"},{"pcpa_file_number":"21375","brand_name":"Venclexta","generic_name":"venetoclax","manufacturer_negotiated_with":"AbbVie Corporation","indication":"in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible.","status":"Concluded with an LOI","cda_amc_project_id":"PC0212-000","inesss_project_id":"","engagement_date":"2021-02-23","close_date":"2021-10-13"},{"pcpa_file_number":"21373","brand_name":"Adcetris","generic_name":"brentuximab vedotin","manufacturer_negotiated_with":"Seattle Genetics Inc.","indication":"Hodgkin\u0026#039;s Lymphoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0214-000","inesss_project_id":"","engagement_date":"2021-02-05","close_date":"2021-04-28"},{"pcpa_file_number":"21371","brand_name":"Adcetris","generic_name":"brentuximab vedotin","manufacturer_negotiated_with":"Seattle Genetics Inc.","indication":"Primary Cutaneous Anaplastic Large Cell Lymphoma (or CD30- Expressing Mycosis Fungoides)","status":"Concluded with an LOI","cda_amc_project_id":"PC0213-000","inesss_project_id":"","engagement_date":"2021-02-05","close_date":"2021-04-28"},{"pcpa_file_number":"21368","brand_name":"Spravato","generic_name":"esketamine hydrochloride","manufacturer_negotiated_with":"Janssen Inc.","indication":"Major Depressive Disorder","status":"Negotiations were not pursued","cda_amc_project_id":"SR0621-000","inesss_project_id":"","engagement_date":"","close_date":"2021-01-27"},{"pcpa_file_number":"21365","brand_name":"Blincyto","generic_name":"blinatumomab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Minimal Residual Disease (MRD)-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (BCP ALL)","status":"Concluded with an LOI","cda_amc_project_id":"PC0204-000","inesss_project_id":"","engagement_date":"2020-12-17","close_date":"2021-05-21"},{"pcpa_file_number":"21362","brand_name":"Riabni","generic_name":"rituximab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Non-Hodgkin\u0026#039;s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA)","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-06-11","close_date":"2021-10-14"},{"pcpa_file_number":"21360","brand_name":"Inclunox","generic_name":"enoxaparin","manufacturer_negotiated_with":"Sandoz Canada Inc.","indication":"Deep vein thrombosis (treatment and prevention)","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-01-28","close_date":"2021-04-15"},{"pcpa_file_number":"21358","brand_name":"Noromby","generic_name":"enoxaparin","manufacturer_negotiated_with":"Juno Pharmaceuticals Corp.","indication":"Deep vein thrombosis (treatment and prevention)","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-01-28","close_date":"2021-05-27"},{"pcpa_file_number":"21350","brand_name":"Nyvepria","generic_name":"pegfilgrastim","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Febrile neutropenia in non-myeloid malignancies","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-01-13","close_date":"2021-04-05"},{"pcpa_file_number":"21348","brand_name":"Trurapi","generic_name":"insulin aspart","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-04-27","close_date":"2021-08-16"},{"pcpa_file_number":"21346","brand_name":"Foquest","generic_name":"methylphenidate","manufacturer_negotiated_with":"Elvium Life Sciences","indication":"Attention-deficit\/hyperactivity disorder (ADHD)","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-06-29","close_date":"2021-06-29"},{"pcpa_file_number":"21343","brand_name":"Suboxone (film)","generic_name":"buprenorphine and naloxone","manufacturer_negotiated_with":"Indivior UK Limited","indication":"Opioid Dependence","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-03-02","close_date":"2021-07-15"},{"pcpa_file_number":"21340","brand_name":"Atectura Breezhaler","generic_name":"indacaterol \/mometasone furoate","manufacturer_negotiated_with":"Valeo Pharma Inc.","indication":"Asthma","status":"Concluded with an LOI","cda_amc_project_id":"SR0646-000","inesss_project_id":"","engagement_date":"2021-06-23","close_date":"2021-09-30"},{"pcpa_file_number":"21337","brand_name":"Enerzair Breezhaler","generic_name":"indacaterol\/glycopyrronium\/mometasone furoate","manufacturer_negotiated_with":"Valeo Pharma Inc.","indication":"Asthma","status":"Concluded with an LOI","cda_amc_project_id":"SR0645-000","inesss_project_id":"","engagement_date":"2021-06-23","close_date":"2021-09-30"},{"pcpa_file_number":"21334","brand_name":"Luxturna","generic_name":"voretigene neparvovec","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Vision loss, inherited retinal dystrophy","status":"Concluded with an LOI","cda_amc_project_id":"SG0643-000","inesss_project_id":"","engagement_date":"2021-11-25","close_date":"2022-09-16"},{"pcpa_file_number":"21326","brand_name":"Hadlima","generic_name":"adalimumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn\u0026#039;s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-11-09","close_date":"2021-01-22"},{"pcpa_file_number":"21324","brand_name":"Idacio","generic_name":"adalimumab","manufacturer_negotiated_with":"Fresenius Kabi Canada Ltd.","indication":"Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn\u0026#039;s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-11-09","close_date":"2021-01-26"},{"pcpa_file_number":"21322","brand_name":"Hyrimoz","generic_name":"adalimumab","manufacturer_negotiated_with":"Sandoz Canada Inc.","indication":"Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn\u0026#039;s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-11-09","close_date":"2021-01-20"},{"pcpa_file_number":"21320","brand_name":"Amgevita","generic_name":"adalimumab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn\u0026#039;s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-11-09","close_date":"2021-01-20"},{"pcpa_file_number":"21318","brand_name":"Hulio","generic_name":"adalimumab","manufacturer_negotiated_with":"BGP Pharma ULC","indication":"Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn\u0026#039;s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-11-09","close_date":"2021-01-20"},{"pcpa_file_number":"21316","brand_name":"Jorveza","generic_name":"budesonide","manufacturer_negotiated_with":"AVIR Pharma Inc.","indication":"Eosinophilic Esophagitis (Induction)","status":"Concluded without agreement","cda_amc_project_id":"SR0634-000","inesss_project_id":"","engagement_date":"2021-10-22","close_date":"2022-07-20"},{"pcpa_file_number":"21312","brand_name":"Duobrii","generic_name":"Halobetasol propionate and tazarotene","manufacturer_negotiated_with":"Bausch Health, Canada Inc.","indication":"Psoriasis, moderate to severe plaque","status":"Concluded with an LOI","cda_amc_project_id":"SR0638-000","inesss_project_id":"","engagement_date":"2021-09-17","close_date":"2021-11-30"},{"pcpa_file_number":"21309","brand_name":"Nexplanon","generic_name":"etonogestrel","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Conception Control","status":"Concluded with an LOI","cda_amc_project_id":"SR0648-000","inesss_project_id":"","engagement_date":"2021-02-24","close_date":"2021-09-20"},{"pcpa_file_number":"21306","brand_name":"Soliris","generic_name":"eculizumab","manufacturer_negotiated_with":"Alexion Pharma Canada Corp.","indication":"Myasthenia Gravis","status":"Concluded without agreement","cda_amc_project_id":"SR0605-000","inesss_project_id":"","engagement_date":"2021-04-01","close_date":"2022-12-12"},{"pcpa_file_number":"21304","brand_name":"Zejula","generic_name":"Niraparib","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Ovarian Cancer, monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy","status":"Concluded with an LOI","cda_amc_project_id":"PC0203-000","inesss_project_id":"","engagement_date":"2020-11-13","close_date":"2021-08-11"},{"pcpa_file_number":"21298","brand_name":"Xtandi","generic_name":"enzalutamide","manufacturer_negotiated_with":"Astellas Pharma Inc.","indication":"Metastatic Castration-Sensitive Prostate Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0209-000","inesss_project_id":"","engagement_date":"2020-10-30","close_date":"2021-07-30"},{"pcpa_file_number":"21295","brand_name":"Cablivi","generic_name":"caplacizumab","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Acquired Thrombotic Thrombocytopenic Purpura (aTTP)","status":"Negotiations were not pursued","cda_amc_project_id":"SR0633-000","inesss_project_id":"","engagement_date":"","close_date":"2020-10-23"},{"pcpa_file_number":"21290","brand_name":"Rituxan SC","generic_name":"rituximab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-08-11","close_date":"2020-10-14"},{"pcpa_file_number":"21289","brand_name":"Tecentriq \u0026amp; Avastin","generic_name":"Atezolizumab \u0026amp; Bevacizumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Non-Squamous Non-Small Cell Lung Cancer","status":"Negotiations were not pursued","cda_amc_project_id":"PC0155-000","inesss_project_id":"","engagement_date":"","close_date":"2020-09-01"},{"pcpa_file_number":"21286","brand_name":"Aimovig","generic_name":"erenumab","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Migraine, Chronic","status":"Concluded without agreement","cda_amc_project_id":"SR0578-000","inesss_project_id":"","engagement_date":"2021-01-25","close_date":"2021-12-13"},{"pcpa_file_number":"21283","brand_name":"Vocabria and Cabenuva","generic_name":"cabotegravir and rilpivirine","manufacturer_negotiated_with":"ViiV Healthcare","indication":"HIV-1 Infection","status":"Concluded with an LOI","cda_amc_project_id":"SR0628-000","inesss_project_id":"","engagement_date":"2020-10-22","close_date":"2021-09-07"},{"pcpa_file_number":"21280","brand_name":"Mayzent","generic_name":"siponimod","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Secondary Progressive Multiple Sclerosis (SPMS)","status":"Concluded with an LOI","cda_amc_project_id":"SR0631-000","inesss_project_id":"","engagement_date":"2021-04-27","close_date":"2021-10-22"},{"pcpa_file_number":"21276","brand_name":"Vascepa","generic_name":"icosapent ethyl","manufacturer_negotiated_with":"HLS Therapeutics Inc.","indication":"Ischemic events in statin-treated patients","status":"Concluded with an LOI","cda_amc_project_id":"SR0619-000","inesss_project_id":"","engagement_date":"2021-01-29","close_date":"2022-04-25"},{"pcpa_file_number":"21272","brand_name":"Stelara","generic_name":"ustekinumab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Ulcerative Colitis","status":"Concluded without agreement","cda_amc_project_id":"SR0627-000","inesss_project_id":"","engagement_date":"2021-04-27","close_date":"2021-07-28"},{"pcpa_file_number":"21270","brand_name":"Soliris","generic_name":"eculizumab","manufacturer_negotiated_with":"Alexion Pharma Canada Corp.","indication":"Neuromyelitis optica spectrum disorder (NMOSD)","status":"Concluded without agreement","cda_amc_project_id":"SR0640-000","inesss_project_id":"","engagement_date":"2021-03-02","close_date":"2022-12-12"},{"pcpa_file_number":"21266","brand_name":"Darzalex SC","generic_name":"Daratumumab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Multiple Myeloma","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-07-10","close_date":"2020-12-16"},{"pcpa_file_number":"21264","brand_name":"Adcetris","generic_name":"brentuximab vedotin","manufacturer_negotiated_with":"Seattle Genetics Inc.","indication":"Peripheral T-cell Lymphoma (PTCL)","status":"Concluded with an LOI","cda_amc_project_id":"PC0199-000","inesss_project_id":"","engagement_date":"2020-07-03","close_date":"2020-09-21"},{"pcpa_file_number":"21261","brand_name":"Cuvposa","generic_name":"Glycopyrrolate","manufacturer_negotiated_with":"Medexus Pharmaceuticals, Inc.","indication":"Pediatric chronic severe drooling reduction (neurologic)","status":"Concluded with an LOI","cda_amc_project_id":"SR0613-000","inesss_project_id":"","engagement_date":"2022-10-24","close_date":"2023-01-16"},{"pcpa_file_number":"21257","brand_name":"Xospata","generic_name":"Gilteritinib","manufacturer_negotiated_with":"Astellas Pharma Inc.","indication":"Acute Myeloid Leukemia (AML)","status":"Concluded with an LOI","cda_amc_project_id":"PC0202-000","inesss_project_id":"","engagement_date":"2020-08-17","close_date":"2021-03-15"},{"pcpa_file_number":"21254","brand_name":"Aermony Respiclick","generic_name":"fluticasone propionate","manufacturer_negotiated_with":"Teva Canada Ltd.","indication":"Asthma","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-10-07","close_date":"2021-02-02"},{"pcpa_file_number":"21252","brand_name":"Kisqali","generic_name":"ribociclib","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Advanced or Metastatic Breast Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0194-000","inesss_project_id":"","engagement_date":"2020-06-22","close_date":"2020-07-14"},{"pcpa_file_number":"21250","brand_name":"Kalydeco","generic_name":"ivacaftor","manufacturer_negotiated_with":"Vertex Pharmaceuticals (Canada) Incorporated","indication":"Cystic Fibrosis In Patients with CFTR Gating Mutations or the R117H Gating Mutation","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-06-12","close_date":"2021-06-03"},{"pcpa_file_number":"21249","brand_name":"Orkambi","generic_name":"lumacaftor\/ivacaftor","manufacturer_negotiated_with":"Vertex Pharmaceuticals (Canada) Incorporated","indication":"Cystic Fibrosis, F508del CFTR mutation","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-06-12","close_date":"2021-06-03"},{"pcpa_file_number":"21248","brand_name":"Contrave","generic_name":"naltrexone hydrochloride and bupropion hydrochloride","manufacturer_negotiated_with":"Bausch Health, Canada Inc.","indication":"Chronic weight management","status":"Negotiations were not pursued","cda_amc_project_id":"SR0610-000","inesss_project_id":"","engagement_date":"","close_date":"2020-10-13"},{"pcpa_file_number":"21244","brand_name":"Nubeqa","generic_name":"Darolutamide","manufacturer_negotiated_with":"Bayer Inc.","indication":"Non-metastatic Castration-resistant prostate cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0196-000","inesss_project_id":"","engagement_date":"2020-10-23","close_date":"2021-02-18"},{"pcpa_file_number":"21241","brand_name":"Erleada","generic_name":"apalutamide","manufacturer_negotiated_with":"Janssen Inc.","indication":"Metastatic Castration-Sensitive Prostate Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0200-000","inesss_project_id":"","engagement_date":"2020-10-09","close_date":"2021-08-17"},{"pcpa_file_number":"21238","brand_name":"Cabometyx","generic_name":"cabozantinib","manufacturer_negotiated_with":"Ipsen Biopharmaceuticals Canada, Inc.","indication":"Hepatocellular Carcinoma (HCC) in adults after prior therapy","status":"Concluded with an LOI","cda_amc_project_id":"PC0186-000","inesss_project_id":"","engagement_date":"2020-11-24","close_date":"2021-08-24"},{"pcpa_file_number":"21235","brand_name":"Crysvita","generic_name":"burosumab","manufacturer_negotiated_with":"Kyowa Kirin Canada, Inc.","indication":"X-Linked Hypophosphatemia","status":"Concluded with an LOI","cda_amc_project_id":"SR0602-000","inesss_project_id":"","engagement_date":"2020-10-09","close_date":"2021-09-10"},{"pcpa_file_number":"21228","brand_name":"Entyvio (SC)","generic_name":"vedolizumab","manufacturer_negotiated_with":"Takeda Canada Inc.","indication":"Ulcerative Colitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0635-000","inesss_project_id":"","engagement_date":"2020-10-19","close_date":"2021-08-13"},{"pcpa_file_number":"21225","brand_name":"Dupixent","generic_name":"dupilumab","manufacturer_negotiated_with":"Sanofi Genzyme Canada","indication":"Atopic dermatitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0636-000","inesss_project_id":"","engagement_date":"2020-07-28","close_date":"2021-02-25"},{"pcpa_file_number":"21223","brand_name":"Beovu","generic_name":"brolucizumab","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Age-Related Macular Degeneration","status":"Concluded with an LOI","cda_amc_project_id":"SR0632-000","inesss_project_id":"","engagement_date":"2021-04-27","close_date":"2021-08-31"},{"pcpa_file_number":"21220","brand_name":"Benlysta","generic_name":"belimumab","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Systemic lupus erythematosus","status":"Concluded with an LOI","cda_amc_project_id":"SR0616-000","inesss_project_id":"","engagement_date":"2023-01-25","close_date":"2024-01-18"},{"pcpa_file_number":"21218","brand_name":"Kisqali (with fulvestrant)","generic_name":"ribociclib with fulvestrant","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Advanced or Metastatic Breast Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0195-000","inesss_project_id":"","engagement_date":"2020-05-11","close_date":"2020-07-14"},{"pcpa_file_number":"21215","brand_name":"Allerject","generic_name":"epinephrine","manufacturer_negotiated_with":"Kaleo Inc","indication":"For the emergency treatment of severe acute allergic reactions (anaphylaxis).","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-05-22","close_date":"2020-07-22"},{"pcpa_file_number":"21210","brand_name":"Otezla","generic_name":"apremilast","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Psoriatic Arthritis","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-01-13","close_date":"2021-03-17"},{"pcpa_file_number":"21208","brand_name":"Otezla","generic_name":"apremilast","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Psoriasis, moderate to severe plaque","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2021-01-13","close_date":"2021-03-17"},{"pcpa_file_number":"21207","brand_name":"Avsola","generic_name":"infliximab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn\u0026#039;s disease and Ulcerative Colitis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-05-15","close_date":"2020-11-02"},{"pcpa_file_number":"21205","brand_name":"Nivestym","generic_name":"filgrastim","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Neutropenia in various indications (Prevention or treatment)","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-04-27","close_date":"2020-06-17"},{"pcpa_file_number":"21203","brand_name":"Ziextenzo","generic_name":"pegfilgrastim","manufacturer_negotiated_with":"Sandoz Canada Inc.","indication":"Febrile neutropenia in non-myeloid malignancies","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-04-27","close_date":"2020-07-22"},{"pcpa_file_number":"21201","brand_name":"Redesca","generic_name":"enoxaparin","manufacturer_negotiated_with":"Valeo Pharma Inc.","indication":"Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-11-02","close_date":"2021-03-24"},{"pcpa_file_number":"21197","brand_name":"Kanjinti","generic_name":"trastuzumab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Early breast cancer, Metastatic breast cancer, Metastatic gastric cancer","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-03-24","close_date":"2020-04-16"},{"pcpa_file_number":"21196","brand_name":"Envarsus PA","generic_name":"tacrolimus","manufacturer_negotiated_with":"Paladin Labs Inc.","indication":"Prophylaxis of Organ Rejection in Allogenic Kidney or Liver Transplant Adult Patients","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-03-16","close_date":"2020-07-30"},{"pcpa_file_number":"21195","brand_name":"Onstryv","generic_name":"safinamide","manufacturer_negotiated_with":"Valeo Pharma Inc.","indication":"Parkinson\u0026#039;s disease","status":"Concluded with an LOI","cda_amc_project_id":"SR0617-000","inesss_project_id":"","engagement_date":"2022-10-24","close_date":"2023-01-16"},{"pcpa_file_number":"21194","brand_name":"Monoferric","generic_name":"iron (iii) isomaltoside 1000","manufacturer_negotiated_with":"Pharmacosmos A\/S","indication":"Iron Deficiency Anemia","status":"Concluded with an LOI","cda_amc_project_id":"SR0622-000","inesss_project_id":"","engagement_date":"2020-07-21","close_date":"2021-02-02"},{"pcpa_file_number":"21193","brand_name":"Lokelma","generic_name":"sodium zirconium cyclosilicate","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Hyperkalemia","status":"Negotiations were not pursued","cda_amc_project_id":"SR0612-000","inesss_project_id":"","engagement_date":"","close_date":"2020-04-16"},{"pcpa_file_number":"21192","brand_name":"Taltz","generic_name":"ixekizumab","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Ankylosing spondylitis","status":"Concluded without agreement","cda_amc_project_id":"SR0630-000","inesss_project_id":"","engagement_date":"2021-01-13","close_date":"2021-03-19"},{"pcpa_file_number":"21191","brand_name":"Vyndaqel","generic_name":"tafamidis","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Transthyretin-mediated amyloidosis","status":"Concluded with an LOI","cda_amc_project_id":"SR0625-000","inesss_project_id":"","engagement_date":"2020-06-10","close_date":"2021-02-04"},{"pcpa_file_number":"21190","brand_name":"Rinvoq","generic_name":"upadacitinib","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Rheumatoid Arthritis","status":"Concluded with an LOI","cda_amc_project_id":"SR0614-000","inesss_project_id":"","engagement_date":"2021-01-21","close_date":"2022-08-08"},{"pcpa_file_number":"21189","brand_name":"Lonsurf","generic_name":"trifluridine\/tipiracil","manufacturer_negotiated_with":"Taiho Pharma Canada Inc.","indication":"Metastatic Gastric Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0197-000","inesss_project_id":"","engagement_date":"2020-07-07","close_date":"2021-01-11"},{"pcpa_file_number":"21188","brand_name":"Riximyo","generic_name":"rituximab","manufacturer_negotiated_with":"Sandoz Canada Inc.","indication":"Rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin\u0026#039;s lymphoma","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-04-24","close_date":"2020-06-19"},{"pcpa_file_number":"21186","brand_name":"Ruxience","generic_name":"rituximab","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Non-Hodgkin\u0026#039;s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA)","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-04-24","close_date":"2020-06-12"},{"pcpa_file_number":"21185","brand_name":"Lutathera","generic_name":"lutetium 177 dotatate","manufacturer_negotiated_with":"Advanced Accelerator Applications","indication":"Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-02-26","close_date":"2020-07-29"},{"pcpa_file_number":"21184","brand_name":"Baqsimi","generic_name":"glucagon","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Severe Hypoglycemia","status":"Concluded with an LOI","cda_amc_project_id":"SR0626-000","inesss_project_id":"","engagement_date":"2020-12-14","close_date":"2021-11-22"},{"pcpa_file_number":"21183","brand_name":"Admelog","generic_name":"insulin lispro","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2020-01-29","close_date":"2020-09-30"},{"pcpa_file_number":"21182","brand_name":"Lorbrena","generic_name":"lorlatinib","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Non-Small Cell Lung Cancer (ALK+)","status":"Negotiations were not pursued","cda_amc_project_id":"PC0183-000","inesss_project_id":"","engagement_date":"","close_date":"2020-04-21"},{"pcpa_file_number":"21181","brand_name":"Rydapt","generic_name":"midostaurin","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Systemic Mastocytosis","status":"Negotiations were not pursued","cda_amc_project_id":"PC0193-000","inesss_project_id":"","engagement_date":"","close_date":"2020-05-25"},{"pcpa_file_number":"21180","brand_name":"Mylotarg","generic_name":"gemtuzumab ozogamicin","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Acute Myeloid Leukemia (AML)","status":"Concluded with an LOI","cda_amc_project_id":"PC0190-000","inesss_project_id":"","engagement_date":"2020-06-17","close_date":"2020-08-12"},{"pcpa_file_number":"21179","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Renal Cell Carcinoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0185-000","inesss_project_id":"","engagement_date":"2020-05-11","close_date":"2020-12-01"},{"pcpa_file_number":"21178","brand_name":"Nerlynx","generic_name":"neratinib","manufacturer_negotiated_with":"Knight Therapeutics Inc.","indication":"Hormone Receptor-Positive Breast Cancer","status":"Negotiations were not pursued","cda_amc_project_id":"PC0172-000","inesss_project_id":"","engagement_date":"2020-02-04","close_date":"2020-02-04"},{"pcpa_file_number":"21176","brand_name":"Cimzia","generic_name":"certolizumab pegol","manufacturer_negotiated_with":"UCB Canada Inc.","indication":"Psoriasis, moderate to severe plaque","status":"Concluded without agreement","cda_amc_project_id":"SR0587-000","inesss_project_id":"","engagement_date":"2020-01-28","close_date":"2021-05-07"},{"pcpa_file_number":"21175","brand_name":"Takhzyro","generic_name":"lanadelumab","manufacturer_negotiated_with":"Shire Pharma Canada ULC","indication":"Hereditary Angioedema","status":"Concluded with an LOI","cda_amc_project_id":"SR0618-000","inesss_project_id":"","engagement_date":"2020-02-21","close_date":"2020-10-30"},{"pcpa_file_number":"21174","brand_name":"Revestive","generic_name":"teduglutide","manufacturer_negotiated_with":"Shire Pharma Canada ULC","indication":"Short Bowel Syndrome (SBS)","status":"Concluded with an LOI","cda_amc_project_id":"SR0606-000","inesss_project_id":"","engagement_date":"2020-02-21","close_date":"2020-10-28"},{"pcpa_file_number":"21173","brand_name":"Verkazia","generic_name":"cyclosporine","manufacturer_negotiated_with":"Santen Incorporated","indication":"Severe Vernal Keratoconjunctivitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0615-000","inesss_project_id":"","engagement_date":"2020-02-27","close_date":"2020-11-20"},{"pcpa_file_number":"21172","brand_name":"Lonsurf","generic_name":"trifluridine\/tipiracil","manufacturer_negotiated_with":"Taiho Pharma Canada Inc.","indication":"Metastatic Colorectal Cancer","status":"Negotiations were not pursued","cda_amc_project_id":"PC0173-000","inesss_project_id":"","engagement_date":"2019-10-18","close_date":"2019-10-18"},{"pcpa_file_number":"21171","brand_name":"Mezera","generic_name":"mesalazine","manufacturer_negotiated_with":"AVIR Pharma Inc.","indication":"Ulcerative Colitis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2019-10-31","close_date":"2020-04-21"},{"pcpa_file_number":"21170","brand_name":"Kadcyla","generic_name":"trastuzumab emtansine","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Early Breast Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0182-000","inesss_project_id":"","engagement_date":"2020-05-21","close_date":"2020-11-05"},{"pcpa_file_number":"21169","brand_name":"Darzalex","generic_name":"Daratumumab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Multiple Myeloma","status":"Concluded with an LOI","cda_amc_project_id":"PC0189-000","inesss_project_id":"","engagement_date":"2021-02-26","close_date":"2022-02-25"},{"pcpa_file_number":"21168","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Squamous Non-Small Cell Lung Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0176-000","inesss_project_id":"","engagement_date":"2020-01-22","close_date":"2020-04-15"},{"pcpa_file_number":"21167","brand_name":"Tecentriq","generic_name":"atezolizumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Extensive stage small cell lung cancer (ES-SCLC), first-line treatment, in combination with a platinum-based chemotherapy and etoposide","status":"Concluded with an LOI","cda_amc_project_id":"PC0156-000","inesss_project_id":"","engagement_date":"2021-09-27","close_date":"2022-02-11"},{"pcpa_file_number":"21166","brand_name":"Lynparza","generic_name":"olaparib","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Ovarian Cancer, monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy","status":"Concluded with an LOI","cda_amc_project_id":"PC0174-000","inesss_project_id":"","engagement_date":"2020-06-18","close_date":"2020-10-21"},{"pcpa_file_number":"21165","brand_name":"Trintellix","generic_name":"vortioxetine","manufacturer_negotiated_with":"Lundbeck Canada Inc.","indication":"Major Depressive Disorder","status":"Concluded with an LOI","cda_amc_project_id":"SR0611-000","inesss_project_id":"","engagement_date":"2020-07-06","close_date":"2020-12-03"},{"pcpa_file_number":"21164","brand_name":"Xultophy","generic_name":"insulin degludec\/liraglutide","manufacturer_negotiated_with":"Novo Nordisk Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded without agreement","cda_amc_project_id":"SR0599-000","inesss_project_id":"","engagement_date":"2020-01-31","close_date":"2021-04-26"},{"pcpa_file_number":"21163","brand_name":"Dovato","generic_name":"dolutegravir\/lamivudine","manufacturer_negotiated_with":"ViiV Healthcare","indication":"HIV-1 Infection","status":"Concluded with an LOI","cda_amc_project_id":"SR0601-000","inesss_project_id":"","engagement_date":"2019-10-04","close_date":"2019-11-21"},{"pcpa_file_number":"21162","brand_name":"Iluvien","generic_name":"fluocinolone acetonide","manufacturer_negotiated_with":"Knight Therapeutics Inc.","indication":"Diabetic Macular Edema","status":"Negotiations were not pursued","cda_amc_project_id":"SR0608-000","inesss_project_id":"","engagement_date":"2019-11-01","close_date":"2019-11-01"},{"pcpa_file_number":"21161","brand_name":"Emerade","generic_name":"epinephrine bitartrate","manufacturer_negotiated_with":"Bausch Health, Canada Inc.","indication":"For the emergency treatment of severe acute allergic reactions (anaphylaxis).","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2019-08-30","close_date":"2020-02-04"},{"pcpa_file_number":"21160","brand_name":"Bosulif","generic_name":"bosutinib","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Chronic Myeloid Leukemia","status":"Concluded with an LOI","cda_amc_project_id":"PA0002-000","inesss_project_id":"","engagement_date":"2019-08-27","close_date":"2020-02-19"},{"pcpa_file_number":"21159","brand_name":"Olumiant","generic_name":"baricitinib","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Rheumatoid Arthritis","status":"Concluded with an LOI","cda_amc_project_id":"SR0597-000","inesss_project_id":"","engagement_date":"2019-09-20","close_date":"2021-05-10"},{"pcpa_file_number":"21158","brand_name":"Orfadin Oral Suspension","generic_name":"nitisinone","manufacturer_negotiated_with":"Sobi Canada Inc.","indication":"Hereditary Tyrosinemia Type 1","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2019-08-09","close_date":"2020-03-30"},{"pcpa_file_number":"21157","brand_name":"Onpattro","generic_name":"patisiran","manufacturer_negotiated_with":"Alnylam Netherlands B.V.","indication":"Hereditary transthyretin-mediated amyloidosis","status":"Concluded with an LOI","cda_amc_project_id":"SR0598-000","inesss_project_id":"","engagement_date":"2019-11-15","close_date":"2020-11-30"},{"pcpa_file_number":"21156","brand_name":"Tegsedi","generic_name":"inotersen","manufacturer_negotiated_with":"Akcea Therapeutics Inc.","indication":"Hereditary transthyretin-mediated amyloidosis","status":"Concluded with an LOI","cda_amc_project_id":"SR0603-000","inesss_project_id":"","engagement_date":"2019-11-29","close_date":"2020-04-30"},{"pcpa_file_number":"21155","brand_name":"Truxima","generic_name":"rituximab","manufacturer_negotiated_with":"Teva Canada Ltd.","indication":"Rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin\u0026#039;s lymphoma","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2019-09-13","close_date":"2020-02-12"},{"pcpa_file_number":"21154","brand_name":"Vitrakvi","generic_name":"larotrectinib","manufacturer_negotiated_with":"Bayer Inc.","indication":"Neurotrophic Tyrosine Receptor Kinase (NTRK) Locally Advanced or Metastatic Solid Tumours","status":"Negotiations were not pursued","cda_amc_project_id":"PC0159-000","inesss_project_id":"","engagement_date":"2019-12-30","close_date":"2019-12-30"},{"pcpa_file_number":"21153","brand_name":"Pomalyst","generic_name":"pomalidomide","manufacturer_negotiated_with":"Celgene Inc.","indication":"Multiple Myeloma (Relapsed)","status":"Negotiations were not pursued","cda_amc_project_id":"PC0165-000","inesss_project_id":"","engagement_date":"","close_date":"2021-06-04"},{"pcpa_file_number":"21152","brand_name":"Idhifa","generic_name":"enasidenib","manufacturer_negotiated_with":"Celgene Inc.","indication":"Acute Myeloid Leukemia (AML)","status":"Negotiations were not pursued","cda_amc_project_id":"PC0144-000","inesss_project_id":"","engagement_date":"","close_date":"2023-06-29"},{"pcpa_file_number":"21151","brand_name":"Revlimid","generic_name":"lenalidomide","manufacturer_negotiated_with":"Celgene Inc.","indication":"Multiple Myeloma","status":"Concluded with an LOI","cda_amc_project_id":"PC0141-000","inesss_project_id":"","engagement_date":"2019-09-24","close_date":"2020-06-10"},{"pcpa_file_number":"21150","brand_name":"Sublocade","generic_name":"buprenorphine","manufacturer_negotiated_with":"Indivior UK Limited","indication":"Opioid Use Disorder","status":"Concluded with an LOI","cda_amc_project_id":"SR0579-000","inesss_project_id":"","engagement_date":"2019-07-09","close_date":"2020-04-08"},{"pcpa_file_number":"21149","brand_name":"Cystadrops","generic_name":"cysteamine","manufacturer_negotiated_with":"Recordati Rare Diseases Canada Inc.","indication":"Corneal cystine crystal deposits","status":"Concluded with an LOI","cda_amc_project_id":"SR0595-000","inesss_project_id":"","engagement_date":"2019-06-26","close_date":"2019-08-22"},{"pcpa_file_number":"21148","brand_name":"Libtayo","generic_name":"cemiplimab","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Cutaneous Squamous Cell Carcinoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0187-000","inesss_project_id":"","engagement_date":"2020-06-08","close_date":"2020-11-04"},{"pcpa_file_number":"21147","brand_name":"Lenvima","generic_name":"lenvatinib","manufacturer_negotiated_with":"Eisai Limited","indication":"Hepatocellular Carcinoma (HCC) in adults after prior therapy","status":"Concluded with an LOI","cda_amc_project_id":"PC0175-000","inesss_project_id":"","engagement_date":"2019-09-27","close_date":"2019-11-08"},{"pcpa_file_number":"21146","brand_name":"Darzalex","generic_name":"Daratumumab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Multiple Myeloma (newly diagnosed)","status":"Concluded with an LOI","cda_amc_project_id":"PC0148-000","inesss_project_id":"","engagement_date":"2019-11-29","close_date":"2022-02-25"},{"pcpa_file_number":"21144","brand_name":"Lutathera","generic_name":"lutetium 177 dotatate","manufacturer_negotiated_with":"Advanced Accelerator Applications","indication":"Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)","status":"Concluded without agreement","cda_amc_project_id":"PC0142-000","inesss_project_id":"","engagement_date":"2019-09-26","close_date":"2019-12-30"},{"pcpa_file_number":"21143","brand_name":"Alunbrig","generic_name":"brigatinib","manufacturer_negotiated_with":"Takeda Canada Inc.","indication":"Non-Squamous Non-Small Cell Lung Cancer","status":"Negotiations were not pursued","cda_amc_project_id":"PC0167-000","inesss_project_id":"","engagement_date":"","close_date":"2019-09-05"},{"pcpa_file_number":"21142","brand_name":"Ninlaro","generic_name":"ixazomib","manufacturer_negotiated_with":"Takeda Canada Inc.","indication":"Multiple Myeloma","status":"Negotiations were not pursued","cda_amc_project_id":"PC0164-000","inesss_project_id":"","engagement_date":"","close_date":"2019-08-02"},{"pcpa_file_number":"21141","brand_name":"Verzenio","generic_name":"abemaciclib","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Advanced or Metastatic Breast Cancer","status":"Concluded without agreement","cda_amc_project_id":"PC0161-000","inesss_project_id":"","engagement_date":"2019-09-30","close_date":"2020-04-09"},{"pcpa_file_number":"21140","brand_name":"Vizimpro","generic_name":"dacomitinib","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Non-Squamous Non-Small Cell Lung Cancer","status":"Concluded without agreement","cda_amc_project_id":"PC0129-000","inesss_project_id":"","engagement_date":"2019-08-13","close_date":"2020-02-11"},{"pcpa_file_number":"21139","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Metastatic Urothelial Carcinoma (first line)","status":"Negotiations were not pursued","cda_amc_project_id":"PC0177-000","inesss_project_id":"","engagement_date":"2019-11-29","close_date":"2019-11-29"},{"pcpa_file_number":"21138","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Melanoma adjuvant therapy","status":"Concluded with an LOI","cda_amc_project_id":"PC0168-000","inesss_project_id":"","engagement_date":"2019-09-13","close_date":"2020-04-15"},{"pcpa_file_number":"21137","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Non-Squamous Non-Small Cell Lung Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0153-000","inesss_project_id":"","engagement_date":"2019-08-13","close_date":"2020-04-15"},{"pcpa_file_number":"21136","brand_name":"Venclexta\/rituximab","generic_name":"venetoclax\/rituximab","manufacturer_negotiated_with":"AbbVie Corporation","indication":"In combination with rituximab (V+R) is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy","status":"Concluded with an LOI","cda_amc_project_id":"PC0162-000","inesss_project_id":"","engagement_date":"2019-06-26","close_date":"2019-10-28"},{"pcpa_file_number":"21135","brand_name":"Xalkori","generic_name":"crizotinib","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"ROS1-positive advanced Non-Small Cell Lung Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0151-000","inesss_project_id":"","engagement_date":"2019-08-27","close_date":"2020-03-20"},{"pcpa_file_number":"21134","brand_name":"Ibrance\/fulvestrant","generic_name":"palbociclib\/fulvestrant","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Advanced or Metastatic Breast Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0150-000","inesss_project_id":"","engagement_date":"2019-08-14","close_date":"2020-04-08"},{"pcpa_file_number":"21133","brand_name":"Imfinzi","generic_name":"durvalumab","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Non-small Cell Lung Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0131-000","inesss_project_id":"","engagement_date":"2019-07-08","close_date":"2019-08-26"},{"pcpa_file_number":"21132","brand_name":"Tafinlar\/Mekinist","generic_name":"dabrafenib\/trametinib","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Melanoma adjuvant therapy","status":"Concluded with an LOI","cda_amc_project_id":"PC0152-000","inesss_project_id":"","engagement_date":"2019-06-11","close_date":"2019-08-30"},{"pcpa_file_number":"21131","brand_name":"Trazimera","generic_name":"trastuzumab","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Early breast cancer, Metastatic breast cancer, Metastatic gastric cancer","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2019-05-31","close_date":"2019-10-17"},{"pcpa_file_number":"21130","brand_name":"Herzuma","generic_name":"trastuzumab","manufacturer_negotiated_with":"Teva Canada Ltd.","indication":"Early breast cancer, Metastatic breast cancer, Metastatic gastric cancer","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2019-05-31","close_date":"2019-11-13"},{"pcpa_file_number":"21129","brand_name":"Ogivri","generic_name":"trastuzumab","manufacturer_negotiated_with":"BGP Pharma ULC","indication":"Early breast cancer, Metastatic breast cancer, Metastatic gastric cancer","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2019-05-30","close_date":"2019-10-03"},{"pcpa_file_number":"21127","brand_name":"Opsumit","generic_name":"macitentan","manufacturer_negotiated_with":"Actelion Pharmaceuticals Ltd.","indication":"Pulmonary Arterial Hypertension","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2019-07-31","close_date":"2020-12-23"},{"pcpa_file_number":"21126","brand_name":"Brilinta","generic_name":"ticagrelor","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Secondary Prevention of Atherothrombotic Events","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2019-05-17","close_date":"2019-06-19"},{"pcpa_file_number":"21125","brand_name":"Triamcinolone Hexacetonide","generic_name":"triamcinolone hexacetonide","manufacturer_negotiated_with":"Medexus Pharmaceuticals, Inc.","indication":"Rheumatoid Arthritis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2019-11-22","close_date":"2020-03-31"},{"pcpa_file_number":"21123","brand_name":"Skyrizi","generic_name":"risankizumab","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Psoriasis, moderate to severe plaque","status":"Concluded with an LOI","cda_amc_project_id":"SR0583-000","inesss_project_id":"","engagement_date":"2019-06-27","close_date":"2019-11-28"},{"pcpa_file_number":"21122","brand_name":"Vyzulta","generic_name":"latanoprostene bunod","manufacturer_negotiated_with":"Bausch Health, Canada Inc.","indication":"Open-angle Glaucoma","status":"Concluded with an LOI","cda_amc_project_id":"SR0590-000","inesss_project_id":"","engagement_date":"2019-08-30","close_date":"2019-11-20"},{"pcpa_file_number":"21121","brand_name":"Blincyto","generic_name":"blinatumomab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL)","status":"Concluded with an LOI","cda_amc_project_id":"PC0146-000","inesss_project_id":"","engagement_date":"2019-07-04","close_date":"2019-09-25"},{"pcpa_file_number":"21120","brand_name":"Folotyn","generic_name":"pralatrexate","manufacturer_negotiated_with":"Servier Canada Inc.","indication":"Peripheral T-cell Lymphoma (PTCL)","status":"Concluded with an LOI","cda_amc_project_id":"PC0138-000","inesss_project_id":"","engagement_date":"2019-06-06","close_date":"2020-01-10"},{"pcpa_file_number":"21119","brand_name":"Botox","generic_name":"onabotulinumtoxin a","manufacturer_negotiated_with":"Allergan Inc.","indication":"Migraine, Chronic","status":"Concluded without agreement","cda_amc_project_id":"SR0584-000","inesss_project_id":"","engagement_date":"2020-02-20","close_date":"2021-09-17"},{"pcpa_file_number":"21118","brand_name":"Xermelo","generic_name":"telotristat","manufacturer_negotiated_with":"Ipsen Biopharmaceuticals Canada, Inc.","indication":"Carcinoid Syndrome","status":"Negotiations were not pursued","cda_amc_project_id":"SR0580-000","inesss_project_id":"","engagement_date":"2019-07-12","close_date":"2019-07-12"},{"pcpa_file_number":"21117","brand_name":"Jublia","generic_name":"efinaconazole","manufacturer_negotiated_with":"Bausch Health, Canada Inc.","indication":"Onychomycosis","status":"Negotiations were not pursued","cda_amc_project_id":"SR0577-000","inesss_project_id":"","engagement_date":"2019-06-19","close_date":"2019-06-19"},{"pcpa_file_number":"21116","brand_name":"Pifeltro","generic_name":"doravirine","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"HIV-1 Infection","status":"Concluded with an LOI","cda_amc_project_id":"SR0582-000","inesss_project_id":"","engagement_date":"2019-06-14","close_date":"2019-10-15"},{"pcpa_file_number":"21115","brand_name":"Delstrigo","generic_name":"doravirine\/lamuvidine\/tenofovir disoproxil fumarate","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"HIV-1 Infection","status":"Concluded with an LOI","cda_amc_project_id":"SR0581-000","inesss_project_id":"","engagement_date":"2019-06-14","close_date":"2019-10-15"},{"pcpa_file_number":"21114","brand_name":"Cresemba","generic_name":"isavuconazole","manufacturer_negotiated_with":"AVIR Pharma Inc.","indication":"Invasive aspergillosis and mucormycosis","status":"Concluded with an LOI","cda_amc_project_id":"SR0586-000","inesss_project_id":"","engagement_date":"2019-07-15","close_date":"2019-11-25"},{"pcpa_file_number":"21113","brand_name":"Unituxin","generic_name":"dinutuximab","manufacturer_negotiated_with":"United Therapeutics","indication":"Neuroblastoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0154-000","inesss_project_id":"","engagement_date":"2019-05-08","close_date":"2019-08-30"},{"pcpa_file_number":"21112","brand_name":"Xtandi","generic_name":"enzalutamide","manufacturer_negotiated_with":"Astellas Pharma Inc.","indication":"Non-metastatic Castration-resistant prostate cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0149-000","inesss_project_id":"","engagement_date":"2019-07-31","close_date":"2020-02-26"},{"pcpa_file_number":"21111","brand_name":"Opdivo","generic_name":"nivolumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Melanoma adjuvant therapy","status":"Concluded with an LOI","cda_amc_project_id":"PC0147-000","inesss_project_id":"","engagement_date":"2019-06-26","close_date":"2019-09-06"},{"pcpa_file_number":"21110","brand_name":"Adcetris","generic_name":"brentuximab vedotin","manufacturer_negotiated_with":"Seattle Genetics Inc.","indication":"Hodgkin\u0026#039;s Lymphoma","status":"Negotiations were not pursued","cda_amc_project_id":"PC0145-000","inesss_project_id":"","engagement_date":"","close_date":"2019-05-17"},{"pcpa_file_number":"21109","brand_name":"Radicava","generic_name":"edaravone","manufacturer_negotiated_with":"Mitsubishi Tanabe Pharma Canada, Inc.","indication":"Amyotrophic Lateral Sclerosis (ALS)","status":"Concluded with an LOI","cda_amc_project_id":"SR0573-000","inesss_project_id":"","engagement_date":"2019-09-24","close_date":"2020-04-15"},{"pcpa_file_number":"21108","brand_name":"Eucrisa","generic_name":"crisaborole","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Atopic dermatitis","status":"Negotiations were not pursued","cda_amc_project_id":"SR0570-000","inesss_project_id":"","engagement_date":"2019-04-16","close_date":"2019-04-16"},{"pcpa_file_number":"21107","brand_name":"Brineura","generic_name":"cerliponase alfa","manufacturer_negotiated_with":"BioMarin Pharmaceutical Inc.","indication":"Neuronal Ceroid Lipofuscinosis Type 2","status":"Concluded with an LOI","cda_amc_project_id":"SR0574-000","inesss_project_id":"","engagement_date":"2019-03-29","close_date":"2020-01-22"},{"pcpa_file_number":"21106","brand_name":"Kalydeco","generic_name":"ivacaftor","manufacturer_negotiated_with":"Vertex Pharmaceuticals (Canada) Incorporated","indication":"Cystic Fibrosis In Patients with CFTR Gating Mutations or the R117H Gating Mutation","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2019-03-29","close_date":"2019-07-17"},{"pcpa_file_number":"21105","brand_name":"Zirabev","generic_name":"bevacizumab","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Metastatic Colorectal Cancer \/ Non-Small Cell Lung Cancer","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2019-03-12","close_date":"2019-08-28"},{"pcpa_file_number":"21104","brand_name":"Spinraza","generic_name":"nusinersen","manufacturer_negotiated_with":"Biogen Canada Inc.","indication":"Spinal Muscular Atrophy","status":"Concluded with an LOI","cda_amc_project_id":"SR0576-000","inesss_project_id":"","engagement_date":"2019-04-25","close_date":"2019-06-26"},{"pcpa_file_number":"21103","brand_name":"Xeljanz","generic_name":"tofacitinib","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Ulcerative Colitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0572-000","inesss_project_id":"","engagement_date":"2019-07-05","close_date":"2020-07-24"},{"pcpa_file_number":"21102","brand_name":"Cabometyx","generic_name":"cabozantinib","manufacturer_negotiated_with":"Ipsen Biopharmaceuticals Canada, Inc.","indication":"Renal Cell Carcinoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0163-000","inesss_project_id":"","engagement_date":"2019-06-07","close_date":"2019-11-05"},{"pcpa_file_number":"21101","brand_name":"Mvasi","generic_name":"bevacizumab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Metastatic Colorectal Cancer \/ Non-Small Cell Lung Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0158-000","inesss_project_id":"","engagement_date":"2019-02-28","close_date":"2019-07-08"},{"pcpa_file_number":"21100","brand_name":"Ella","generic_name":"ulipristal acetate","manufacturer_negotiated_with":"Allergan Inc.","indication":"Conception Control","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2019-02-22","close_date":"2019-06-21"},{"pcpa_file_number":"21099","brand_name":"Segluromet","generic_name":"ertugliflozin\/metformin hydrochloride","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded without agreement","cda_amc_project_id":"SR0566-000","inesss_project_id":"","engagement_date":"2019-03-20","close_date":"2020-03-31"},{"pcpa_file_number":"21098","brand_name":"Steglatro","generic_name":"ertugliflozin","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded without agreement","cda_amc_project_id":"SR0565-000","inesss_project_id":"","engagement_date":"2019-03-20","close_date":"2020-03-31"},{"pcpa_file_number":"21097","brand_name":"Fulphila","generic_name":"pegfilgrastim","manufacturer_negotiated_with":"BGP Pharma ULC","indication":"Febrile neutropenia in non-myeloid malignancies","status":"Concluded with an LOI","cda_amc_project_id":"SE0588-000","inesss_project_id":"","engagement_date":"2019-02-28","close_date":"2019-09-23"},{"pcpa_file_number":"21096","brand_name":"Xeljanz XR","generic_name":"tofacitinib","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Rheumatoid Arthritis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2019-01-30","close_date":"2019-07-09"},{"pcpa_file_number":"21095","brand_name":"Humira (citrate-free)","generic_name":"adalimumab citrate-free","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Multiple Indications","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2019-01-30","close_date":"2020-04-16"},{"pcpa_file_number":"21094","brand_name":"Ozempic","generic_name":"semaglutide","manufacturer_negotiated_with":"Novo Nordisk Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded with an LOI","cda_amc_project_id":"SR0594-000","inesss_project_id":"","engagement_date":"2019-01-31","close_date":"2019-07-26"},{"pcpa_file_number":"21093","brand_name":"Herceptin SC","generic_name":"trastuzumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Breast Cancer","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2019-01-31","close_date":"2019-10-29"},{"pcpa_file_number":"21092","brand_name":"Tagrisso","generic_name":"osimertinib","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Non-Small Cell Lung Cancer (First-line, locally advanced or metastatic)","status":"Concluded with an LOI","cda_amc_project_id":"PC0137-000","inesss_project_id":"","engagement_date":"2019-03-14","close_date":"2019-11-19"},{"pcpa_file_number":"21091","brand_name":"Lenvima","generic_name":"lenvatinib","manufacturer_negotiated_with":"Eisai Limited","indication":"Advanced or Metastatic Clear-cell Renal Cell Carcinoma","status":"Negotiations were not pursued","cda_amc_project_id":"PC0140-000","inesss_project_id":"","engagement_date":"","close_date":"2019-01-31"},{"pcpa_file_number":"21090","brand_name":"Harvoni","generic_name":"ledipasvir\/sofosbuvir","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"Chronic Hepatitis C","status":"Concluded with an LOI","cda_amc_project_id":"SF0465-000","inesss_project_id":"","engagement_date":"","close_date":"2017-02-17"},{"pcpa_file_number":"21089","brand_name":"Velphoro","generic_name":"sucroferric oxyhydroxide","manufacturer_negotiated_with":"Vifor Fresenius Medical Care Renal Pharma","indication":"Hyperphosphatemia, end-stage renal disease","status":"Concluded with an LOI","cda_amc_project_id":"SR0571-000","inesss_project_id":"","engagement_date":"2019-04-12","close_date":"2019-09-17"},{"pcpa_file_number":"21088","brand_name":"Soliqua","generic_name":"lixisenatide\/insulin glargine","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded with an LOI","cda_amc_project_id":"SR0564-000","inesss_project_id":"","engagement_date":"2019-04-16","close_date":"2019-11-21"},{"pcpa_file_number":"21087","brand_name":"Perjeta\/Herceptin","generic_name":"pertuzumab\/trastuzumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Early Breast Cancer","status":"Negotiations were not pursued","cda_amc_project_id":"PC0127-000","inesss_project_id":"","engagement_date":"","close_date":"2018-12-28"},{"pcpa_file_number":"21086","brand_name":"Opdivo","generic_name":"nivolumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Hepatocellular Carcinoma (HCC) in adults after prior therapy","status":"Negotiations were not pursued","cda_amc_project_id":"PC0134-000","inesss_project_id":"","engagement_date":"","close_date":"2019-01-29"},{"pcpa_file_number":"21085","brand_name":"Daklinza","generic_name":"daclatasvir","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Chronic Hepatitis C","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2016-07-22","close_date":"2017-02-17"},{"pcpa_file_number":"21084","brand_name":"Januvia","generic_name":"sitagliptin phosphate","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2018-11-02","close_date":"2020-03-10"},{"pcpa_file_number":"21083","brand_name":"Opdivo-Yervoy","generic_name":"nivolumab-ipilimumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Renal Cell Carcinoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0132-000","inesss_project_id":"","engagement_date":"2018-12-28","close_date":"2019-03-20"},{"pcpa_file_number":"21082","brand_name":"Gazyva","generic_name":"obinutuzumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Follicular lymphoma, Relapsed or refractory","status":"Negotiations were not pursued","cda_amc_project_id":"PC0126-000","inesss_project_id":"","engagement_date":"","close_date":"2018-12-07"},{"pcpa_file_number":"21081","brand_name":"Erleada","generic_name":"apalutamide","manufacturer_negotiated_with":"Janssen Inc.","indication":"Non-metastatic Castration-resistant prostate cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0133-000","inesss_project_id":"","engagement_date":"2019-03-14","close_date":"2019-07-09"},{"pcpa_file_number":"21080","brand_name":"Xarelto","generic_name":"rivaroxaban","manufacturer_negotiated_with":"Bayer Inc.","indication":"Prevention of stroke and cardiovascular events in coronary and peripheral artery disease.","status":"Concluded with an LOI","cda_amc_project_id":"SR0569-000","inesss_project_id":"","engagement_date":"2019-03-29","close_date":"2019-11-15"},{"pcpa_file_number":"21079","brand_name":"Ozurdex","generic_name":"dexamethasone","manufacturer_negotiated_with":"Allergan Inc.","indication":"Diabetic Macular Edema","status":"Negotiations were not pursued","cda_amc_project_id":"SR0535-000","inesss_project_id":"","engagement_date":"","close_date":"2018-11-29"},{"pcpa_file_number":"21078","brand_name":"Biktarvy","generic_name":"bictegravir\/emtricitabine\/tenofovir alafenamide","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"HIV-1 Infection","status":"Concluded with an LOI","cda_amc_project_id":"SR0567-000","inesss_project_id":"","engagement_date":"2019-02-27","close_date":"2019-06-14"},{"pcpa_file_number":"21077","brand_name":"Fibristal","generic_name":"ulipristal acetate","manufacturer_negotiated_with":"Allergan Inc.","indication":"Uterine fibroids (signs and symptoms)","status":"Concluded with an LOI","cda_amc_project_id":"SF0528-000","inesss_project_id":"","engagement_date":"2018-09-28","close_date":"2019-08-06"},{"pcpa_file_number":"21076","brand_name":"Alecensaro","generic_name":"alectinib","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Non-Small Cell Lung Cancer (First Line)","status":"Concluded with an LOI","cda_amc_project_id":"PC0125-000","inesss_project_id":"","engagement_date":"2018-09-07","close_date":"2018-12-11"},{"pcpa_file_number":"21075","brand_name":"Praluent","generic_name":"alirocumab","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Atherosclerotic cardiovascular disease","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2018-08-08","close_date":"2019-10-04"},{"pcpa_file_number":"21074","brand_name":"Orkambi","generic_name":"lumacaftor\/ivacaftor","manufacturer_negotiated_with":"Vertex Pharmaceuticals (Canada) Incorporated","indication":"Cystic Fibrosis, F508del CFTR mutation","status":"Negotiations were not pursued","cda_amc_project_id":"SR0559-000","inesss_project_id":"","engagement_date":"","close_date":"2019-02-19"},{"pcpa_file_number":"21073","brand_name":"Arbesda RespiClick","generic_name":"fluticasone propionate\/salmeterol xinafoate","manufacturer_negotiated_with":"Teva Canada Ltd.","indication":"Asthma","status":"Concluded without agreement","cda_amc_project_id":"SR0540-000","inesss_project_id":"","engagement_date":"2019-04-12","close_date":"2019-07-31"},{"pcpa_file_number":"21072","brand_name":"Aermony Respiclick","generic_name":"fluticasone propionate","manufacturer_negotiated_with":"Teva Canada Ltd.","indication":"Asthma","status":"Concluded without agreement","cda_amc_project_id":"SR0539-000","inesss_project_id":"","engagement_date":"2019-04-12","close_date":"2019-07-31"},{"pcpa_file_number":"21071","brand_name":"Viberzi","generic_name":"eluxadoline","manufacturer_negotiated_with":"Allergan Inc.","indication":"Irritable Bowel Syndrome","status":"Negotiations were not pursued","cda_amc_project_id":"SR0560-000","inesss_project_id":"","engagement_date":"","close_date":"2018-11-07"},{"pcpa_file_number":"21070","brand_name":"Kanuma","generic_name":"sebelipase alfa","manufacturer_negotiated_with":"Alexion Pharma GmbH","indication":"Lysosomal acid lipase deficiency","status":"Concluded with an LOI","cda_amc_project_id":"SR0544-000","inesss_project_id":"","engagement_date":"2018-11-30","close_date":"2020-10-21"},{"pcpa_file_number":"21069","brand_name":"Trelegy Ellipta","generic_name":"fluticasone furoate\/umeclidinium\/vilanterol","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Chronic Obstructive Pulmonary Disease (COPD)","status":"Concluded with an LOI","cda_amc_project_id":"SR0562-000","inesss_project_id":"","engagement_date":"2018-11-30","close_date":"2019-09-09"},{"pcpa_file_number":"21068","brand_name":"Mavenclad","generic_name":"cladribine","manufacturer_negotiated_with":"EMD Serono Canada, a division of EMD Inc.","indication":"Multiple Sclerosis, Relapsing","status":"Concluded with an LOI","cda_amc_project_id":"SR0546-000","inesss_project_id":"","engagement_date":"2019-02-14","close_date":"2019-11-22"},{"pcpa_file_number":"21067","brand_name":"Nucynta","generic_name":"tapentadol hydrochloride","manufacturer_negotiated_with":"Paladin Labs Inc.","indication":"Pain, severe","status":"Negotiations were not pursued","cda_amc_project_id":"SR0563-000","inesss_project_id":"","engagement_date":"","close_date":"2018-11-29"},{"pcpa_file_number":"21066","brand_name":"Fasenra","generic_name":"benralizumab","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Eosinophilic Asthma","status":"Concluded with an LOI","cda_amc_project_id":"SR0561-000","inesss_project_id":"","engagement_date":"2018-11-30","close_date":"2019-05-03"},{"pcpa_file_number":"21065","brand_name":"Dysport Therapeutic","generic_name":"abobotulinumtoxina","manufacturer_negotiated_with":"Ipsen Biopharmaceuticals Canada, Inc.","indication":"Lower Limb Spasticity","status":"Concluded with an LOI","cda_amc_project_id":"SR0556-000","inesss_project_id":"","engagement_date":"2018-08-30","close_date":"2018-08-30"},{"pcpa_file_number":"21064","brand_name":"Nitisinone","generic_name":"nitisinone","manufacturer_negotiated_with":"Cycle Pharmaceuticals Ltd.","indication":"Hereditary Tyrosinemia Type 1","status":"Concluded with an LOI","cda_amc_project_id":"SR0554-000","inesss_project_id":"","engagement_date":"2018-08-21","close_date":"2018-11-28"},{"pcpa_file_number":"21063","brand_name":"Taltz","generic_name":"ixekizumab","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Psoriatic Arthritis","status":"Concluded with an LOI","cda_amc_project_id":"SR0558-000","inesss_project_id":"","engagement_date":"2018-10-03","close_date":"2018-11-08"},{"pcpa_file_number":"21062","brand_name":"Duodopa","generic_name":"levodopa\/carbidopa","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Parkinson\u0026#039;s disease","status":"Concluded with an LOI","cda_amc_project_id":"SR0557-000","inesss_project_id":"","engagement_date":"2018-12-28","close_date":"2019-04-18"},{"pcpa_file_number":"21061","brand_name":"Probuphine","generic_name":"buprenorphine","manufacturer_negotiated_with":"Knight Therapeutics Inc.","indication":"Opioid Use Disorder","status":"Concluded with an LOI","cda_amc_project_id":"SR0550-000","inesss_project_id":"","engagement_date":"2018-11-30","close_date":"2019-05-03"},{"pcpa_file_number":"21060","brand_name":"Ozanex","generic_name":"ozenoxacin","manufacturer_negotiated_with":"Ferrer Internacional","indication":"Impetigo","status":"Negotiations were not pursued","cda_amc_project_id":"SR0553-000","inesss_project_id":"","engagement_date":"","close_date":"2018-11-30"},{"pcpa_file_number":"21059","brand_name":"Symtuza","generic_name":"darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide","manufacturer_negotiated_with":"Janssen Inc.","indication":"HIV-1 Infection","status":"Concluded without agreement","cda_amc_project_id":"SR0552-000","inesss_project_id":"","engagement_date":"2019-02-27","close_date":"2019-05-22"},{"pcpa_file_number":"21058","brand_name":"Lonsurf","generic_name":"trifluridine\/tipiracil","manufacturer_negotiated_with":"Taiho Pharma Canada Inc.","indication":"Metastatic Colorectal Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0122-000","inesss_project_id":"","engagement_date":"2019-05-30","close_date":"2019-08-08"},{"pcpa_file_number":"21057","brand_name":"Besponsa","generic_name":"inotuzumab ozogamicin","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Acute Lymphoblastic Leukemia (ALL)","status":"Concluded with an LOI","cda_amc_project_id":"PC0121-000","inesss_project_id":"","engagement_date":"2018-09-07","close_date":"2019-02-06"},{"pcpa_file_number":"21056","brand_name":"Tecentriq","generic_name":"atezolizumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Non-small Cell Lung Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0115-000","inesss_project_id":"","engagement_date":"2018-07-20","close_date":"2018-11-29"},{"pcpa_file_number":"21055","brand_name":"Dupixent","generic_name":"dupilumab","manufacturer_negotiated_with":"Sanofi Genzyme Canada","indication":"Atopic dermatitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0533-000","inesss_project_id":"","engagement_date":"2018-11-22","close_date":"2019-09-17"},{"pcpa_file_number":"21054","brand_name":"Lapelga","generic_name":"pegfilgrastim","manufacturer_negotiated_with":"Apobiologix, a Division of Apotex Inc.","indication":"Febrile Neutropenia","status":"Concluded with an LOI","cda_amc_project_id":"SE0555-000","inesss_project_id":"","engagement_date":"2018-10-10","close_date":"2019-02-28"},{"pcpa_file_number":"21053","brand_name":"Siliq","generic_name":"brodalumab","manufacturer_negotiated_with":"Valeant Canada","indication":"Psoriasis, moderate to severe plaque","status":"Concluded with an LOI","cda_amc_project_id":"SR0547-000","inesss_project_id":"","engagement_date":"2018-10-05","close_date":"2018-12-14"},{"pcpa_file_number":"21052","brand_name":"Prevymis","generic_name":"letermovir","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Cytomegalovirus infection prophylaxis","status":"Concluded with an LOI","cda_amc_project_id":"SR0545-000","inesss_project_id":"","engagement_date":"2018-11-29","close_date":"2019-12-18"},{"pcpa_file_number":"21051","brand_name":"Juluca","generic_name":"dolutegravir\/rilpivirine","manufacturer_negotiated_with":"ViiV Healthcare","indication":"HIV-1 Infection","status":"Concluded with an LOI","cda_amc_project_id":"SR0551-000","inesss_project_id":"","engagement_date":"2018-08-03","close_date":"2019-02-13"},{"pcpa_file_number":"21050","brand_name":"Akynzeo","generic_name":"netupitant\/palonosetron","manufacturer_negotiated_with":"Purdue Pharma","indication":"Nausea and vomiting (chemotherapy induced) prevention","status":"Concluded with an LOI","cda_amc_project_id":"SR0548-000","inesss_project_id":"","engagement_date":"2018-09-19","close_date":"2019-04-24"},{"pcpa_file_number":"21049","brand_name":"Toujeo","generic_name":"insulin glargine injection","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2018-06-14","close_date":"2018-09-12"},{"pcpa_file_number":"21048","brand_name":"Rituxan SC","generic_name":"rituximab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Chronic lymphocytic leukemia","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2018-06-04","close_date":"2018-08-13"},{"pcpa_file_number":"21047","brand_name":"Kevzara","generic_name":"sarilumab","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Rheumatoid Arthritis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2018-06-14","close_date":"2019-02-26"},{"pcpa_file_number":"21046","brand_name":"Dysport Therapeutic","generic_name":"abobotulinumtoxina","manufacturer_negotiated_with":"Ipsen Biopharmaceuticals Canada, Inc.","indication":"Upper Limb Spasticity","status":"Concluded with an LOI","cda_amc_project_id":"SR0517-000","inesss_project_id":"","engagement_date":"2018-05-04","close_date":"2018-07-17"},{"pcpa_file_number":"21045","brand_name":"Dysport Therapeutic","generic_name":"abobotulinumtoxina","manufacturer_negotiated_with":"Ipsen Biopharmaceuticals Canada, Inc.","indication":"Cervical dystonia","status":"Concluded with an LOI","cda_amc_project_id":"SR0512-000","inesss_project_id":"","engagement_date":"2018-05-04","close_date":"2018-07-17"},{"pcpa_file_number":"21044","brand_name":"Enstilar","generic_name":"calcipotriol\/betamethasone","manufacturer_negotiated_with":"LEO Pharma Inc.","indication":"Psoriasis, moderate to severe plaque","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2018-05-10","close_date":"2018-08-27"},{"pcpa_file_number":"21043","brand_name":"Opdivo","generic_name":"nivolumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Classic Hodgkin\u0026#039;s Lymphoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0120-000","inesss_project_id":"","engagement_date":"2018-10-09","close_date":"2019-10-04"},{"pcpa_file_number":"21042","brand_name":"Kisqali","generic_name":"ribociclib","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Advanced or Metastatic Breast Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0112-000","inesss_project_id":"","engagement_date":"2018-08-17","close_date":"2019-04-26"},{"pcpa_file_number":"21041","brand_name":"Lartruvo","generic_name":"olaratumab","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Advanced Soft Tissue Sarcoma","status":"Concluded without agreement","cda_amc_project_id":"PC0111-000","inesss_project_id":"","engagement_date":"2018-07-26","close_date":"2019-01-31"},{"pcpa_file_number":"21040","brand_name":"Stivarga","generic_name":"regorafenib","manufacturer_negotiated_with":"Bayer Inc.","indication":"Unresectable Hepatocellular Carcinoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0119-000","inesss_project_id":"","engagement_date":"2018-09-10","close_date":"2019-03-07"},{"pcpa_file_number":"21039","brand_name":"Alecensaro","generic_name":"alectinib","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Non-small cell lung cancer (NSCLC), locally advanced or metastatic","status":"Concluded with an LOI","cda_amc_project_id":"PC0114-000","inesss_project_id":"","engagement_date":"2018-09-07","close_date":"2018-12-11"},{"pcpa_file_number":"21038","brand_name":"Vectibix","generic_name":"panitumumab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Left Sided Metastatic Colorectal Cancer","status":"Negotiations were not pursued","cda_amc_project_id":"PC0118-000","inesss_project_id":"","engagement_date":"","close_date":"2018-05-10"},{"pcpa_file_number":"21037","brand_name":"Bavencio","generic_name":"avelumab","manufacturer_negotiated_with":"EMD Serono Canada, a division of EMD Inc.","indication":"Metastatic Merkel Cell Carcinoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0124-000","inesss_project_id":"","engagement_date":"2018-07-16","close_date":"2019-01-17"},{"pcpa_file_number":"21036","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Metastatic Urothelial Carcinoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0117-000","inesss_project_id":"","engagement_date":"2018-08-27","close_date":"2020-04-15"},{"pcpa_file_number":"21035","brand_name":"Venclexta","generic_name":"venetoclax","manufacturer_negotiated_with":"AbbVie Corporation","indication":"As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and who have failed a B-Cell Receptor Inhibitor (BCRi)","status":"Concluded with an LOI","cda_amc_project_id":"PC0105-000","inesss_project_id":"","engagement_date":"2018-06-21","close_date":"2019-03-06"},{"pcpa_file_number":"21034","brand_name":"Adcetris","generic_name":"brentuximab vedotin","manufacturer_negotiated_with":"Seattle Genetics Inc.","indication":"Hodgkin\u0026#039;s Lymphoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0116-000","inesss_project_id":"","engagement_date":"2018-06-22","close_date":"2019-03-13"},{"pcpa_file_number":"21033","brand_name":"Ocrevus","generic_name":"ocrelizumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Primary Progressive Multiple Sclerosis","status":"Concluded with an LOI","cda_amc_project_id":"SR0542-000","inesss_project_id":"","engagement_date":"2018-07-19","close_date":"2019-02-13"},{"pcpa_file_number":"21032","brand_name":"MDK-Nitisinone","generic_name":"nitisinone","manufacturer_negotiated_with":"MendeliKABS Inc","indication":"Hereditary Tyrosinemia Type 1","status":"Concluded with an LOI","cda_amc_project_id":"SR0538-000","inesss_project_id":"","engagement_date":"2018-08-20","close_date":"2018-11-28"},{"pcpa_file_number":"21031","brand_name":"Monoprost","generic_name":"latanoprost","manufacturer_negotiated_with":"Laboratoires Thea","indication":"Glaucoma and Ocular Hypertension","status":"Concluded without agreement","cda_amc_project_id":"SR0541-000","inesss_project_id":"","engagement_date":"2018-09-28","close_date":"2019-08-28"},{"pcpa_file_number":"21030","brand_name":"Actemra","generic_name":"tocilizumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Giant Cell Arteritis","status":"Concluded with an LOI","cda_amc_project_id":"SR0534-000","inesss_project_id":"","engagement_date":"2018-07-26","close_date":"2018-12-06"},{"pcpa_file_number":"21029","brand_name":"Vemlidy","generic_name":"tenofovir alafenamide","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"Hepatitis B","status":"Concluded without agreement","cda_amc_project_id":"SR0537-000","inesss_project_id":"","engagement_date":"2018-09-25","close_date":"2018-10-31"},{"pcpa_file_number":"21028","brand_name":"Ilaris","generic_name":"canakinumab","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Systemic juvenile idiopathic arthritis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2018-04-27","close_date":"2018-11-19"},{"pcpa_file_number":"21027","brand_name":"Renflexis","generic_name":"infliximab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Rheumatic Conditions","status":"Concluded with an LOI","cda_amc_project_id":"SE0532-000","inesss_project_id":"","engagement_date":"2018-04-13","close_date":"2018-07-27"},{"pcpa_file_number":"21026","brand_name":"Izba","generic_name":"travoprost","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Open-angle Glaucoma","status":"Concluded with an LOI","cda_amc_project_id":"SR0516-000","inesss_project_id":"","engagement_date":"2018-04-12","close_date":"2018-12-06"},{"pcpa_file_number":"21025","brand_name":"Rexulti","generic_name":"brexpiprazole","manufacturer_negotiated_with":"Otsuka Canada Pharmaceutical Inc.","indication":"Schizophrenia","status":"Concluded with an LOI","cda_amc_project_id":"SR0514-000","inesss_project_id":"","engagement_date":"2018-04-04","close_date":"2018-12-14"},{"pcpa_file_number":"21024","brand_name":"Galafold","generic_name":"migalastat","manufacturer_negotiated_with":"Amicus Therapeutics","indication":"Fabry Disease","status":"Concluded with an LOI","cda_amc_project_id":"SR0522-000","inesss_project_id":"","engagement_date":"2018-03-28","close_date":"2018-08-28"},{"pcpa_file_number":"21023","brand_name":"Fiasp","generic_name":"insulin aspart","manufacturer_negotiated_with":"Novo Nordisk Canada Inc.","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2018-03-16","close_date":"2019-01-30"},{"pcpa_file_number":"21022","brand_name":"Pomalyst","generic_name":"pomalidomide","manufacturer_negotiated_with":"Celgene Inc.","indication":"Multiple Myeloma","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2018-03-09","close_date":"2018-07-25"},{"pcpa_file_number":"21021","brand_name":"Mictoryl Pediatric","generic_name":"propiverine hydrochloride","manufacturer_negotiated_with":"Duchesnay Inc.","indication":"Overactive Bladder","status":"Concluded with an LOI","cda_amc_project_id":"SR0504-000","inesss_project_id":"","engagement_date":"2017-08-30","close_date":"2018-02-12"},{"pcpa_file_number":"21020","brand_name":"Jevtana","generic_name":"cabazitaxel","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Metastatic Castration-Resistant Prostate Cancer","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2018-02-28","close_date":"2018-11-07"},{"pcpa_file_number":"21019","brand_name":"Rosiver","generic_name":"ivermectin","manufacturer_negotiated_with":"Galderma Canada Inc.","indication":"Rosacea","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2018-02-23","close_date":"2018-05-23"},{"pcpa_file_number":"21018","brand_name":"Rydapt","generic_name":"midostaurin","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Acute Myeloid Leukemia (AML)","status":"Concluded with an LOI","cda_amc_project_id":"PC0108-000","inesss_project_id":"","engagement_date":"2018-02-02","close_date":"2018-07-05"},{"pcpa_file_number":"21017","brand_name":"Lynparza","generic_name":"olaparib","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Ovarian Cancer, monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy","status":"Concluded with an LOI","cda_amc_project_id":"PC0103-000","inesss_project_id":"","engagement_date":"2017-10-10","close_date":"2018-05-15"},{"pcpa_file_number":"21016","brand_name":"Tagrisso","generic_name":"osimertinib","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Non-Squamous Non-Small Cell Lung Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0076-000","inesss_project_id":"","engagement_date":"2017-09-29","close_date":"2018-07-30"},{"pcpa_file_number":"21015","brand_name":"Gazyva","generic_name":"obinutuzumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Follicular Lymphoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0091-000","inesss_project_id":"","engagement_date":"2017-10-10","close_date":"2018-01-16"},{"pcpa_file_number":"21014","brand_name":"Orfadin","generic_name":"nitisinone","manufacturer_negotiated_with":"Sobi Canada Inc.","indication":"Hereditary Tyrosinemia Type 1","status":"Concluded with an LOI","cda_amc_project_id":"SR0531-000","inesss_project_id":"","engagement_date":"2018-08-20","close_date":"2018-11-28"},{"pcpa_file_number":"21013","brand_name":"Tremfya","generic_name":"guselkumab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Psoriasis, moderate to severe plaque","status":"Concluded without agreement","cda_amc_project_id":"SR0530-000","inesss_project_id":"","engagement_date":"2018-10-30","close_date":"2019-06-21"},{"pcpa_file_number":"21012","brand_name":"Procysbi","generic_name":"cysteamine bitartrate","manufacturer_negotiated_with":"Horizon Therapeutics Ireland DAC","indication":"Nephropathic cystinosis","status":"Concluded with an LOI","cda_amc_project_id":"SR0526-000","inesss_project_id":"","engagement_date":"2018-02-09","close_date":"2018-07-20"},{"pcpa_file_number":"21011","brand_name":"Maviret","generic_name":"glecaprevir\/pibrentasvir","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Chronic Hepatitis C","status":"Concluded with an LOI","cda_amc_project_id":"SR0523-000","inesss_project_id":"","engagement_date":"2018-06-29","close_date":"2018-12-19"},{"pcpa_file_number":"21010","brand_name":"Movapo","generic_name":"apomorphine hydrochloride","manufacturer_negotiated_with":"Paladin Labs Inc.","indication":"Parkinson\u0026#039;s disease","status":"Concluded with an LOI","cda_amc_project_id":"SR0527-000","inesss_project_id":"","engagement_date":"2018-06-29","close_date":"2019-03-27"},{"pcpa_file_number":"21009","brand_name":"Vosevi","generic_name":"sofosbuvir\/velpatasvir\/voxilaprevir","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"Chronic Hepatitis C","status":"Concluded with an LOI","cda_amc_project_id":"SR0529-000","inesss_project_id":"","engagement_date":"2018-02-14","close_date":"2018-02-14"},{"pcpa_file_number":"21008","brand_name":"Spinraza","generic_name":"nusinersen","manufacturer_negotiated_with":"Biogen Canada Inc.","indication":"Spinal Muscular Atrophy","status":"Concluded with an LOI","cda_amc_project_id":"SR0525-000","inesss_project_id":"","engagement_date":"2018-01-29","close_date":"2018-09-26"},{"pcpa_file_number":"21007","brand_name":"Zykadia","generic_name":"ceritinib","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Non-Squamous Non-Small Cell Lung Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0094-000","inesss_project_id":"","engagement_date":"2017-07-13","close_date":"2018-03-20"},{"pcpa_file_number":"21006","brand_name":"Viacoram","generic_name":"perindopril arginine\/amlodipine","manufacturer_negotiated_with":"Servier Canada Inc.","indication":"Hypertension","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2018-04-19","close_date":"2019-05-22"},{"pcpa_file_number":"21005","brand_name":"Adlyxine","generic_name":"lixisenatide","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded with an LOI","cda_amc_project_id":"SR0520-000","inesss_project_id":"","engagement_date":"2018-04-27","close_date":"2019-11-21"},{"pcpa_file_number":"21004","brand_name":"Repatha","generic_name":"evolocumab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Primary hyperlipidemia and mixed dyslipidemia","status":"Concluded without agreement","cda_amc_project_id":"SR0515-000","inesss_project_id":"","engagement_date":"2018-08-08","close_date":"2019-07-25"},{"pcpa_file_number":"21003","brand_name":"Ocrevus","generic_name":"ocrelizumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Multiple Sclerosis, Relapsing","status":"Concluded with an LOI","cda_amc_project_id":"SR0519-000","inesss_project_id":"","engagement_date":"2018-07-19","close_date":"2019-02-13"},{"pcpa_file_number":"21002","brand_name":"Tresiba","generic_name":"insulin degludec","manufacturer_negotiated_with":"Novo Nordisk Canada Inc.","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"SR0521-000","inesss_project_id":"","engagement_date":"2018-04-30","close_date":"2018-07-26"},{"pcpa_file_number":"21001","brand_name":"Stivarga","generic_name":"regorafenib","manufacturer_negotiated_with":"Bayer Inc.","indication":"Metastatic Colorectal Cancer","status":"Negotiations were not pursued","cda_amc_project_id":"PC0046-000","inesss_project_id":"","engagement_date":"","close_date":"2015-08-31"},{"pcpa_file_number":"21000","brand_name":"VPRIV","generic_name":"velaglucerase","manufacturer_negotiated_with":"Shire Pharma Canada ULC","indication":"Gaucher disease","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2017-11-17","close_date":"2018-04-16"},{"pcpa_file_number":"20999","brand_name":"Elelyso","generic_name":"taliglucerase alfa","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Gaucher disease","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2017-11-17","close_date":"2018-05-17"},{"pcpa_file_number":"20998","brand_name":"Cerezyme","generic_name":"imiglucerase","manufacturer_negotiated_with":"Sanofi Genzyme Canada","indication":"Gaucher disease","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2017-11-16","close_date":"2018-05-31"},{"pcpa_file_number":"20997","brand_name":"Kyleena","generic_name":"levonorgestrel","manufacturer_negotiated_with":"Bayer Inc.","indication":"Conception Control","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2017-09-29","close_date":"2018-04-20"},{"pcpa_file_number":"20996","brand_name":"Invega Trinza","generic_name":"paliperidone palmitate","manufacturer_negotiated_with":"Janssen Inc.","indication":"Schizophrenia","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2016-10-21","close_date":"2018-02-05"},{"pcpa_file_number":"20995","brand_name":"Strensiq","generic_name":"asfotase alfa","manufacturer_negotiated_with":"Alexion Pharma GmbH","indication":"Pediatric-onset hypophosphatasia","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2017-06-07","close_date":"2018-01-09"},{"pcpa_file_number":"20994","brand_name":"Narcan","generic_name":"naloxone hydrochloride","manufacturer_negotiated_with":"Adapt Pharma Operations Limited","indication":"Opioid Overdose","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2017-06-26","close_date":"2018-01-03"},{"pcpa_file_number":"20993","brand_name":"Methadose","generic_name":"methadone hydrochloride","manufacturer_negotiated_with":"Mallinckrodt Canada ULC","indication":"Opioid Dependence","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2017-07-28","close_date":"2017-11-30"},{"pcpa_file_number":"20992","brand_name":"Metoject","generic_name":"methotrexate","manufacturer_negotiated_with":"Medexus Pharmaceuticals, Inc.","indication":"Rheumatic Conditions","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2016-06-01","close_date":"2017-11-20"},{"pcpa_file_number":"20991","brand_name":"Copaxone","generic_name":"glatiramer acetate","manufacturer_negotiated_with":"Teva Canada Ltd.","indication":"Clinically Isolated Syndrome","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2016-11-22","close_date":"2018-11-29"},{"pcpa_file_number":"20990","brand_name":"Botox","generic_name":"onabotulinumtoxin a","manufacturer_negotiated_with":"Allergan Inc.","indication":"Multiple Indications","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2016-12-16","close_date":"2018-02-28"},{"pcpa_file_number":"20989","brand_name":"Faslodex","generic_name":"fulvestrant","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Breast Cancer, Locally Advanced or Metastatic","status":"Concluded without agreement","cda_amc_project_id":"PC0110-000","inesss_project_id":"","engagement_date":"2018-08-03","close_date":"2019-01-29"},{"pcpa_file_number":"20988","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Classic Hodgkin\u0026#039;s Lymphoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0109-000","inesss_project_id":"","engagement_date":"2018-10-10","close_date":"2020-04-15"},{"pcpa_file_number":"20987","brand_name":"Onivyde","generic_name":"irinotecan liposome","manufacturer_negotiated_with":"Servier Canada Inc.","indication":"Metastatic Pancreatic Cancer","status":"Concluded without agreement","cda_amc_project_id":"PC0107-000","inesss_project_id":"","engagement_date":"2019-01-25","close_date":"2019-06-07"},{"pcpa_file_number":"20986","brand_name":"Opdivo-Yervoy","generic_name":"nivolumab-ipilimumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Metastatic Melanoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0098-000","inesss_project_id":"","engagement_date":"2018-06-13","close_date":"2019-03-20"},{"pcpa_file_number":"20985","brand_name":"Glatect","generic_name":"glatiramer acetate","manufacturer_negotiated_with":"Pendopharm, a division of Pharmascience Inc.","indication":"Multiple Sclerosis, Relapsing-Remitting","status":"Concluded with an LOI","cda_amc_project_id":"SE0510-000","inesss_project_id":"","engagement_date":"2017-09-08","close_date":"2018-03-01"},{"pcpa_file_number":"20984","brand_name":"Cerdelga","generic_name":"eliglustat","manufacturer_negotiated_with":"Sanofi Genzyme Canada","indication":"Gaucher disease","status":"Concluded without agreement","cda_amc_project_id":"SR0511-000","inesss_project_id":"","engagement_date":"2017-11-16","close_date":"2018-05-31"},{"pcpa_file_number":"20983","brand_name":"Ocaliva","generic_name":"obeticholic acid","manufacturer_negotiated_with":"Intercept Pharma Canada","indication":"Primary biliary cholangitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0509-000","inesss_project_id":"","engagement_date":"2017-12-08","close_date":"2018-06-27"},{"pcpa_file_number":"20982","brand_name":"Caprelsa","generic_name":"vandetanib","manufacturer_negotiated_with":"Sanofi Genzyme Canada","indication":"Medullary Thyroid Cancer","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2017-12-28","close_date":"2018-06-01"},{"pcpa_file_number":"20981","brand_name":"Erelzi","generic_name":"etanercept","manufacturer_negotiated_with":"Sandoz Canada Inc.","indication":"Ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis","status":"Concluded with an LOI","cda_amc_project_id":"SE0513-000","inesss_project_id":"","engagement_date":"2017-04-21","close_date":"2017-10-17"},{"pcpa_file_number":"20980","brand_name":"Zinbryta","generic_name":"daclizumab beta","manufacturer_negotiated_with":"Biogen Canada Inc.","indication":"Multiple Sclerosis, Relapsing","status":"Negotiations were not pursued","cda_amc_project_id":"SR0508-000","inesss_project_id":"","engagement_date":"","close_date":"2018-03-29"},{"pcpa_file_number":"20979","brand_name":"Darzalex","generic_name":"Daratumumab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Multiple Myeloma","status":"Concluded with an LOI","cda_amc_project_id":"PC0104-000","inesss_project_id":"","engagement_date":"2018-03-09","close_date":"2018-11-14"},{"pcpa_file_number":"20978","brand_name":"Lixiana","generic_name":"edoxaban","manufacturer_negotiated_with":"Servier Canada Inc.","indication":"Venous thromboembolism, treatment and recurrence prevention","status":"Concluded with an LOI","cda_amc_project_id":"SR0499-000","inesss_project_id":"","engagement_date":"2018-07-20","close_date":"2019-02-05"},{"pcpa_file_number":"20977","brand_name":"Odefsey","generic_name":"emtricitabine\/rilpivirine\/tenofovir alafenamide","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"HIV-1 Infection","status":"Concluded with an LOI","cda_amc_project_id":"SR0507-000","inesss_project_id":"","engagement_date":"2017-08-04","close_date":"2018-06-06"},{"pcpa_file_number":"20976","brand_name":"Lancora","generic_name":"ivabradine","manufacturer_negotiated_with":"Servier Canada Inc.","indication":"Heart failure, NYHA class II or III","status":"Concluded with an LOI","cda_amc_project_id":"SR0506-000","inesss_project_id":"","engagement_date":"2017-12-08","close_date":"2018-08-22"},{"pcpa_file_number":"20975","brand_name":"Fibristal","generic_name":"ulipristal acetate","manufacturer_negotiated_with":"Allergan Inc.","indication":"Uterine fibroids (signs and symptoms) - 2nd cycle pre-surgery","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2017-09-25","close_date":"2018-09-28"},{"pcpa_file_number":"20974","brand_name":"Mictoryl","generic_name":"propiverine hydrochloride","manufacturer_negotiated_with":"Duchesnay Inc.","indication":"Overactive Bladder","status":"Concluded without agreement","cda_amc_project_id":"SR0504-000","inesss_project_id":"","engagement_date":"2017-08-30","close_date":"2018-02-12"},{"pcpa_file_number":"20973","brand_name":"Kevzara","generic_name":"sarilumab","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Rheumatoid Arthritis","status":"Concluded without agreement","cda_amc_project_id":"SR0503-000","inesss_project_id":"","engagement_date":"2017-07-28","close_date":"2017-10-26"},{"pcpa_file_number":"20972","brand_name":"Blincyto","generic_name":"blinatumomab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Acute Lymphoblastic Leukemia (ALL)","status":"Concluded with an LOI","cda_amc_project_id":"PC0097-000","inesss_project_id":"","engagement_date":"2017-12-29","close_date":"2019-01-15"},{"pcpa_file_number":"20971","brand_name":"Actikerall","generic_name":"fluorouracil\/salicylic acid","manufacturer_negotiated_with":"Cipher","indication":"Hyperkeratotic actinic keratosis","status":"Concluded with an LOI","cda_amc_project_id":"SR0498-000","inesss_project_id":"","engagement_date":"2018-02-23","close_date":"2018-08-22"},{"pcpa_file_number":"20970","brand_name":"Stelara","generic_name":"ustekinumab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Crohn\u0026#039;s disease","status":"Concluded without agreement","cda_amc_project_id":"SR0501-000","inesss_project_id":"","engagement_date":"2018-02-09","close_date":"2019-03-29"},{"pcpa_file_number":"20969","brand_name":"Lixiana","generic_name":"edoxaban","manufacturer_negotiated_with":"Servier Canada Inc.","indication":"Non-valvular atrial fibrillation, prevention of stroke and systemic embolism","status":"Concluded with an LOI","cda_amc_project_id":"SR0500-000","inesss_project_id":"","engagement_date":"2018-07-20","close_date":"2019-02-05"},{"pcpa_file_number":"20968","brand_name":"Blincyto","generic_name":"blinatumomab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Acute Lymphoblastic Leukemia (ALL), Pediatric","status":"Concluded with an LOI","cda_amc_project_id":"PC0099-000","inesss_project_id":"","engagement_date":"2017-12-29","close_date":"2019-01-15"},{"pcpa_file_number":"20967","brand_name":"Ravicti","generic_name":"glycerol phenylbutyrate","manufacturer_negotiated_with":"Horizon Therapeutics Ireland DAC","indication":"Urea cycle disorders","status":"Concluded with an LOI","cda_amc_project_id":"SR0497-000","inesss_project_id":"","engagement_date":"2017-04-21","close_date":"2017-12-12"},{"pcpa_file_number":"20966","brand_name":"Hemangiol","generic_name":"propranolol oral solution","manufacturer_negotiated_with":"Pierre Fabre","indication":"Infantile hemangioma","status":"Concluded with an LOI","cda_amc_project_id":"SR0496-000","inesss_project_id":"","engagement_date":"2017-08-04","close_date":"2018-07-16"},{"pcpa_file_number":"20965","brand_name":"Brivlera","generic_name":"brivaracetam","manufacturer_negotiated_with":"UCB Canada Inc.","indication":"Epilepsy, partial-onset seizures","status":"Concluded with an LOI","cda_amc_project_id":"SR0484-000","inesss_project_id":"","engagement_date":"2017-05-29","close_date":"2018-10-22"},{"pcpa_file_number":"20964","brand_name":"Ibrance","generic_name":"palbociclib","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Advanced Breast Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0093-000","inesss_project_id":"","engagement_date":"2017-05-15","close_date":"2017-12-21"},{"pcpa_file_number":"20963","brand_name":"Quinsair","generic_name":"levofloxacin","manufacturer_negotiated_with":"Raptor Pharmaceuticals Inc.","indication":"Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections","status":"Concluded with an LOI","cda_amc_project_id":"SR0493-000","inesss_project_id":"","engagement_date":"2017-05-29","close_date":"2018-10-11"},{"pcpa_file_number":"20962","brand_name":"Rituxan","generic_name":"rituximab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Acute Lymphoblastic Leukemia (ALL)","status":"Negotiations were not pursued","cda_amc_project_id":"PC0102-000","inesss_project_id":"","engagement_date":"","close_date":"2017-12-08"},{"pcpa_file_number":"20961","brand_name":"Kyprolis","generic_name":"carfilzomib","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Multiple Myeloma","status":"Concluded with an LOI","cda_amc_project_id":"PC0084-000","inesss_project_id":"","engagement_date":"2017-06-02","close_date":"2017-12-08"},{"pcpa_file_number":"20960","brand_name":"Uptravi","generic_name":"selexipag","manufacturer_negotiated_with":"Actelion Pharmaceuticals Ltd.","indication":"Pulmonary Arterial Hypertension","status":"Concluded with an LOI","cda_amc_project_id":"SR0482-000","inesss_project_id":"","engagement_date":"2017-04-13","close_date":"2017-12-12"},{"pcpa_file_number":"20959","brand_name":"Synjardy","generic_name":"empagliflozin\/metformin","manufacturer_negotiated_with":"Boehringer Ingelheim (Canada) Ltd.","indication":"Diabetes Mellitus, Type 2","status":"Concluded with an LOI","cda_amc_project_id":"SR0489-000","inesss_project_id":"","engagement_date":"2018-09-11","close_date":"2018-09-11"},{"pcpa_file_number":"20958","brand_name":"Taltz","generic_name":"ixekizumab","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Psoriasis, moderate to severe plaque","status":"Concluded with an LOI","cda_amc_project_id":"SR0481-000","inesss_project_id":"","engagement_date":"2017-05-05","close_date":"2017-12-29"},{"pcpa_file_number":"20957","brand_name":"Kuvan","generic_name":"sapropterin dihydrochloride","manufacturer_negotiated_with":"BioMarin Pharmaceutical Inc.","indication":"Phenylketonuria","status":"Concluded with an LOI","cda_amc_project_id":"SR0472-000","inesss_project_id":"","engagement_date":"2017-05-05","close_date":"2020-02-13"},{"pcpa_file_number":"20956","brand_name":"Jardiance","generic_name":"empagliflozin","manufacturer_negotiated_with":"Boehringer Ingelheim (Canada) Ltd.","indication":"Diabetes Mellitus, Type 2 with high cardiovascular risk","status":"Concluded with an LOI","cda_amc_project_id":"SR0488-000","inesss_project_id":"","engagement_date":"2016-08-19","close_date":"2018-09-11"},{"pcpa_file_number":"20955","brand_name":"Invokamet","generic_name":"canagliflozin\/metformin hydrochloride","manufacturer_negotiated_with":"Janssen Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded without agreement","cda_amc_project_id":"SR0480-000","inesss_project_id":"","engagement_date":"2017-05-05","close_date":"2017-10-20"},{"pcpa_file_number":"20954","brand_name":"Brilinta","generic_name":"ticagrelor","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Prevention of atherothrombotic events with history of myocardial infarction","status":"Concluded without agreement","cda_amc_project_id":"SR0474-000","inesss_project_id":"","engagement_date":"2017-08-04","close_date":"2017-11-30"},{"pcpa_file_number":"20953","brand_name":"Descovy","generic_name":"emtricitabine\/tenofovir alafenamide","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"HIV-1 Infection","status":"Concluded without agreement","cda_amc_project_id":"SR0470-000","inesss_project_id":"","engagement_date":"2017-08-04","close_date":"2018-06-08"},{"pcpa_file_number":"20952","brand_name":"Cosentyx","generic_name":"secukinumab","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Ankylosing spondylitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0475-000","inesss_project_id":"","engagement_date":"2017-04-13","close_date":"2017-12-19"},{"pcpa_file_number":"20951","brand_name":"Cosentyx","generic_name":"secukinumab","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Psoriatic Arthritis","status":"Concluded with an LOI","cda_amc_project_id":"SR0476-000","inesss_project_id":"","engagement_date":"2017-04-13","close_date":"2017-12-19"},{"pcpa_file_number":"20950","brand_name":"Revestive","generic_name":"teduglutide","manufacturer_negotiated_with":"Shire Pharma Canada ULC","indication":"Short Bowel Syndrome (SBS)","status":"Concluded with an LOI","cda_amc_project_id":"SR0459-000","inesss_project_id":"","engagement_date":"2017-06-30","close_date":"2018-08-07"},{"pcpa_file_number":"20949","brand_name":"Praluent","generic_name":"alirocumab","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Primary hypercholesterolemia (non-familial and heterozygous familial)","status":"Concluded with an LOI","cda_amc_project_id":"SR0469-000","inesss_project_id":"","engagement_date":"2016-08-26","close_date":"2018-08-02"},{"pcpa_file_number":"20948","brand_name":"Kyprolis","generic_name":"carfilzomib","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Multiple Myeloma","status":"Concluded with an LOI","cda_amc_project_id":"PC0067-000","inesss_project_id":"","engagement_date":"2016-10-14","close_date":"2017-12-08"},{"pcpa_file_number":"20947","brand_name":"Trulicity","generic_name":"dulaglutide","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded without agreement","cda_amc_project_id":"SR0462-000","inesss_project_id":"","engagement_date":"2017-07-07","close_date":"2019-09-27"},{"pcpa_file_number":"20946","brand_name":"Nucala","generic_name":"mepolizumab","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Severe Eosinophilic Asthma","status":"Concluded with an LOI","cda_amc_project_id":"SR0461-000","inesss_project_id":"","engagement_date":"2016-10-21","close_date":"2017-11-24"},{"pcpa_file_number":"20945","brand_name":"Vimizim","generic_name":"elosulfase alfa","manufacturer_negotiated_with":"BioMarin Pharmaceutical Inc.","indication":"Mucopolysaccharidosis IVA (Morquio A syndrome)","status":"Concluded with an LOI","cda_amc_project_id":"SR0456-000","inesss_project_id":"","engagement_date":"2016-10-28","close_date":"2018-11-29"},{"pcpa_file_number":"20944","brand_name":"Xolair","generic_name":"omalizumab","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Severe Persistent Asthma","status":"Concluded without agreement","cda_amc_project_id":"SR0457-000","inesss_project_id":"","engagement_date":"2016-10-21","close_date":"2019-06-25"},{"pcpa_file_number":"20943","brand_name":"Fycompa","generic_name":"perampanel","manufacturer_negotiated_with":"Eisai Limited","indication":"Epilepsy, primary generalized tonic-clonic seizures","status":"Concluded with an LOI","cda_amc_project_id":"SR0458-000","inesss_project_id":"","engagement_date":"2016-08-15","close_date":"2019-07-02"},{"pcpa_file_number":"20942","brand_name":"Pheburane","generic_name":"sodium phenylbutyrate","manufacturer_negotiated_with":"M\ufffddunik Canada Inc.","indication":"Urea cycle disorders","status":"Concluded with an LOI","cda_amc_project_id":"SR0452-000","inesss_project_id":"","engagement_date":"2017-04-21","close_date":"2017-11-20"},{"pcpa_file_number":"20941","brand_name":"Naglazyme","generic_name":"galsulfase","manufacturer_negotiated_with":"BioMarin Pharmaceutical Inc.","indication":"Mucopolysaccharidosis VI","status":"Negotiations were not pursued","cda_amc_project_id":"SR0434-000","inesss_project_id":"","engagement_date":"2017-01-31","close_date":"2017-01-31"},{"pcpa_file_number":"20940","brand_name":"Repatha","generic_name":"evolocumab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Primary hyperlipidemia and mixed dyslipidemia","status":"Concluded with an LOI","cda_amc_project_id":"SR0441-000","inesss_project_id":"","engagement_date":"2016-08-26","close_date":"2017-10-23"},{"pcpa_file_number":"20939","brand_name":"Prolia","generic_name":"denosumab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Osteoporosis in Men","status":"Concluded with an LOI","cda_amc_project_id":"SR0414-000","inesss_project_id":"","engagement_date":"2015-12-09","close_date":"2017-10-17"},{"pcpa_file_number":"20938","brand_name":"Kalydeco","generic_name":"ivacaftor","manufacturer_negotiated_with":"Vertex Pharmaceuticals (Canada) Incorporated","indication":"Cystic Fibrosis (CFTR gating mutations)","status":"Concluded without agreement","cda_amc_project_id":"SR0379-000","inesss_project_id":"","engagement_date":"2015-01-27","close_date":"2017-10-24"},{"pcpa_file_number":"20937","brand_name":"Truvada","generic_name":"emtricitabine\/tenofovir disoproxil fumarate","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"HIV-1 infection, pre-exposure prophylaxis","status":"Negotiations were not pursued","cda_amc_project_id":"SR0479-000","inesss_project_id":"","engagement_date":"","close_date":"2017-09-08"},{"pcpa_file_number":"20936","brand_name":"Strensiq","generic_name":"asfotase alfa","manufacturer_negotiated_with":"Alexion Pharma GmbH","indication":"Pediatric-onset hypophosphatasia","status":"Concluded without agreement","cda_amc_project_id":"SR0443-000","inesss_project_id":"","engagement_date":"2016-06-30","close_date":"2017-02-09"},{"pcpa_file_number":"20935","brand_name":"Tafinlar\/Mekinist","generic_name":"dabrafenib\/trametinib","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Non-Small Cell Lung Cancer (with CNS metastases)","status":"Negotiations were not pursued","cda_amc_project_id":"PC0106-000","inesss_project_id":"","engagement_date":"","close_date":"2017-11-30"},{"pcpa_file_number":"20934","brand_name":"Giotrif","generic_name":"afatinib","manufacturer_negotiated_with":"Boehringer Ingelheim (Canada) Ltd.","indication":"Advanced Non-Small Cell Lung Cancer","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2017-07-07","close_date":"2017-11-23"},{"pcpa_file_number":"20933","brand_name":"Opdivo","generic_name":"nivolumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Head and Neck Squamous Cell Carcinoma (HNSCC)","status":"Concluded with an LOI","cda_amc_project_id":"PC0095-000","inesss_project_id":"","engagement_date":"2017-09-29","close_date":"2017-11-20"},{"pcpa_file_number":"20932","brand_name":"Simponi IV","generic_name":"golimumab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Rheumatoid Arthritis","status":"Concluded without agreement","cda_amc_project_id":"SR0351-000","inesss_project_id":"","engagement_date":"2014-10-06","close_date":"2016-04-19"},{"pcpa_file_number":"20931","brand_name":"Stivarga","generic_name":"regorafenib","manufacturer_negotiated_with":"Bayer Inc.","indication":"Gastrointestinal Stromal Tumours","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2017-08-11","close_date":"2017-11-09"},{"pcpa_file_number":"20930","brand_name":"Basaglar","generic_name":"Insulin Glargine","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Diabetes Mellitus, Type 1 \u0026amp; 2","status":"Concluded with an LOI","cda_amc_project_id":"SE0451-000","inesss_project_id":"","engagement_date":"2016-06-15","close_date":"2017-07-07"},{"pcpa_file_number":"20929","brand_name":"Mifegymiso","generic_name":"mifepristone and misoprostol","manufacturer_negotiated_with":"Celopharma","indication":"Medical termination of pregnancy","status":"Concluded with an LOI","cda_amc_project_id":"SR0502-000","inesss_project_id":"","engagement_date":"2017-04-21","close_date":"2017-07-05"},{"pcpa_file_number":"20928","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Non-small Cell Lung Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0101-000","inesss_project_id":"","engagement_date":"2017-09-08","close_date":"2017-11-01"},{"pcpa_file_number":"20927","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Non-small Cell Lung Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0077-000","inesss_project_id":"","engagement_date":"2017-01-30","close_date":"2017-11-01"},{"pcpa_file_number":"20926","brand_name":"Neupro","generic_name":"rotigotine","manufacturer_negotiated_with":"UCB Canada Inc.","indication":"Parkinson\u0026#039;s disease","status":"Concluded with an LOI","cda_amc_project_id":"SR0432-000","inesss_project_id":"","engagement_date":"2016-02-09","close_date":"2017-06-23"},{"pcpa_file_number":"20925","brand_name":"Brenzys","generic_name":"etanercept","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Rheumatoid Arthritis and Ankylosing Spondylitis","status":"Concluded with an LOI","cda_amc_project_id":"SE0485-000","inesss_project_id":"","engagement_date":"2016-11-14","close_date":"2017-06-19"},{"pcpa_file_number":"20924","brand_name":"Afinitor","generic_name":"everolimus","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Neuroendocrine tumours of Gastrointestinal or Lung origin","status":"Concluded with an LOI","cda_amc_project_id":"PC0083-000","inesss_project_id":"","engagement_date":"2017-03-31","close_date":"2017-09-01"},{"pcpa_file_number":"20923","brand_name":"XigDuo","generic_name":"dapagliflozin\/metformin hydrochloride","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded with an LOI","cda_amc_project_id":"SR0468-000","inesss_project_id":"","engagement_date":"2017-04-13","close_date":"2017-06-13"},{"pcpa_file_number":"20922","brand_name":"Humira","generic_name":"adalimumab","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Ulcerative Colitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0450-000","inesss_project_id":"","engagement_date":"2016-05-31","close_date":"2017-05-23"},{"pcpa_file_number":"20921","brand_name":"Avastin","generic_name":"bevacizumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Platinum-Resistant Ovarian Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0066-000","inesss_project_id":"","engagement_date":"2016-07-15","close_date":"2017-08-21"},{"pcpa_file_number":"20920","brand_name":"Avastin","generic_name":"bevacizumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Metastatic Colorectal Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0055-000","inesss_project_id":"","engagement_date":"2016-01-20","close_date":"2017-08-21"},{"pcpa_file_number":"20919","brand_name":"Sublinox","generic_name":"zolpidem tartrate","manufacturer_negotiated_with":"Valeant Canada","indication":"Insomnia, short-term treatment","status":"Negotiations were not pursued","cda_amc_project_id":"SR0314-000","inesss_project_id":"","engagement_date":"","close_date":"2013-10-24"},{"pcpa_file_number":"20918","brand_name":"Ninlaro","generic_name":"ixazomib","manufacturer_negotiated_with":"Takeda Canada Inc.","indication":"Multiple Myeloma","status":"Negotiations were not pursued","cda_amc_project_id":"PC0088-000","inesss_project_id":"","engagement_date":"","close_date":"2017-08-18"},{"pcpa_file_number":"20917","brand_name":"Eylea","generic_name":"aflibercept","manufacturer_negotiated_with":"Bayer Inc.","indication":"Macular edema secondary to branch retinal vein occlusion","status":"Concluded with an LOI","cda_amc_project_id":"SR0460-000","inesss_project_id":"","engagement_date":"2017-02-22","close_date":"2017-03-13"},{"pcpa_file_number":"20916","brand_name":"Genvoya","generic_name":"elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"HIV-1 Infection","status":"Concluded with an LOI","cda_amc_project_id":"SR0449-000","inesss_project_id":"","engagement_date":"2016-08-15","close_date":"2017-03-13"},{"pcpa_file_number":"20915","brand_name":"Entresto","generic_name":"sacubitril\/valsartan","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Heart failure, NYHA class II or III","status":"Concluded with an LOI","cda_amc_project_id":"SR0447-000","inesss_project_id":"","engagement_date":"2016-06-30","close_date":"2017-03-06"},{"pcpa_file_number":"20914","brand_name":"Entyvio","generic_name":"vedolizumab","manufacturer_negotiated_with":"Takeda Canada Inc.","indication":"Crohn\u0026#039;s disease","status":"Concluded with an LOI","cda_amc_project_id":"SR0487-000","inesss_project_id":"","engagement_date":"2016-11-08","close_date":"2017-03-03"},{"pcpa_file_number":"20913","brand_name":"Entyvio","generic_name":"vedolizumab","manufacturer_negotiated_with":"Takeda Canada Inc.","indication":"Ulcerative Colitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0421-000","inesss_project_id":"","engagement_date":"2016-05-26","close_date":"2017-03-03"},{"pcpa_file_number":"20912","brand_name":"Epclusa","generic_name":"sofosbuvir\/velpatasvir","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"Chronic Hepatitis C","status":"Concluded with an LOI","cda_amc_project_id":"SR0486-000","inesss_project_id":"","engagement_date":"2016-10-26","close_date":"2017-02-17"},{"pcpa_file_number":"20911","brand_name":"Sunvepra","generic_name":"asunaprevir","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Chronic Hepatitis C","status":"Concluded with an LOI","cda_amc_project_id":"SR0418-000","inesss_project_id":"","engagement_date":"2016-07-20","close_date":"2017-02-17"},{"pcpa_file_number":"20910","brand_name":"Zepatier","generic_name":"elbasvir\/grazoprevir","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Chronic Hepatitis C","status":"Concluded with an LOI","cda_amc_project_id":"SR0454-000","inesss_project_id":"","engagement_date":"2016-04-14","close_date":"2017-02-17"},{"pcpa_file_number":"20909","brand_name":"Otezla","generic_name":"apremilast","manufacturer_negotiated_with":"Celgene Inc.","indication":"Psoriatic Arthritis","status":"Concluded without agreement","cda_amc_project_id":"SR0437-000","inesss_project_id":"","engagement_date":"2017-06-26","close_date":"2017-09-08"},{"pcpa_file_number":"20908","brand_name":"Plegridy","generic_name":"peginterferon beta-1a","manufacturer_negotiated_with":"Biogen Canada Inc.","indication":"Multiple Sclerosis, Relapsing","status":"Concluded with an LOI","cda_amc_project_id":"SR0440-000","inesss_project_id":"","engagement_date":"2016-06-17","close_date":"2017-02-14"},{"pcpa_file_number":"20907","brand_name":"Opsumit","generic_name":"macitentan","manufacturer_negotiated_with":"Actelion Pharmaceuticals Ltd.","indication":"Pulmonary Arterial Hypertension","status":"Concluded without agreement","cda_amc_project_id":"SR0364-000","inesss_project_id":"","engagement_date":"2015-03-25","close_date":"2015-12-18"},{"pcpa_file_number":"20906","brand_name":"Caprelsa","generic_name":"vandetanib","manufacturer_negotiated_with":"Sanofi Genzyme Canada","indication":"Medullary Thyroid Cancer","status":"Concluded without agreement","cda_amc_project_id":"PC0090-000","inesss_project_id":"","engagement_date":"2017-06-02","close_date":"2017-08-16"},{"pcpa_file_number":"20905","brand_name":"Jakavi","generic_name":"ruxolintib","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Polycythemia vera","status":"Concluded with an LOI","cda_amc_project_id":"PC0065-000","inesss_project_id":"","engagement_date":"2016-06-30","close_date":"2017-08-08"},{"pcpa_file_number":"20904","brand_name":"Alecensaro","generic_name":"alectinib","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Non-Small Cell Lung Cancer (with CNS metastases)","status":"Negotiations were not pursued","cda_amc_project_id":"PC0092-000","inesss_project_id":"","engagement_date":"","close_date":"2017-07-31"},{"pcpa_file_number":"20903","brand_name":"Stelara","generic_name":"ustekinumab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Psoriatic Arthritis","status":"Negotiations were not pursued","cda_amc_project_id":"SR0359-000","inesss_project_id":"","engagement_date":"","close_date":"2014-11-27"},{"pcpa_file_number":"20902","brand_name":"Votrient","generic_name":"pazopanib hydrochloride","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Metastatic Renal Cell Carcinoma","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2017-03-31","close_date":"2017-07-03"},{"pcpa_file_number":"20901","brand_name":"Signifor","generic_name":"pasireotide diaspartate","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Cushing\u0026#039;s disease","status":"Negotiations were not pursued","cda_amc_project_id":"SR0372-000","inesss_project_id":"","engagement_date":"","close_date":"2015-04-30"},{"pcpa_file_number":"20900","brand_name":"Samsca","generic_name":"tolvaptan","manufacturer_negotiated_with":"Otsuka Canada Pharmaceutical Inc.","indication":"Hyponatremia, non-hypovolemic","status":"Negotiations were not pursued","cda_amc_project_id":"SR0283-000","inesss_project_id":"","engagement_date":"","close_date":"2014-01-31"},{"pcpa_file_number":"20899","brand_name":"Imbruvica","generic_name":"ibrutinib","manufacturer_negotiated_with":"Janssen Inc.","indication":"Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.","status":"Concluded with an LOI","cda_amc_project_id":"PC0082-000","inesss_project_id":"","engagement_date":"2016-12-20","close_date":"2017-06-27"},{"pcpa_file_number":"20898","brand_name":"Grastofil","generic_name":"filgrastim","manufacturer_negotiated_with":"ApoPharm Inc.","indication":"Neutropenia in various indications (Prevention or treatment)","status":"Concluded with an LOI","cda_amc_project_id":"SE0446-000","inesss_project_id":"","engagement_date":"2016-06-15","close_date":"2016-12-12"},{"pcpa_file_number":"20897","brand_name":"Xolair","generic_name":"omalizumab","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Chronic Idiopathic Urticaria","status":"Concluded with an LOI","cda_amc_project_id":"SR0398-000","inesss_project_id":"","engagement_date":"2015-07-17","close_date":"2016-11-28"},{"pcpa_file_number":"20896","brand_name":"Imbruvica","generic_name":"ibrutinib","manufacturer_negotiated_with":"Janssen Inc.","indication":"Mantle Cell Lymphoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0073-000","inesss_project_id":"","engagement_date":"2016-08-12","close_date":"2017-06-27"},{"pcpa_file_number":"20895","brand_name":"Lenvima","generic_name":"lenvatinib","manufacturer_negotiated_with":"Eisai Limited","indication":"Differentiated Thyroid Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0080-000","inesss_project_id":"","engagement_date":"2017-04-04","close_date":"2017-06-16"},{"pcpa_file_number":"20894","brand_name":"Mozobil","generic_name":"plerixafor","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Non-Hodgkin\u0026#039;s Lymphoma and Multiple Myeloma","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2017-04-18","close_date":"2017-06-06"},{"pcpa_file_number":"20893","brand_name":"Rituxan SC","generic_name":"rituximab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Acute Lymphoblastic Leukemia (ALL)","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2016-12-14","close_date":"2017-05-24"},{"pcpa_file_number":"20892","brand_name":"Otezla","generic_name":"apremilast","manufacturer_negotiated_with":"Celgene Inc.","indication":"Psoriasis, moderate to severe plaque","status":"Concluded without agreement","cda_amc_project_id":"SR0400-000","inesss_project_id":"","engagement_date":"2017-06-26","close_date":"2017-09-08"},{"pcpa_file_number":"20891","brand_name":"Forxiga","generic_name":"dapagliflozin","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded with an LOI","cda_amc_project_id":"SR0428-000","inesss_project_id":"","engagement_date":"2016-05-27","close_date":"2016-10-03"},{"pcpa_file_number":"20890","brand_name":"Vectibix","generic_name":"panitumumab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Metastatic Colorectal Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0060-000","inesss_project_id":"","engagement_date":"2015-12-23","close_date":"2017-05-22"},{"pcpa_file_number":"20889","brand_name":"Cotellic - Zelboraf","generic_name":"cobimetinib - vemurafenib","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Metastatic Melanoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0070-000","inesss_project_id":"","engagement_date":"2016-08-12","close_date":"2017-05-11"},{"pcpa_file_number":"20888","brand_name":"Esbriet","generic_name":"pirfenidone","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Pulmonary fibrosis (idiopathic, mild to moderate)","status":"Concluded with an LOI","cda_amc_project_id":"SR0393-000","inesss_project_id":"","engagement_date":"2015-04-30","close_date":"2016-09-11"},{"pcpa_file_number":"20887","brand_name":"Ferriprox","generic_name":"deferiprone","manufacturer_negotiated_with":"ApoPharm Inc.","indication":"Transfusional iron overload due to thalassemia","status":"Concluded with an LOI","cda_amc_project_id":"SR0448-000","inesss_project_id":"","engagement_date":"2016-05-13","close_date":"2016-09-07"},{"pcpa_file_number":"20886","brand_name":"Ofev","generic_name":"nintedanib","manufacturer_negotiated_with":"Boehringer Ingelheim (Canada) Ltd.","indication":"Idiopathic pulmonary fibrosis (IPF)","status":"Concluded with an LOI","cda_amc_project_id":"SR0426-000","inesss_project_id":"","engagement_date":"2015-10-27","close_date":"2016-08-29"},{"pcpa_file_number":"20885","brand_name":"Simponi SC","generic_name":"golimumab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Ulcerative Colitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0341-000","inesss_project_id":"","engagement_date":"2014-05-23","close_date":"2016-08-12"},{"pcpa_file_number":"20884","brand_name":"Arnuity Ellipta","generic_name":"fluticasone furoate","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Asthma","status":"Concluded with an LOI","cda_amc_project_id":"SR0439-000","inesss_project_id":"","engagement_date":"2016-04-13","close_date":"2016-08-08"},{"pcpa_file_number":"20883","brand_name":"Breo Ellipta","generic_name":"fluticasone furoate\/vilanterol","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Asthma","status":"Concluded with an LOI","cda_amc_project_id":"SR0442-000","inesss_project_id":"","engagement_date":"2016-04-13","close_date":"2016-07-11"},{"pcpa_file_number":"20882","brand_name":"Opdivo","generic_name":"nivolumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Metastatic Renal Cell Carcinoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0074-000","inesss_project_id":"","engagement_date":"2016-11-18","close_date":"2017-01-20"},{"pcpa_file_number":"20881","brand_name":"Cosentyx","generic_name":"secukinumab","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Psoriasis, moderate to severe plaque","status":"Concluded with an LOI","cda_amc_project_id":"SR0407-000","inesss_project_id":"","engagement_date":"2015-12-15","close_date":"2016-06-08"},{"pcpa_file_number":"20880","brand_name":"Opdivo","generic_name":"nivolumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Non-small Cell Lung Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0069-000","inesss_project_id":"","engagement_date":"2016-07-04","close_date":"2017-01-20"},{"pcpa_file_number":"20879","brand_name":"Opdivo","generic_name":"nivolumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Metastatic Melanoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0063-000","inesss_project_id":"","engagement_date":"2016-05-04","close_date":"2017-01-20"},{"pcpa_file_number":"20878","brand_name":"Lemtrada","generic_name":"alemtuzumab","manufacturer_negotiated_with":"Sanofi Genzyme Canada","indication":"Multiple Sclerosis, Relapsing-Remitting","status":"Concluded with an LOI","cda_amc_project_id":"SR0405-000","inesss_project_id":"","engagement_date":"2015-07-28","close_date":"2016-05-11"},{"pcpa_file_number":"20877","brand_name":"Xeljanz","generic_name":"tofacitinib","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Rheumatoid Arthritis","status":"Concluded with an LOI","cda_amc_project_id":"SR0380-000","inesss_project_id":"","engagement_date":"2015-07-21","close_date":"2016-04-26"},{"pcpa_file_number":"20876","brand_name":"Daklinza","generic_name":"daclatasvir","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Chronic Hepatitis C","status":"Concluded without agreement","cda_amc_project_id":"SR0417-000","inesss_project_id":"","engagement_date":"","close_date":"2016-03-17"},{"pcpa_file_number":"20875","brand_name":"Zydelig","generic_name":"idelalisib","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"Follicular lymphoma, Relapsed or refractory","status":"Negotiations were not pursued","cda_amc_project_id":"PC0075-000","inesss_project_id":"","engagement_date":"","close_date":"2017-01-13"},{"pcpa_file_number":"20874","brand_name":"Jardiance","generic_name":"empagliflozin","manufacturer_negotiated_with":"Boehringer Ingelheim (Canada) Ltd.","indication":"Diabetes Mellitus, Type 2 with high cardiovascular risk","status":"Concluded with an LOI","cda_amc_project_id":"SR0427-000","inesss_project_id":"","engagement_date":"2016-03-03","close_date":"2016-04-13"},{"pcpa_file_number":"20873","brand_name":"Trajenta\/Jentaduo","generic_name":"linagliptin (linagliptin\/metformin)","manufacturer_negotiated_with":"Boehringer Ingelheim (Canada) Ltd.","indication":"Diabetes Mellitus, Type 2","status":"Concluded with an LOI","cda_amc_project_id":"SR0244-000","inesss_project_id":"","engagement_date":"2015-09-04","close_date":"2016-04-12"},{"pcpa_file_number":"20872","brand_name":"Nesina","generic_name":"alogliptin","manufacturer_negotiated_with":"Takeda Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Negotiations were not pursued","cda_amc_project_id":"SR0368-000","inesss_project_id":"","engagement_date":"","close_date":"2015-01-28"},{"pcpa_file_number":"20871","brand_name":"Prezcobix","generic_name":"darunavir\/cobicistat","manufacturer_negotiated_with":"Janssen Inc.","indication":"HIV-1 Infection","status":"Concluded with an LOI","cda_amc_project_id":"SR0381-000","inesss_project_id":"","engagement_date":"2015-06-10","close_date":"2016-03-24"},{"pcpa_file_number":"20870","brand_name":"Inspiolto Respimat","generic_name":"tiotropium\/olodaterol","manufacturer_negotiated_with":"Boehringer Ingelheim (Canada) Ltd.","indication":"Heart failure, NYHA class II","status":"Concluded with an LOI","cda_amc_project_id":"SR0436-000","inesss_project_id":"","engagement_date":"2016-02-22","close_date":"2016-03-02"},{"pcpa_file_number":"20869","brand_name":"Spiriva Respimat","generic_name":"tiotropium bromide","manufacturer_negotiated_with":"Boehringer Ingelheim (Canada) Ltd.","indication":"Chronic Obstructive Pulmonary Disease (COPD)","status":"Concluded with an LOI","cda_amc_project_id":"SR0412-000","inesss_project_id":"","engagement_date":"2015-08-21","close_date":"2016-03-02"},{"pcpa_file_number":"20868","brand_name":"Byetta","generic_name":"exenatide","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded without agreement","cda_amc_project_id":"SR0246-000","inesss_project_id":"","engagement_date":"2012-06-01","close_date":"2013-06-13"},{"pcpa_file_number":"20867","brand_name":"Blincyto","generic_name":"blinatumomab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Acute Lymphoblastic Leukemia (ALL)","status":"Concluded with an LOI","cda_amc_project_id":"PC0064-000","inesss_project_id":"","engagement_date":"2016-04-27","close_date":"2017-01-09"},{"pcpa_file_number":"20866","brand_name":"Januvia","generic_name":"sitagliptin phosphate","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded with an LOI","cda_amc_project_id":"SR0181-000","inesss_project_id":"","engagement_date":"2015-09-04","close_date":"2016-02-08"},{"pcpa_file_number":"20865","brand_name":"Janumet","generic_name":"sitagliptin phosphate","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded with an LOI","cda_amc_project_id":"SR0182-000","inesss_project_id":"","engagement_date":"2015-09-04","close_date":"2016-02-08"},{"pcpa_file_number":"20864","brand_name":"Kazano","generic_name":"alogliptin\/metformin","manufacturer_negotiated_with":"Takeda Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Negotiations were not pursued","cda_amc_project_id":"SR0367-000","inesss_project_id":"","engagement_date":"","close_date":"2015-01-28"},{"pcpa_file_number":"20863","brand_name":"Cimzia","generic_name":"certolizumab pegol","manufacturer_negotiated_with":"UCB Canada Inc.","indication":"Ankylosing spondylitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0385-000","inesss_project_id":"","engagement_date":"2015-10-05","close_date":"2016-01-06"},{"pcpa_file_number":"20862","brand_name":"Butrans","generic_name":"buprenorphine","manufacturer_negotiated_with":"Purdue Pharma","indication":"Pain, persistent (moderate intensity)","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2017-05-15","close_date":"2017-08-18"},{"pcpa_file_number":"20861","brand_name":"Actemra SC","generic_name":"tocilizumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Rheumatoid Arthritis","status":"Concluded with an LOI","cda_amc_project_id":"SR0374-000","inesss_project_id":"","engagement_date":"2015-05-01","close_date":"2015-12-16"},{"pcpa_file_number":"20860","brand_name":"Incruse Ellipta","generic_name":"umeclidinium","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Chronic Obstructive Pulmonary Disease (COPD)","status":"Concluded with an LOI","cda_amc_project_id":"SR0422-000","inesss_project_id":"","engagement_date":"2015-10-23","close_date":"2015-12-15"},{"pcpa_file_number":"20859","brand_name":"Duaklir Genuair","generic_name":"aclidinium bromide\/formoterol fumarate dihydrate","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Chronic Obstructive Pulmonary Disease (COPD)","status":"Concluded with an LOI","cda_amc_project_id":"SR0423-000","inesss_project_id":"","engagement_date":"2015-10-23","close_date":"2015-12-15"},{"pcpa_file_number":"20858","brand_name":"Inflectra","generic_name":"infliximab","manufacturer_negotiated_with":"Hospira Healthcare Corporation","indication":"Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis","status":"Concluded with an LOI","cda_amc_project_id":"SE0384-000","inesss_project_id":"","engagement_date":"2015-01-14","close_date":"2015-11-19"},{"pcpa_file_number":"20857","brand_name":"Jinarc","generic_name":"tolvaptan","manufacturer_negotiated_with":"Otsuka Canada Pharmaceutical Inc.","indication":"Autosomal dominant polycystic kidney disease (ADPKD)","status":"Negotiations were not pursued","cda_amc_project_id":"SR0435-000","inesss_project_id":"","engagement_date":"","close_date":"2016-06-10"},{"pcpa_file_number":"20856","brand_name":"Imbruvica","generic_name":"ibrutinib","manufacturer_negotiated_with":"Janssen Inc.","indication":"Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma","status":"Negotiations were not pursued","cda_amc_project_id":"PC0082-000","inesss_project_id":"","engagement_date":"","close_date":"2016-12-23"},{"pcpa_file_number":"20855","brand_name":"Darzalex","generic_name":"Daratumumab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Multiple Myeloma","status":"Negotiations were not pursued","cda_amc_project_id":"PC0079-000","inesss_project_id":"","engagement_date":"","close_date":"2016-12-23"},{"pcpa_file_number":"20854","brand_name":"Intuniv XR","generic_name":"guanfacine hydrochloride","manufacturer_negotiated_with":"Shire Pharma Canada ULC","indication":"Attention-deficit\/hyperactivity disorder (ADHD)","status":"Negotiations were not pursued","cda_amc_project_id":"SR0349-000","inesss_project_id":"","engagement_date":"","close_date":"2014-11-18"},{"pcpa_file_number":"20853","brand_name":"Aptiom","generic_name":"eslicarbazepine acetate","manufacturer_negotiated_with":"Sunovion Pharmaceuticals Canada Inc.","indication":"Epilepsy, partial-onset seizures","status":"Concluded with an LOI","cda_amc_project_id":"SR0391-000","inesss_project_id":"","engagement_date":"2015-06-15","close_date":"2015-09-08"},{"pcpa_file_number":"20852","brand_name":"Simbrinza","generic_name":"brinzolamide\/brimonidine","manufacturer_negotiated_with":"Alcon Canada Inc.","indication":"Glaucoma and Ocular Hypertension","status":"Concluded with an LOI","cda_amc_project_id":"SR0403-000","inesss_project_id":"","engagement_date":"2015-08-06","close_date":"2015-08-27"},{"pcpa_file_number":"20851","brand_name":"Humira","generic_name":"adalimumab","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Hidradenitis Suppurativa","status":"Negotiations were not pursued","cda_amc_project_id":"SR0455-000","inesss_project_id":"","engagement_date":"","close_date":"2016-12-22"},{"pcpa_file_number":"20850","brand_name":"Cyramza","generic_name":"ramucirumab","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Advanced or Metastatic Gastric Cancer or Gastro-esophageal Junction (GEJ) Adenocarcinoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0059-000","inesss_project_id":"","engagement_date":"2015-11-12","close_date":"2016-10-27"},{"pcpa_file_number":"20849","brand_name":"Eliquis","generic_name":"apixaban","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Thromboembolic events (venous), treatment and prevention of recurrence","status":"Concluded with an LOI","cda_amc_project_id":"SR0397-000","inesss_project_id":"","engagement_date":"2015-06-11","close_date":"2015-07-09"},{"pcpa_file_number":"20848","brand_name":"Holkira Pak","generic_name":"ombitasvir\/paritaprevir\/ritonavir\/dasabuvir","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Chronic Hepatitis C","status":"Concluded with an LOI","cda_amc_project_id":"SR0406-000","inesss_project_id":"","engagement_date":"2015-04-27","close_date":"2015-06-16"},{"pcpa_file_number":"20847","brand_name":"Abilify Maintena","generic_name":"aripiprazole","manufacturer_negotiated_with":"Otsuka Canada Pharmaceutical Inc.","indication":"Schizophrenia","status":"Concluded with an LOI","cda_amc_project_id":"SR0366-000","inesss_project_id":"","engagement_date":"2015-01-29","close_date":"2015-06-14"},{"pcpa_file_number":"20846","brand_name":"Grastek","generic_name":"phleum pratense","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Allergy","status":"Negotiations were not pursued","cda_amc_project_id":"SR0352-000","inesss_project_id":"","engagement_date":"","close_date":"2014-10-30"},{"pcpa_file_number":"20845","brand_name":"Yondelis","generic_name":"trabectedin","manufacturer_negotiated_with":"Janssen Inc.","indication":"Metastatic Liposarcoma or Leiomyosarcoma","status":"Negotiations were not pursued","cda_amc_project_id":"PC0071-000","inesss_project_id":"","engagement_date":"","close_date":"2016-10-14"},{"pcpa_file_number":"20844","brand_name":"Fentora","generic_name":"fentanyl buccal","manufacturer_negotiated_with":"Teva Canada Ltd.","indication":"Pain (breakthrough), cancer (adults)","status":"Negotiations were not pursued","cda_amc_project_id":"SR0494-000","inesss_project_id":"","engagement_date":"","close_date":"2017-03-31"},{"pcpa_file_number":"20843","brand_name":"Fampyra","generic_name":"fampridine","manufacturer_negotiated_with":"Biogen Canada Inc.","indication":"Multiple Sclerosis, improve walking disability","status":"Negotiations were not pursued","cda_amc_project_id":"SR0275-000","inesss_project_id":"","engagement_date":"","close_date":"2014-01-31"},{"pcpa_file_number":"20842","brand_name":"Sylvant","generic_name":"siltuximab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Multicentric Castleman\u0026#039;s Disease (MCD)","status":"Concluded with an LOI","cda_amc_project_id":"PC0052-000","inesss_project_id":"","engagement_date":"2015-08-08","close_date":"2016-09-30"},{"pcpa_file_number":"20841","brand_name":"Anoro Ellipta","generic_name":"umeclidinium\/vilanterol","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Chronic Obstructive Pulmonary Disease (COPD)","status":"Concluded with an LOI","cda_amc_project_id":"SR0371-000","inesss_project_id":"","engagement_date":"2015-02-04","close_date":"2015-05-01"},{"pcpa_file_number":"20840","brand_name":"Revlimid","generic_name":"lenalidomide","manufacturer_negotiated_with":"Celgene Inc.","indication":"Multiple Myeloma (newly diagnosed)","status":"Concluded with an LOI","cda_amc_project_id":"PC0061-000","inesss_project_id":"","engagement_date":"2015-12-10","close_date":"2016-09-14"},{"pcpa_file_number":"20839","brand_name":"Rebif","generic_name":"interferon beta-1a","manufacturer_negotiated_with":"EMD Serono Canada, a division of EMD Inc.","indication":"Clinically Isolated Syndrome","status":"Concluded with an LOI","cda_amc_project_id":"SR0298-000","inesss_project_id":"","engagement_date":"2013-10-11","close_date":"2015-04-21"},{"pcpa_file_number":"20838","brand_name":"Ultibro Breezhaler","generic_name":"indacaterol\/glycopyrronium","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Chronic Obstructive Pulmonary Disease (COPD)","status":"Concluded with an LOI","cda_amc_project_id":"SR0369-000","inesss_project_id":"","engagement_date":"2015-01-26","close_date":"2015-04-20"},{"pcpa_file_number":"20837","brand_name":"Myrbetriq","generic_name":"mirabegron","manufacturer_negotiated_with":"Astellas Pharma Inc.","indication":"Overactive Bladder","status":"Concluded with an LOI","cda_amc_project_id":"SR0363-000","inesss_project_id":"","engagement_date":"2015-01-14","close_date":"2015-04-08"},{"pcpa_file_number":"20836","brand_name":"Tivicay","generic_name":"dolutegravir","manufacturer_negotiated_with":"ViiV Healthcare","indication":"HIV-1 Infection","status":"Concluded with an LOI","cda_amc_project_id":"SR0357-000","inesss_project_id":"","engagement_date":"2014-10-28","close_date":"2015-04-08"},{"pcpa_file_number":"20835","brand_name":"Inspra","generic_name":"eplerenone","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Post myocardial infarction","status":"Concluded with an LOI","cda_amc_project_id":"SR0342-000","inesss_project_id":"","engagement_date":"2014-05-09","close_date":"2015-03-31"},{"pcpa_file_number":"20834","brand_name":"Iclusig","generic_name":"ponatinib","manufacturer_negotiated_with":"Paladin Labs Inc.","indication":"Chronic Myeloid Leukemia\/Acute Lymphoblastic Leukemia","status":"Concluded with an LOI","cda_amc_project_id":"PC0056-000","inesss_project_id":"","engagement_date":"2015-10-28","close_date":"2016-07-04"},{"pcpa_file_number":"20833","brand_name":"Sovaldi","generic_name":"sofosbuvir","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"Chronic Hepatitis C","status":"Concluded with an LOI","cda_amc_project_id":"SR0356-000","inesss_project_id":"","engagement_date":"2014-09-02","close_date":"2015-02-05"},{"pcpa_file_number":"20832","brand_name":"Breo Ellipta","generic_name":"fluticasone furoate\/vilanterol","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Chronic Obstructive Pulmonary Disease (COPD)","status":"Concluded with an LOI","cda_amc_project_id":"SR0358-000","inesss_project_id":"","engagement_date":"2014-10-06","close_date":"2015-02-03"},{"pcpa_file_number":"20831","brand_name":"Egrifta","generic_name":"tesamorelin","manufacturer_negotiated_with":"Theratechnologies Inc.","indication":"Lipodystrophy, HIV-infected patients","status":"Negotiations were not pursued","cda_amc_project_id":"SR0477-000","inesss_project_id":"","engagement_date":"","close_date":"2016-10-14"},{"pcpa_file_number":"20830","brand_name":"Edarbyclor","generic_name":"azilsartan medoxomil\/chlorthalidone","manufacturer_negotiated_with":"Takeda Canada Inc.","indication":"Hypertension","status":"Negotiations were not pursued","cda_amc_project_id":"SR0318-000","inesss_project_id":"","engagement_date":"","close_date":"2013-11-12"},{"pcpa_file_number":"20829","brand_name":"Zydelig","generic_name":"idelalisib","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"Chronic lymphocytic leukemia","status":"Concluded with an LOI","cda_amc_project_id":"PC0057-000","inesss_project_id":"","engagement_date":"2015-09-24","close_date":"2016-06-03"},{"pcpa_file_number":"20828","brand_name":"Edarbi","generic_name":"azilsartan medoxomil","manufacturer_negotiated_with":"Takeda Canada Inc.","indication":"Hypertension","status":"Negotiations were not pursued","cda_amc_project_id":"SR0317-000","inesss_project_id":"","engagement_date":"","close_date":"2013-11-12"},{"pcpa_file_number":"20827","brand_name":"Dymista","generic_name":"azelastine\/fluticasone propionate","manufacturer_negotiated_with":"Meda Pharmaceuticals","indication":"Seasonal allergic rhinitis","status":"Negotiations were not pursued","cda_amc_project_id":"SR0408-000","inesss_project_id":"","engagement_date":"","close_date":"2015-07-24"},{"pcpa_file_number":"20826","brand_name":"Tafinlar\/Mekinist","generic_name":"dabrafenib\/trametinib","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Metastatic Melanoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0053-000","inesss_project_id":"","engagement_date":"2015-09-18","close_date":"2016-05-25"},{"pcpa_file_number":"20825","brand_name":"Cortiment","generic_name":"budesonide","manufacturer_negotiated_with":"Ferring Canada Inc.","indication":"Ulcerative Colitis","status":"Negotiations were not pursued","cda_amc_project_id":"SR0491-000","inesss_project_id":"","engagement_date":"","close_date":"2017-04-07"},{"pcpa_file_number":"20824","brand_name":"Jetrea","generic_name":"ocriplasmin","manufacturer_negotiated_with":"Alcon Canada Inc.","indication":"Vitreomacular Adhesion","status":"Concluded with an LOI","cda_amc_project_id":"SR0337-000","inesss_project_id":"","engagement_date":"2014-03-04","close_date":"2014-10-10"},{"pcpa_file_number":"20823","brand_name":"Constella","generic_name":"linaclotide","manufacturer_negotiated_with":"Forest Laboratories Canada","indication":"Irritable bowel syndrome with constipation","status":"Negotiations were not pursued","cda_amc_project_id":"SR0409-000","inesss_project_id":"","engagement_date":"","close_date":"2015-11-02"},{"pcpa_file_number":"20822","brand_name":"Xarelto","generic_name":"rivaroxaban","manufacturer_negotiated_with":"Bayer Inc.","indication":"Thromboembolic events (venous), pulmonary embolism","status":"Concluded with an LOI","cda_amc_project_id":"SR0327-000","inesss_project_id":"","engagement_date":"2014-05-28","close_date":"2014-07-29"},{"pcpa_file_number":"20821","brand_name":"Keytruda","generic_name":"pembrolizumab","manufacturer_negotiated_with":"Merck Canada Inc.","indication":"Metastatic Melanoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0058-000","inesss_project_id":"","engagement_date":"2015-12-08","close_date":"2016-02-10"},{"pcpa_file_number":"20820","brand_name":"Zykadia","generic_name":"ceritinib","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Non-Small Cell Lung Cancer (metastatic)","status":"Negotiations were not pursued","cda_amc_project_id":"PC0062-000","inesss_project_id":"","engagement_date":"","close_date":"2016-02-05"},{"pcpa_file_number":"20819","brand_name":"Bosulif","generic_name":"bosutinib","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Chronic Myeloid Leukemia","status":"Concluded with an LOI","cda_amc_project_id":"PC0039-000","inesss_project_id":"","engagement_date":"","close_date":"2015-11-09"},{"pcpa_file_number":"20818","brand_name":"Bystolic","generic_name":"nebivolol","manufacturer_negotiated_with":"Allergan Inc.","indication":"Hypertension","status":"Negotiations were not pursued","cda_amc_project_id":"SR0307-000","inesss_project_id":"","engagement_date":"","close_date":"2013-08-22"},{"pcpa_file_number":"20817","brand_name":"Avastin","generic_name":"bevacizumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Cervical Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0045-000","inesss_project_id":"","engagement_date":"2015-04-30","close_date":"2015-11-04"},{"pcpa_file_number":"20816","brand_name":"Xalkori","generic_name":"crizotinib","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Non-Small Cell Lung Cancer (First Line)","status":"Concluded with an LOI","cda_amc_project_id":"PC0054-000","inesss_project_id":"","engagement_date":"2015-07-17","close_date":"2015-10-08"},{"pcpa_file_number":"20815","brand_name":"Istodax","generic_name":"romidepsin","manufacturer_negotiated_with":"Celgene Inc.","indication":"Peripheral T-cell Lymphoma (PTCL)","status":"Concluded with an LOI","cda_amc_project_id":"PC0048-000","inesss_project_id":"","engagement_date":"2015-06-02","close_date":"2015-09-16"},{"pcpa_file_number":"20814","brand_name":"Perjeta\/Herceptin","generic_name":"pertuzumab\/trastuzumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Neoadjuvant Breast Cancer","status":"Negotiations were not pursued","cda_amc_project_id":"PC0050-000","inesss_project_id":"","engagement_date":"","close_date":"2015-07-29"},{"pcpa_file_number":"20813","brand_name":"Apprilon","generic_name":"doxycycline monohydrate","manufacturer_negotiated_with":"Galderma Canada Inc.","indication":"Rosacea","status":"Negotiations were not pursued","cda_amc_project_id":"SR0279-000","inesss_project_id":"","engagement_date":"","close_date":"2013-12-17"},{"pcpa_file_number":"20812","brand_name":"Nexavar","generic_name":"sorafenib","manufacturer_negotiated_with":"Bayer Inc.","indication":"Metastatic Progressive Differentiated Thyroid Carcinoma","status":"Negotiations were not pursued","cda_amc_project_id":"PC0049-000","inesss_project_id":"","engagement_date":"","close_date":"2015-07-29"},{"pcpa_file_number":"20811","brand_name":"Aloxi IV","generic_name":"palonosetron hydrochloride","manufacturer_negotiated_with":"Eisai Limited","indication":"Nausea and vomiting (chemotherapy induced) prevention","status":"Negotiations were not pursued","cda_amc_project_id":"SR0294-000","inesss_project_id":"","engagement_date":"","close_date":"2013-08-21"},{"pcpa_file_number":"20810","brand_name":"Aloxi","generic_name":"palonosetron hydrochloride","manufacturer_negotiated_with":"Eisai Limited","indication":"Nausea and vomiting (chemotherapy induced) prevention","status":"Negotiations were not pursued","cda_amc_project_id":"SR0294-000","inesss_project_id":"","engagement_date":"","close_date":"2013-08-21"},{"pcpa_file_number":"20809","brand_name":"Xtandi","generic_name":"enzalutamide","manufacturer_negotiated_with":"Astellas Pharma Inc.","indication":"Metastatic Castration-Resistant Prostate Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0044-000","inesss_project_id":"","engagement_date":"2015-06-24","close_date":"2015-07-22"},{"pcpa_file_number":"20808","brand_name":"Afinitor","generic_name":"everolimus","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Subependymal giant cell astrocytoma associated with tuberous sclerosis complex","status":"Negotiations were not pursued","cda_amc_project_id":"SR0376-000","inesss_project_id":"","engagement_date":"","close_date":"2015-06-30"},{"pcpa_file_number":"20807","brand_name":"Imbruvica","generic_name":"ibrutinib","manufacturer_negotiated_with":"Janssen Inc.","indication":"Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0043-000","inesss_project_id":"","engagement_date":"2015-03-06","close_date":"2015-06-02"},{"pcpa_file_number":"20806","brand_name":"Gazyva","generic_name":"obinutuzumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.","status":"Concluded with an LOI","cda_amc_project_id":"PC0041-000","inesss_project_id":"","engagement_date":"2015-02-10","close_date":"2015-05-15"},{"pcpa_file_number":"20805","brand_name":"Abraxane","generic_name":"nab-paclitaxel","manufacturer_negotiated_with":"Celgene Inc.","indication":"Metastatic Pancreatic Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0037-000","inesss_project_id":"","engagement_date":"2014-10-29","close_date":"2015-03-02"},{"pcpa_file_number":"20804","brand_name":"Yervoy","generic_name":"ipilimumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Advanced Melanoma, first-line","status":"Concluded with an LOI","cda_amc_project_id":"PC0042-000","inesss_project_id":"","engagement_date":"","close_date":"2015-03-02"},{"pcpa_file_number":"20803","brand_name":"Arzerra","generic_name":"ofatumumab","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.","status":"Negotiations were not pursued","cda_amc_project_id":"PC0038-000","inesss_project_id":"","engagement_date":"","close_date":"2015-02-27"},{"pcpa_file_number":"20802","brand_name":"Afinitor","generic_name":"everolimus","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex (TSC)","status":"Negotiations were not pursued","cda_amc_project_id":"SR0315-000","inesss_project_id":"","engagement_date":"","close_date":"2013-11-01"},{"pcpa_file_number":"20801","brand_name":"Adempas","generic_name":"riociguat","manufacturer_negotiated_with":"Bayer Inc.","indication":"Pulmonary Arterial Hypertension (WHO group 1)","status":"Negotiations were not pursued","cda_amc_project_id":"SR0438-000","inesss_project_id":"","engagement_date":"","close_date":"2017-01-31"},{"pcpa_file_number":"20800","brand_name":"Abilify","generic_name":"aripiprazole","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Major Depressive Disorder","status":"Negotiations were not pursued","cda_amc_project_id":"SR0354-000","inesss_project_id":"","engagement_date":"","close_date":"2014-12-02"},{"pcpa_file_number":"20799","brand_name":"Pomalyst","generic_name":"pomalidomide","manufacturer_negotiated_with":"Celgene Inc.","indication":"Multiple Myeloma","status":"Concluded with an LOI","cda_amc_project_id":"PC0036-000","inesss_project_id":"","engagement_date":"2014-08-21","close_date":"2015-01-23"},{"pcpa_file_number":"20798","brand_name":"Zaltrap","generic_name":"aflibercept","manufacturer_negotiated_with":"Regeneron","indication":"Metastatic Colorectal Cancer","status":"Negotiations were not pursued","cda_amc_project_id":"PC0035-000","inesss_project_id":"","engagement_date":"","close_date":"2014-09-25"},{"pcpa_file_number":"20797","brand_name":"Effient","generic_name":"prasugrel","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Acute Coronary Syndrome","status":"Concluded with an LOI","cda_amc_project_id":"SR0263-000","inesss_project_id":"","engagement_date":"2012-10-01","close_date":"2013-08-07"},{"pcpa_file_number":"20796","brand_name":"Seebri","generic_name":"glycopyrronium bromide","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Chronic Obstructive Pulmonary Disease (COPD)","status":"Concluded with an LOI","cda_amc_project_id":"SR0300-000","inesss_project_id":"","engagement_date":"2013-06-01","close_date":"2013-07-29"},{"pcpa_file_number":"20795","brand_name":"Stribild","generic_name":"elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"HIV-1 Infection","status":"Concluded with an LOI","cda_amc_project_id":"SR0301-000","inesss_project_id":"","engagement_date":"2013-06-10","close_date":"2013-07-11"},{"pcpa_file_number":"20794","brand_name":"Stivarga","generic_name":"regorafenib","manufacturer_negotiated_with":"Bayer Inc.","indication":"Gastrointestinal Stromal Tumours","status":"Concluded with an LOI","cda_amc_project_id":"PC0034-000","inesss_project_id":"","engagement_date":"","close_date":"2014-08-11"},{"pcpa_file_number":"20793","brand_name":"Abilify","generic_name":"aripiprazole","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Schizophrenia and Related Psychotic Disorders","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2016-06-01","close_date":"2017-03-31"},{"pcpa_file_number":"20792","brand_name":"Tysabri","generic_name":"natalizumab","manufacturer_negotiated_with":"Biogen Canada Inc.","indication":"Multiple Sclerosis, Relapsing-Remitting","status":"Concluded with an LOI","cda_amc_project_id":"SR0133-000","inesss_project_id":"","engagement_date":"2013-12-01","close_date":"2013-05-09"},{"pcpa_file_number":"20791","brand_name":"Revlimid","generic_name":"lenalidomide","manufacturer_negotiated_with":"Celgene Inc.","indication":"Multiple Myeloma","status":"Concluded with an LOI","cda_amc_project_id":"PC0029-000","inesss_project_id":"","engagement_date":"2013-11-12","close_date":"2014-07-25"},{"pcpa_file_number":"20790","brand_name":"Giotrif","generic_name":"afatinib","manufacturer_negotiated_with":"Boehringer Ingelheim (Canada) Ltd.","indication":"Advanced Non-Small Cell Lung Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0032-000","inesss_project_id":"","engagement_date":"2014-05-09","close_date":"2014-07-03"},{"pcpa_file_number":"20789","brand_name":"Mekinist","generic_name":"trametinib","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Metastatic Melanoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0030-000","inesss_project_id":"","engagement_date":"2013-11-18","close_date":"2014-06-25"},{"pcpa_file_number":"20788","brand_name":"Onbrez","generic_name":"indacaterol","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Chronic Obstructive Pulmonary Disease (COPD)","status":"Concluded with an LOI","cda_amc_project_id":"SR0273-000","inesss_project_id":"","engagement_date":"2012-12-01","close_date":"2013-04-12"},{"pcpa_file_number":"20787","brand_name":"Gilenya","generic_name":"fingolimod","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Multiple Sclerosis","status":"Concluded with an LOI","cda_amc_project_id":"SR0228-000","inesss_project_id":"","engagement_date":"2012-07-01","close_date":"2013-03-04"},{"pcpa_file_number":"20786","brand_name":"Tafinlar","generic_name":"dabrafenib","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Metastatic Melanoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0025-000","inesss_project_id":"","engagement_date":"","close_date":"2014-06-25"},{"pcpa_file_number":"20785","brand_name":"Xarelto","generic_name":"rivaroxaban","manufacturer_negotiated_with":"Bayer Inc.","indication":"Atrial fibrillation, stroke prevention","status":"Concluded with an LOI","cda_amc_project_id":"SR0257-000","inesss_project_id":"","engagement_date":"","close_date":"2012-06-19"},{"pcpa_file_number":"20784","brand_name":"Pradaxa","generic_name":"dabigatran etexilate","manufacturer_negotiated_with":"Boehringer Ingelheim (Canada) Ltd.","indication":"Atrial fibrillation prevention of stroke and systemic embolism","status":"Concluded with an LOI","cda_amc_project_id":"SR0214-000","inesss_project_id":"","engagement_date":"2013-08-21","close_date":"2012-03-22"},{"pcpa_file_number":"20783","brand_name":"Victoza","generic_name":"liraglutide","manufacturer_negotiated_with":"Novo Nordisk Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2018-01-31","close_date":"2019-03-29"},{"pcpa_file_number":"20782","brand_name":"Humira","generic_name":"adalimumab","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Hidradenitis Suppurativa","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2017-07-24","close_date":"2017-10-23"},{"pcpa_file_number":"20781","brand_name":"Cinqair","generic_name":"reslizumab","manufacturer_negotiated_with":"Teva Canada Ltd.","indication":"Eosinophilic Asthma","status":"Concluded without agreement","cda_amc_project_id":"SR0495-000","inesss_project_id":"","engagement_date":"2017-07-24","close_date":"2018-11-15"},{"pcpa_file_number":"20780","brand_name":"Erivedge","generic_name":"vismodegib","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Advanced Basal Cell Carcinoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0015-000","inesss_project_id":"","engagement_date":"2014-01-21","close_date":"2014-04-01"},{"pcpa_file_number":"20779","brand_name":"Kadcyla","generic_name":"trastuzumab emtansine","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Metastatic Breast Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0024-000","inesss_project_id":"","engagement_date":"","close_date":"2014-03-31"},{"pcpa_file_number":"20778","brand_name":"Alimta","generic_name":"pemetrexed","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Advanced Non-Squamous Non-Small Cell Lung Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0027-000","inesss_project_id":"","engagement_date":"2013-12-09","close_date":"2014-02-28"},{"pcpa_file_number":"20777","brand_name":"Adcetris","generic_name":"brentuximab vedotin","manufacturer_negotiated_with":"Seattle Genetics Inc.","indication":"Systemic Anaplastic Large Cell Lymphoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0021-000","inesss_project_id":"","engagement_date":"2013-09-04","close_date":"2014-01-31"},{"pcpa_file_number":"20776","brand_name":"Xiaflex","generic_name":"collagenase clostridium histolyticum","manufacturer_negotiated_with":"Auxillium Pharmaceuticals Inc.","indication":"Dupuytren\u0026#039;s contracture with a palpable cord","status":"Negotiations were not pursued","cda_amc_project_id":"SR0287-000","inesss_project_id":"","engagement_date":"","close_date":"2014-03-18"},{"pcpa_file_number":"20775","brand_name":"Xgeva","generic_name":"denosumab","manufacturer_negotiated_with":"Amgen Canada Inc.","indication":"Prevention of skeletal-related events due to bone metastases from breast cancer","status":"Negotiations were not pursued","cda_amc_project_id":"SR0433-000","inesss_project_id":"","engagement_date":"","close_date":"2017-01-31"},{"pcpa_file_number":"20774","brand_name":"Zytiga","generic_name":"abiraterone","manufacturer_negotiated_with":"Janssen Inc.","indication":"Metastatic Castration-Resistant Prostate Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0028-000","inesss_project_id":"","engagement_date":"2013-11-12","close_date":"2014-01-23"},{"pcpa_file_number":"20773","brand_name":"Victoza","generic_name":"liraglutide","manufacturer_negotiated_with":"Novo Nordisk Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"","close_date":"2016-06-17"},{"pcpa_file_number":"20772","brand_name":"Erbitux","generic_name":"cetuximab","manufacturer_negotiated_with":"Eli Lilly Canada Inc.","indication":"Metastatic Colorectal Cancer","status":"Negotiations were not pursued","cda_amc_project_id":"PC0031-000","inesss_project_id":"","engagement_date":"","close_date":"2014-01-21"},{"pcpa_file_number":"20771","brand_name":"Votrient","generic_name":"pazopanib hydrochloride","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Metastatic Renal Cell Carcinoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0022-000","inesss_project_id":"","engagement_date":"","close_date":"2013-12-02"},{"pcpa_file_number":"20770","brand_name":"Technivie","generic_name":"ombitasvir\/paritaprevir\/ritonavir","manufacturer_negotiated_with":"AbbVie Corporation","indication":"Chronic Hepatitis C (genotype 4)","status":"Concluded without agreement","cda_amc_project_id":"SR0444-000","inesss_project_id":"","engagement_date":"2016-04-14","close_date":"2017-02-17"},{"pcpa_file_number":"20769","brand_name":"Soliris","generic_name":"eculizumab","manufacturer_negotiated_with":"Alexion Pharma Canada Corp.","indication":"Atypical hemolytic uremic syndrome","status":"Concluded without agreement","cda_amc_project_id":"SR0304-000","inesss_project_id":"","engagement_date":"2015-08-06","close_date":"2016-02-16"},{"pcpa_file_number":"20768","brand_name":"Inlyta","generic_name":"axitinib","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Metastatic Renal Cell Carcinoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0013-000","inesss_project_id":"","engagement_date":"2013-05-06","close_date":"2013-11-22"},{"pcpa_file_number":"20767","brand_name":"Perjeta\/Herceptin","generic_name":"pertuzumab\/trastuzumab","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Metastatic Breast Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0018-000","inesss_project_id":"","engagement_date":"2013-08-02","close_date":"2013-10-18"},{"pcpa_file_number":"20766","brand_name":"Afinitor","generic_name":"everolimus","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Pancreatic Neuroendocrine Tumors","status":"Concluded with an LOI","cda_amc_project_id":"PC0007-000","inesss_project_id":"","engagement_date":"2013-08-26","close_date":"2013-10-11"},{"pcpa_file_number":"20765","brand_name":"Jadenu","generic_name":"deferasirox","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Chronic Iron Overload","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2016-11-02","close_date":"2017-04-04"},{"pcpa_file_number":"20764","brand_name":"Rosiver","generic_name":"ivermectin","manufacturer_negotiated_with":"Galderma Canada Inc.","indication":"Rosacea","status":"Concluded without agreement","cda_amc_project_id":"SR0429-000","inesss_project_id":"","engagement_date":"2016-04-15","close_date":"2016-08-26"},{"pcpa_file_number":"20763","brand_name":"Sovaldi","generic_name":"sofosbuvir","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"Chronic Hepatitis C","status":"Concluded with an LOI","cda_amc_project_id":"SF0464-000","inesss_project_id":"","engagement_date":"","close_date":"2017-02-17"},{"pcpa_file_number":"20762","brand_name":"Xtandi","generic_name":"enzalutamide","manufacturer_negotiated_with":"Astellas Pharma Inc.","indication":"Metastatic Castration-Resistant Prostate Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0023-000","inesss_project_id":"","engagement_date":"2013-08-07","close_date":"2013-09-23"},{"pcpa_file_number":"20761","brand_name":"Metadol-D","generic_name":"methadone hydrochloride","manufacturer_negotiated_with":"Paladin Labs Inc.","indication":"Opioid Dependence","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2016-10-28","close_date":"2016-12-19"},{"pcpa_file_number":"20760","brand_name":"Revolade","generic_name":"eltrombopag","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Thrombocytopenia associated with chronic hepatitis c infection","status":"Negotiations were not pursued","cda_amc_project_id":"SR0377-000","inesss_project_id":"","engagement_date":"","close_date":"2015-05-28"},{"pcpa_file_number":"20759","brand_name":"Picato","generic_name":"ingenol mebutate","manufacturer_negotiated_with":"LEO Pharma Inc.","indication":"Actinic keratosis","status":"Negotiations were not pursued","cda_amc_project_id":"SR0330-000","inesss_project_id":"","engagement_date":"","close_date":"2014-12-02"},{"pcpa_file_number":"20758","brand_name":"Inflectra","generic_name":"infliximab","manufacturer_negotiated_with":"Hospira Healthcare Corporation","indication":"Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn\u0026#039;s disease and Ulcerative Colitis","status":"Concluded with an LOI","cda_amc_project_id":"SE0483-000","inesss_project_id":"","engagement_date":"","close_date":"2016-10-31"},{"pcpa_file_number":"20757","brand_name":"Replagal","generic_name":"agalsidase alfa","manufacturer_negotiated_with":"Shire Pharma Canada ULC","indication":"Fabry Disease","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2016-08-19","close_date":"2016-10-01"},{"pcpa_file_number":"20756","brand_name":"Fabrazyme","generic_name":"agalsidase beta","manufacturer_negotiated_with":"Sanofi Genzyme Canada","indication":"Fabry Disease","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2016-08-19","close_date":"2016-09-30"},{"pcpa_file_number":"20755","brand_name":"Orkambi","generic_name":"lumacaftor\/ivacaftor","manufacturer_negotiated_with":"Vertex Pharmaceuticals (Canada) Incorporated","indication":"Cystic Fibrosis, F508del CFTR mutation","status":"Negotiations were not pursued","cda_amc_project_id":"SR0471-000","inesss_project_id":"","engagement_date":"","close_date":"2016-11-22"},{"pcpa_file_number":"20754","brand_name":"Jakavi","generic_name":"ruxolintib","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Myelofibrosis","status":"Concluded with an LOI","cda_amc_project_id":"PC0012-000","inesss_project_id":"","engagement_date":"2013-02-01","close_date":"2013-09-03"},{"pcpa_file_number":"20753","brand_name":"Tobi Podhaler","generic_name":"tobramycin","manufacturer_negotiated_with":"Novartis Pharmaceuticals Canada Inc.","indication":"Pseuodomonas aeruginosa infections in cystic fibrosis","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2015-07-28","close_date":"2016-04-19"},{"pcpa_file_number":"20752","brand_name":"Campral","generic_name":"acamprosate calcium","manufacturer_negotiated_with":"Mylan Pharmaceuticals LLC","indication":"Alcohol Abstinence","status":"Concluded without agreement","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2017-03-31","close_date":"2017-09-29"},{"pcpa_file_number":"20751","brand_name":"Sutent","generic_name":"sunitinib malate","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Pancreatic Neuroendocrine Tumors","status":"Concluded with an LOI","cda_amc_project_id":"PC0004-000","inesss_project_id":"","engagement_date":"2012-12-01","close_date":"2013-08-14"},{"pcpa_file_number":"20750","brand_name":"Zaxine","generic_name":"rifaximin","manufacturer_negotiated_with":"Lupin Pharma Canada Ltd.","indication":"Hepatic Encephalopathy","status":"Concluded with an LOI","cda_amc_project_id":"SR0388-000","inesss_project_id":"","engagement_date":"","close_date":"2016-03-02"},{"pcpa_file_number":"20749","brand_name":"Juxtapid","generic_name":"lomitapide","manufacturer_negotiated_with":"Aegerion Pharmaceuticals Canada Ltd.","indication":"Homozygous Familial Hypercholesterolemia","status":"Negotiations were not pursued","cda_amc_project_id":"SR0386-000","inesss_project_id":"","engagement_date":"","close_date":"2015-05-26"},{"pcpa_file_number":"20748","brand_name":"Tykerb \u0026amp; Letrozole","generic_name":"lapatinib","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Early breast cancer, Metastatic breast cancer, Metastatic gastric cancer","status":"Negotiations were not pursued","cda_amc_project_id":"PC0019-000","inesss_project_id":"","engagement_date":"","close_date":"2013-08-09"},{"pcpa_file_number":"20747","brand_name":"Xalkori","generic_name":"crizotinib","manufacturer_negotiated_with":"Pfizer Canada ULC","indication":"Non-Squamous Non-Small Cell Lung Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0017-000","inesss_project_id":"","engagement_date":"2013-05-28","close_date":"2013-08-08"},{"pcpa_file_number":"20746","brand_name":"Fibristal","generic_name":"ulipristal acetate","manufacturer_negotiated_with":"Allergan Inc.","indication":"Uterine fibroids (signs and symptoms)","status":"Concluded with an LOI","cda_amc_project_id":"SR0326-000","inesss_project_id":"","engagement_date":"","close_date":"2015-09-18"},{"pcpa_file_number":"20745","brand_name":"Firazyr","generic_name":"icatibant","manufacturer_negotiated_with":"Shire Pharma Canada ULC","indication":"Hereditary Angioedema","status":"Concluded with an LOI","cda_amc_project_id":"SR0375-000","inesss_project_id":"","engagement_date":"","close_date":"2015-08-28"},{"pcpa_file_number":"20744","brand_name":"Invokana","generic_name":"canagliflozin","manufacturer_negotiated_with":"Janssen Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded with an LOI","cda_amc_project_id":"SR0370-000","inesss_project_id":"","engagement_date":"","close_date":"2015-07-02"},{"pcpa_file_number":"20743","brand_name":"Diacomit","generic_name":"stiripentol","manufacturer_negotiated_with":"Biocodex SA","indication":"Dravet Syndrome (DS)","status":"Concluded with an LOI","cda_amc_project_id":"SR0360-000","inesss_project_id":"","engagement_date":"","close_date":"2015-05-11"},{"pcpa_file_number":"20742","brand_name":"Triumeq","generic_name":"dolutegravir\/abacavir\/lamivudine","manufacturer_negotiated_with":"ViiV Healthcare","indication":"HIV-1 Infection","status":"Concluded with an LOI","cda_amc_project_id":"SR0387-000","inesss_project_id":"","engagement_date":"","close_date":"2015-04-08"},{"pcpa_file_number":"20741","brand_name":"Eylea","generic_name":"aflibercept","manufacturer_negotiated_with":"Bayer Inc.","indication":"Age-Related Macular Degeneration","status":"Concluded with an LOI","cda_amc_project_id":"SR0361-000","inesss_project_id":"","engagement_date":"","close_date":"2015-03-27"},{"pcpa_file_number":"20740","brand_name":"Ibavyr","generic_name":"ribavirin","manufacturer_negotiated_with":"Pendopharm, a division of Pharmascience Inc.","indication":"Chronic Hepatitis C","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2014-10-16","close_date":"2015-03-03"},{"pcpa_file_number":"20739","brand_name":"Halaven","generic_name":"eribulin","manufacturer_negotiated_with":"Eisai Limited","indication":"Metastatic Breast Cancer","status":"Concluded with an LOI","cda_amc_project_id":"PC0005-000","inesss_project_id":"","engagement_date":"2012-11-01","close_date":"2013-07-02"},{"pcpa_file_number":"20738","brand_name":"Remicade","generic_name":"infliximab","manufacturer_negotiated_with":"Janssen Inc.","indication":"Rheumatoid Arthritis, Ulcerative Colitis and Crohn\u0026#039;s Disease","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2014-10-30","close_date":"2015-02-23"},{"pcpa_file_number":"20737","brand_name":"Harvoni","generic_name":"ledipasvir\/sofosbuvir","manufacturer_negotiated_with":"Gilead Sciences Canada Inc.","indication":"Chronic Hepatitis C","status":"Concluded with an LOI","cda_amc_project_id":"SR0395-000","inesss_project_id":"","engagement_date":"","close_date":"2015-02-05"},{"pcpa_file_number":"20736","brand_name":"Advair","generic_name":"salmeterol xinafoate\/fluticasone propionate","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Chronic Obstructive Pulmonary Disease (COPD) and Asthma","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2014-10-06","close_date":"2015-02-03"},{"pcpa_file_number":"20735","brand_name":"Valtrex","generic_name":"valacyclovir","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Specific Viral Infections","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"2014-08-08","close_date":"2015-01-27"},{"pcpa_file_number":"20734","brand_name":"Adempas","generic_name":"riociguat","manufacturer_negotiated_with":"Bayer Inc.","indication":"Pulmonary hypertension, chronic thromboembolic","status":"Concluded with an LOI","cda_amc_project_id":"SR0353-000","inesss_project_id":"","engagement_date":"","close_date":"2015-01-23"},{"pcpa_file_number":"20733","brand_name":"Onglyza","generic_name":"saxagliptin","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Diabetes Mellitus, Type 2","status":"Concluded with an LOI","cda_amc_project_id":"SR0329-000","inesss_project_id":"","engagement_date":"","close_date":"2015-01-09"},{"pcpa_file_number":"20732","brand_name":"Soliris","generic_name":"eculizumab","manufacturer_negotiated_with":"Alexion Pharma Canada Corp.","indication":"Paroxysmal nocturnal hemoglobinuria (PNH)","status":"Concluded with an LOI","cda_amc_project_id":"SR0176-000","inesss_project_id":"","engagement_date":"","close_date":"2014-10-05"},{"pcpa_file_number":"20731","brand_name":"Aubagio","generic_name":"teriflunomide","manufacturer_negotiated_with":"Sanofi Genzyme Canada","indication":"Multiple Sclerosis, Relapsing","status":"Concluded with an LOI","cda_amc_project_id":"SR0350-000","inesss_project_id":"","engagement_date":"","close_date":"2014-09-26"},{"pcpa_file_number":"20730","brand_name":"Orencia","generic_name":"abatacept","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Rheumatoid Arthritis","status":"Concluded with an LOI","cda_amc_project_id":"SR0299-000","inesss_project_id":"","engagement_date":"","close_date":"2014-09-10"},{"pcpa_file_number":"20729","brand_name":"Galexos","generic_name":"simeprevir","manufacturer_negotiated_with":"Janssen Inc.","indication":"Chronic Hepatitis C","status":"Concluded with an LOI","cda_amc_project_id":"SR0347-000","inesss_project_id":"","engagement_date":"","close_date":"2014-08-20"},{"pcpa_file_number":"20728","brand_name":"Esbriet","generic_name":"pirfenidone","manufacturer_negotiated_with":"Hoffmann-La Roche Ltd.","indication":"Pulmonary fibrosis (idiopathic, mild to moderate)","status":"Concluded with an LOI","cda_amc_project_id":"SR0292-000","inesss_project_id":"","engagement_date":"","close_date":"2014-08-15"},{"pcpa_file_number":"20727","brand_name":"Tudorza Genuair","generic_name":"aclidinium bromide","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Chronic Obstructive Pulmonary Disease (COPD)","status":"Concluded with an LOI","cda_amc_project_id":"SR0346-000","inesss_project_id":"","engagement_date":"","close_date":"2014-07-16"},{"pcpa_file_number":"20726","brand_name":"Kalydeco","generic_name":"ivacaftor","manufacturer_negotiated_with":"Vertex Pharmaceuticals (Canada) Incorporated","indication":"Cystic Fibrosis patients (G551D mutation)","status":"Concluded with an LOI","cda_amc_project_id":"SR0291-000","inesss_project_id":"","engagement_date":"","close_date":"2014-06-16"},{"pcpa_file_number":"20725","brand_name":"Lodalis","generic_name":"colesevelam hydrochloride","manufacturer_negotiated_with":"Valeant Canada","indication":"Hypercholesterolemia","status":"Concluded with an LOI","cda_amc_project_id":"SR0274-000","inesss_project_id":"","engagement_date":"","close_date":"2014-04-16"},{"pcpa_file_number":"20724","brand_name":"Tecfidera","generic_name":"dimethyl fumarate","manufacturer_negotiated_with":"Biogen Canada Inc.","indication":"Multiple Sclerosis, Relapsing","status":"Concluded with an LOI","cda_amc_project_id":"SR0309-000","inesss_project_id":"","engagement_date":"","close_date":"2014-04-10"},{"pcpa_file_number":"20723","brand_name":"Treanda","generic_name":"bendamustine hydrochloride","manufacturer_negotiated_with":"Lundbeck Canada Inc.","indication":"Non-Hodgkin\u0026#039;s Lymphoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0010-000","inesss_project_id":"","engagement_date":"2013-02-19","close_date":"2013-04-25"},{"pcpa_file_number":"20722","brand_name":"Oralair","generic_name":"grass pollen allergen extract","manufacturer_negotiated_with":"Paladin Labs Inc.","indication":"Allergic Rhinitis","status":"Concluded with an LOI","cda_amc_project_id":"SR0290-000","inesss_project_id":"","engagement_date":"","close_date":"2014-02-17"},{"pcpa_file_number":"20721","brand_name":"Benlysta","generic_name":"belimumab","manufacturer_negotiated_with":"GlaxoSmithKline Inc.","indication":"Systemic lupus erythematosus","status":"Negotiations were not pursued","cda_amc_project_id":"SR0251-000","inesss_project_id":"","engagement_date":"","close_date":"2014-01-31"},{"pcpa_file_number":"20720","brand_name":"Mozobil","generic_name":"plerixafor","manufacturer_negotiated_with":"Sanofi-Aventis Canada Inc.","indication":"Non-Hodgkin\u0026#039;s Lymphoma and Multiple Myeloma","status":"Concluded with an LOI","cda_amc_project_id":"SR0265-000","inesss_project_id":"","engagement_date":"","close_date":"2014-01-06"},{"pcpa_file_number":"20719","brand_name":"Yervoy","generic_name":"ipilimumab","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Advanced Melanoma","status":"Concluded with an LOI","cda_amc_project_id":"PC0003-000","inesss_project_id":"","engagement_date":"2012-06-01","close_date":"2012-08-28"},{"pcpa_file_number":"20718","brand_name":"Dificid","generic_name":"fidaxomicin","manufacturer_negotiated_with":"Optimer Pharmaceuticals","indication":"Clostridium difficile infection","status":"Concluded with an LOI","cda_amc_project_id":"SR0285-000","inesss_project_id":"","engagement_date":"","close_date":"2013-11-13"},{"pcpa_file_number":"20717","brand_name":"Eliquis","generic_name":"apixaban","manufacturer_negotiated_with":"Bristol Myers Squibb Canada Inc.","indication":"Thromboembolic events prevention, (atrial fibrillation)","status":"Concluded with an LOI","cda_amc_project_id":"SR0288-000","inesss_project_id":"","engagement_date":"","close_date":"2013-10-10"},{"pcpa_file_number":"20716","brand_name":"Replagal","generic_name":"agalsidase alfa","manufacturer_negotiated_with":"Shire Pharma Canada ULC","indication":"Fabry Disease","status":"Concluded with an LOI","cda_amc_project_id":"","inesss_project_id":"","engagement_date":"","close_date":"2013-09-24"},{"pcpa_file_number":"20715","brand_name":"Fabrazyme","generic_name":"agalsidase beta","manufacturer_negotiated_with":"Sanofi Genzyme Canada","indication":"Fabry Disease","status":"Concluded with an LOI","cda_amc_project_id":"SR0028-000","inesss_project_id":"","engagement_date":"","close_date":"2013-09-20"},{"pcpa_file_number":"20714","brand_name":"Brilinta","generic_name":"ticagrelor","manufacturer_negotiated_with":"AstraZeneca Canada Inc.","indication":"Thrombotic events in Acute Coronary Syndromes, Prevention","status":"Concluded with an LOI","cda_amc_project_id":"SR0234-000","inesss_project_id":"","engagement_date":"","close_date":"2012-09-12"}]